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Abstract 
 
 
 Glutathione S-transferases (GST) are a superfamily of detoxifying enzymes 
present in most life forms. They catalyse the conjugation of the tripeptide 
glutathione (GSH) to a wide variety of exogenous and endogenous compounds with 
electrophilic functional groups to form more soluble and non-toxic peptide 
derivatives. The over-expression of the human class Pi enzyme (hGSTP1) in 
tumours has been associated with multi-drug resistance. The work presented in this 
thesis is focused on the four polymorphisms of the hGSTP1 enzyme and their 
reactivity towards five anticancer nitrosourea drugs. 
    The coding sequences of hGSTP1-A, -C and -D enzymes were obtained 
from the hGSTP1-B cDNA through successive cloning into the pGEM-T and pET-
28a vectors, and site directed mutagenesis. This was followed by protein over-
expression and purification by nickel affinity chromatography and gel filtration. 
 Activity and inhibition assays, wavelength scans, mass spectrometry, 
denitrosation and thermofluor shift assays were performed to investigate the 
relationship between the four isozymes and the anticancer drugs (carmustine, 
lomustine, semustine, streptozocin and ethylnitrosourea). The enzymes were 
assayed for activity with 1-clhoro-2,4-dinitrobenzene (CDNB) and hGSTP1-A and -
D were found to be more active towards this substrate than the other hGSTP1 
variants. These two variants share residue Ile104 which could influence catalysis 
towards different substrates. The mass spectrometry and denitrosation assays have 
shown that these drugs do not constitute substrates for the hGSTP1 enzymes. The 
inhibition assays suggested that the four drugs may be weak inhibitors of the 
hGSTP1 variants. However, the thermal shift assays did not show increased protein 
stability in the presence of the drugs. 
 The hGSTP1-D protein was successfully crystallised which allowed 
determination of the first crystallographic structure of this variant. This has allowed 
a detailed comparison of hGSTP1-D with other hGSTP1 protein structures 
available. The side chains of both amino acid residues Ile104 and Val113 of 
hGSTP1-D appear to occupy positions in the same orientation as the side chains of 
equivalent residues of other hGSTP1 enzymes. The use of the same crystallisation 
conditions for co-crystallisation studies with hGSTP1-D and glutathione or the 
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nitrosourea drugs did not result in protein crystals but further optimisation should be 
carried out.  
 Nonetheless, the findings of this project have helped to understand the 
relationship of the hGSTP1 natural variant enzymes with the five nitrosourea 
anticancer drugs and to realise that drug resistance in tumours over-expressing this 
class of hGSTs is not due to the fast metabolism of these drugs but most probably 
to the role that these enzymes play in cell apoptosis and survival.       
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Chapter 1 – Introduction 
 
 
1.1 Glutathione S-Transferase Enzymes  
 
Glutathione S-transferases (GST; EC 2.5.1.18) constitute a superfamily of 
multifunctional enzymes, ubiquitously distributed in most life forms, such as 
animals, plants, insects, parasites, yeast, fungi and bacteria (Parl, 2005; Frova, 
2006; Aliya et al., 2003). They are phase II detoxification enzymes that catalyse the 
conjugation of the tripeptide glutathione (GSH: γ-Glu-Cys-Gly) to a wide range of 
exogenous and endogenous compounds with electrophilic functional groups 
(products of oxidative stress, environmental pollutants and carcinogens), in order to 
form more soluble, non-toxic peptide derivatives, ready to be excreted or 
compartmentalised by the phase III detoxification system (Frova, 2006; Parl, 2005). 
However, numerous examples are known where the product of the initial 
conjugation is still reactive, or even more reactive than the parent compound 
(Bladeren, 2000). Table 1.1 describes the human detoxification system. 
 
Table 1.1 - Major participants of the human detoxification system (adapted from 
Liska, 1998).  
Human Detoxification System 
Phase I *  
(activation reactions)                    
Phase II  
(conjugation reactions ) 
Phase III **  
(antiporter activity) 
Cyp3A4,5 Epoxide hydrolase MDRI 
Cyp2C8,9,18 Glutathione transferases MDRII 
Cyp1A2 Glucuronyl transferases 
 Cyp2E1 Sulfotransferase 
 Cyp2A6 N- and O- methyl transferases 
 Cyp2D6 N-acetyl transferases 
 Cyp2B6 Amino acid transferases 
 * Composed mainly of the cytochrome P450 supergene family; ** Composed mainly 
of the multi-drug resistance genes 1and 2. 
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GSTs are dimeric proteins encoded by a family of distinct genes with limited 
structural homologies. Based on their sequence homology, and structural, 
biochemical and immunoreactivity properties, human cytosolic GSTs have been 
categorised into seven classes, namely GST Alpha, Mu, Pi, Sigma, Omega, Theta, 
and Zeta. GSTs are thought to have evolved from a single common ancestor and 
their substrate specificity and diversity have been reshaped by gene duplication, 
gene recombination, and an accumulation of mutations (Ali-Osman, 1997; Parl, 
2005).   
 
1.1.1 GST Superfamily 
 
Glutathione S-transferases represent around 1% of the total cellular protein 
and are found in most aerobic eukaryotes and some prokaryotes (Salinas et al., 
1999). The classification system originally developed for mammalian GSTs has 
proven robust enough to be extended to non-mammalian enzymes; conversely, 
new classes described originally in non-mammalian sources have later been found 
also in mammals (Sheehan et al., 2001). Usually, to include two GSTs in one class 
they need a minimum of 40% sequence identity, and when less than 30% identical, 
they are then allocated to different classes (McGoldrick et al., 2005).  
There are three main subfamilies of GSTs generally recognized, and each is 
encoded by different multigene families: 
 Soluble or cytosolic GSTs (also named canonical); 
 Microsomal GSTs, now termed MAPEG (membrane associated 
proteins involved in eicosanoid and glutathione metabolism); 
 Plasmid-encoded bacterial fosfomycin-resistan GSTs (Frova, 2006). 
 
Kappa GSTs, in mitochondria, were previously considered to be part of the 
soluble GSTs. However, recent evidence suggests that they constitute a distinct 
subfamily instead (Robinson et al., 2004). Furthermore, microsomal GSTs with 
primary and tertiary structure more similar to the Alpha class soluble GSTs than to 
MAPEGs have been identified (Prabhu et al., 2001). Therefore, it is possible that 
the number of GST subfamilies is substantially larger than previously thought. 
Additionally, genomics and postgenomics studies are continuously finding more 
links with ‘‘related protein families’’ whose relationship to the GSTs can be quite 
tenuous and sometimes disputable (Frova, 2006). Those related families include 
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glutaredoxins (Xia et al., 2001; Collison & Grant, 2003), chloride intracellular 
channels (Harrop et al., 2001), dehydroascorbate reductases (Dixon et al., 2002), 
selenocysteine glutathione peroxidises (Epp et al., 1983), bacterial DsbA (Martin et 
al., 1993), eukaryotic protein elongation factors (Jeppesen et al., 2003), all of which 
share with GSTs a basic structural motif, the thioredoxin fold (Frova, 2006). 
 
1.1.1.1. Soluble or cytosolic GSTs  
 
The cytosolic GSTs are ubiquitously present in all aerobic organisms and are 
by far the most abundant, these being 15–20 different cytosolic GST genes 
identified in man and other mammalian species (Hayes et al., 2005), over 10 in 
insects (Ranson et al., 1998), 40–60 in plants (McGonigle et al., 2000; Wagner et 
al., 2002) and 10–15 in bacteria (Vuilleumier and Pagni, 2002).  
Cytosolic GSTs have been identifiyed and placed into numerous classes 
according to different criteria that include nucleotide/amino acid sequence, physical 
structure of the genes (intron number and position) but also through proteomics 
research. Amongst other techniques, the latter can involve glutathione affinity 
chromatography, two-dimensional electrophoresis, peptide mass fingerprinting, 
HPLC, mass spectrometry, immunoreactivity with specific antibodies or activity-
based probes, multidimensional protein identification technology, protein structural 
analysis by X-ray christallography and bioinformatics. Some GSTs are ubiquitous 
throughout taxa and even kingdoms, while others are specific to each organism 
(Adam et al., 2002; Frova, 2006; Whalen et al., 2008; Chandramouli & Qian, 2009).  
Seven classes of cytosolic GSTs are recognized in mammals, Alpha, Mu, Pi, 
Sigma, Theta, Zeta and Omega. Plants have six classes, Theta, Zeta, Lambda, Phi, 
Tau and DHAR (dehydroascorbate reductases), while five classes have been 
recognized in insects, Delta, Sigma, Theta, Zeta and Omega. Bacteria certainly 
possess a specific class named Beta, in addition to other enzymes more related to 
Theta and possibly other classes (Table 1.2) (Frova, 2006). 
This subfamily was initially discovered and characterized in mammals, 
followed later by a few enzymes from plants, insects and other organisms, which 
produced a confusing situation, as different nomenclature was adopted for each 
organism. On top of that, the first non-mammalian enzymes had very limited 
similarities with the well studied human Alpha, Mu and Pi classes, and 
consequently they were allocated to the Theta class, which at the time was the 
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most heterogeneous and comprehensive class. However, the discovery of 
sequencing techniques permitted the recognition of an abundant number of GST 
genes in many different organisms, which led to the adoption of the existing 
mammalian system also for non-mammalian GSTs (Edwards et al., 2000; 
Chelvanayagam et al., 2001). 
 
Table 1.2 - Common and specific cytosolic GST classes in major taxa (modified 
from Frova, 2006). 
Taxa Common Genes/Species Specific Genes/Species 
Mammals Zeta (Z) 2 Alpha (A) 4-6 
 Theta (T) 2 Mu (M) 5-6 
 Omega (O) 1 Pi (P) 1-2 
 Sigma (S) 1   
Insects Zeta (Z) 1 Delta (D) 2-4 
 Theta (T) 1   
 Omega (O) 1 Phi (F) ?-16 
 Sigma (S) 1 Tau (U) ?-39 
Plants Zeta (Z) 2 
Lambda 
(L) 1-2 
 Theta (T) 1-3 DHAR 1-3 
Bacteria Theta (T) ? Beta (B) 6-15 
 ?    
? - unknown 
 
The Committee for Human Gene Nomenclature states that for each GST 
gene or subunit, the species of origin should be indicated by a three-letter prefix 
(Hsa for Homo sapiens, Mmu for Mus musculus, etc.), followed by GST and a letter 
indicating the class, and a progressive number indicating the order of gene 
discovery in the species. For enzymes, subunit composition is indicated. Thus, 
HsaGSTM1 and HsaGSTM2 define the first and second gene, or encoded subunit, 
of Mu class reported in man, while HsaGSTM1-2 indicates the heterodimer of 
human M1 and M2 subunits (Edwards et al., 2000; Chelvanayagam et al., 2001).  
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1.1.1.2. Microsomal or MAPEG GSTs 
 
Microsomal or MAPEG GSTs are also ubiquitous enzymes as their presence 
has been reported in a vast spectrum of organisms throughout the evolutionary 
scale (Pflugmacher et al., 2000; Bresell et al., 2005). Nevertheless, this GST 
subfamily possesses a much inferior number of classes and globally, is less 
characterised than the cytosolic GSTs (Frova, 2006). 
The majority of the microsomal enzymes are involved in the synthesis of 
eicosanoids, leukotrienes and prostglandins, catalyzing GSH dependent 
transferase or isomerase reactions, while others like the human MGST1 have 
different functions (Morgenstern et al., 1982).  
The human MGST1 was the first microsomal GST to be characterised, its 
catalytic activities are more typical of cytosolic GSTs rather than being involved in 
either leukotriene or prostglandin biosynthesis. MGST1 is thought to be essentially 
a detoxication enzyme involved in the cellular defence against toxic xenobiotics and 
products of oxidative stress. It catalyzes GSH conjugation to several halogenated 
arenes, polyhalogenated unsaturated hydrocarbons and GSH-dependent reduction 
of lipid hydroperoxides (Morgenstern & DePierre, 1983; Mosialou et al., 1995; 
Hayes et al., 2005).  
Bioinformatic approaches led to the identification of two additional 
microsomal proteins, MGST2 and MGST3, which were found to catalyze the 
conjugation of GSH to leukotriene A4 and thus the formation of leukotriene C4. They 
also possess peroxidase activity as they catalyze the GSH-dependent reduction of 
5-hydroxyperoxyeicosatetraenoic acid to 5-hydroxyeicosatetraenoic acid; and may 
be involved in the detoxification of xenobiotics and in cell protection against 
oxidative damage (Jakobsson et al., 1996, Jakobsson et al., 1997; Hayes et al., 
2005).  
Microsomal GSTs are completely different from the cytosolic enzymes. The 
sequence identity with cytosolic GSTs is less than 10%, the subunits are shorter, 
with approximately 150 amino acids, and the structure is completely different. They 
have transmembrane domains, the amino and carboxyl termini of the protein 
protruding into the luminal side of the membrane, while putative sites for GSH and 
substrate binding are located in loops facing the cytosol (Lam et al., 1997; 
Busenlehner et al., 2004). According to hydropathy plots and 3D structural maps, 
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the number of transmembrane domains is likely to be four (Bresell et al., 2005; 
Schmidt-Krey et al., 2000, Schmidt-Krey et al. 2004).   
The tertiary and quaternary structures of mammalian cytosolic and 
microsomal GSTs are completely different, which excludes a common origin 
between them, emphasising the idea of a convergent functional evolution 
(Armstrong, 1997; Schmidt-Krey et al., 2000). 
 
1.1.1.3. Plasmid-encoded bacterial fosfomycin-resistan GSTs 
 
 
Resistance of bacteria to fosfomycin, an antibiotic that inhibits the synthesis 
of peptidoglycan by blocking the formation of N-acetylmuramic acid, is exerted by 
three mechanisms. Two of them are positioned on the chromosome and the third is 
of plasmid origin (Arca et al., 1990).  
The plasmid-encoded resistance to fosfomycin is exerted by a gene that is 
located in a transposon, encoding a 16 KDa protein with GST activity of about 140 
amino acids present in the cytoplasm (Arca et al., 1990; Vuilleumier et al., 1997). 
The gene product catalyzes the formation of an adduct between fosfomycin 
and glutathione through the opening of the epoxide ring of the antibiotic and the 
bonding of its C-1 to the sulfydryl group of the tripeptide cysteine, which results in 
inactivation of fosfomycin. That enzyme resembles those of glutathione S-
transferases present in eukaryotic organisms, and like them glutathione is also an 
obligate substrate for these enzymes in order to bind harmful compounds and 
protect the cells in a similar way (Arca et al., 1990; Suarez et al., 1991).  However, 
the eukaryotic GSTs cannot modify fosfomycin and, conversely, the bacterial 
enzyme does not support their typical reaction of binding between glutathione and 
1-chloro-2,4-dinitrobenzene (CDNB) (Arca et al., 1990; Suarez et al., 1991).  
 
1.1.2 Cytosolic GSTs 
 
1.2.1.1 Structure-function relationship 
 
The knowledge of structure-function relationships in this important enzyme 
subfamily have been greatly increasing duo to the availability of large scale genome 
data, expressed sequence tag databases novel sequence alignment procedures 
and the determination of three-dimensional structures by X-ray crystallography 
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(Sheehan et al., 2001). This knowledge has had a major impact on the 
understanding of the catalytic mechanisms of the GSTs, the evolution of the protein 
fold, and the molecular basis for their participation in the detoxification of 
endogenous and xenobiotic electrophiles (Armstrong, 1997).   
Specifically, GSTs catalyse the conjugation of the glutathione (gamma-1-
glutamyl-1-cysteinylglycine; GSH) to a wide variety of endogenous and exogenous 
electrophilic compounds through the general reaction, GSH + R-X  GSR + HX, 
illustrated on figure 1.1 (Armstrong, 1997; Townsend et al., 2003):  
 
 
Figure 1.1 - Glutathione conjugation to a generic xenobiotic (X) via GST results in 
the formation of glutathione-S conjugate (taken from Townsend et al., 2003). 
 
Cytosolic GSTs exist as dimeric proteins, with subunit molecular weights of 
approximately 25 KDa (Eaton & Bammler, 1999), and an average length of 200-250 
amino acids (Frova, 2006). Generally they contain two binding sites, a GSH binding 
site (G site) and a second substrate-binding site (H site). Each subunit consists of 
the following two domains, as shown in figure 1.2: 
1. The smaller N-terminal α/β helices, domain I, which includes residues 1–
78 of Alpha and Theta class, 1–82 of class Mu, 1– 74 of class Pi and Sigma. Most 
of the amino acids form the G site; 
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2. The larger α helix, domain II, includes residues 86–222 of class Alpha, 
90–217 of class Mu, 81–209 of class Pi, 81–202 of class Sigma and 85–208 of 
class Theta. Most of these amino acids form the H site (Aliya et al., 2003).  
The G-site may be common to all GST subunits, containing specific residues 
critical for GSH binding and catalytic activity (Tyr7 of the mammalian Alpha/Mu/Pi 
classes and Ser17 of the ubiquitous Theta and Zeta), whereas the H-site is specific 
for each subunit, and provides a hydrophobic environment for the binding of 
structurally diverse electrophilic substrates (Aliya et al., 2003; Frova, 2006; Eaton 
Bammler, 1999). The Tyr/Ser hydroxyl group acts as hydrogen bond donor to the 
thiol group of GSH, promoting the formation and stabilization of the highly reactive 
thiolate anion, which is the target for nucleophilic attack of an electrophilic 
substrate. The substrate specificity of GST isozymes was determined by a number 
of residues in the H-site, and the association between two subunits to create an 
intersubuit-binding site for ligands. This intrasubunit-binding site allows a GSH-
conjugate formed by one subunit to be sequestered by the adjacent subunit, limiting 
the product inhibition and maintaining the quaternary structure (Aliya et al., 2003; 
(Dirr et al., 1994a; Armstrong, 1997; Armstrong, 1998).  
The main intersubunit interactions occur between domain I of one subunit 
and domain II of the other. In Alpha/Mu/Pi/Omega and Phi classes the protein 
surfaces and the interactions engaged in dimerisation are hydrophobic, whereas in 
the Theta/Sigma/Beta/Tau classes the interactions are basically hydrophilic (Frova, 
2006).   
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Figure 1.2 – A ribbon diagram of the wheat Tau class GST TaGSTU4 monomer. α-
helices are drawn as ribbons, β-strands as arrows. The inhibitor S-hexylglutathione 
is represented in ball-and-stick coloured according to atom type. α-helices and β-
strands are numbered. Thick light blue and red arrows indicate the glutathione 
binding (G-site) and substrate binding (H-site) sites. Thin black arrows indicate the 
position of the catalytic residue Ser (S), cis-Pro in the omonimous loop and the 
short sequence linking domains I and II (taken from Frova, 2006).  
 
GSTs are either homodimers, if their subunits are identical or heterodimers 
when the subunits are different, and each subunit is encoded by independent 
genes. Heterodimerisation occurs only with subunits of the same class, as 
monomers of different classes cannot dimerise due to incompatibility of the 
interfacial residues (figure 1.3) (Dixon et al., 2002a). GSTs are non-allosteric 
enzymes with one active site per monomer where each active site functions 
independently from the other. However, the enzyme quaternary structure is vital for 
the activity since residues from one subunit complete the active site of the other 
(Salinas et al., 1999).  
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Figure 1.3 – Ribbon diagram of the wheat Tau class TaGSTU4-4 dimer. α-helices 
are drawn as ribbons, β-strands as arrows. The inhibitor S-hexylglutathione is 
represented in ball-and-stick coloured according to atom type. The dimeric structure 
of the enzyme, where the two-fold axis relating to the dimer subunits normal to the 
plane are illustrated on the left, and in the plane of the page in the right (taken from 
Frova, 2006). 
  
 
The N-terminal domain I is classified as part of the thioredoxin superfamily 
fold, which also includes glutaredoxin, disulfide-bond formation facilitator, and 
glutathione peroxidase. This domain constitutes approximately one-third of the 
protein and consists of four β-sheets with three flanking α-helices, βαβαββα as 
shown in figure 1.4. It is formed by two typical structural motifs, the N-ter β1α1β2 and 
the C-ter β3β4α3, linked together by a long loop containing an α-helix, α2. This helix 
α2 and the strand β3 are connected by a loop containing a cis-Proline, which is 
highly conserved in all GSTs and very important to maintain the protein in a 
catalytically competent structure. However, it does not play a direct role in catalysis 
(Sheehan et al., 2001; Armstrong, 1997; Frova, 2006). The C-terminal, which 
represents two-thirds of the protein, is an all-α-helical domain with a unique protein 
fold, consisting of a bundle of helices (Armstrong, 1997).  
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Figure 1.4 – Schematic diagram representing the dimeric thioredoxin fold. a) In the 
diagram, α-helices are shown as ribbons, while β-sheets are shown as arrows. The 
four β-sheets are essentially co-planar, with one helix (α2) shown above this plane 
and the other two a-helices (α1 and α3) shown below the plane. The Pro loop links 
α2 to β3. In GSTs, domain 2 is connected to the C-terminus by a short linker 
peptide. b) In thioredoxin itself, β-sheets are shown as arrows, while α-helices are 
shown as ribbons. The thioredoxin fold has an extra β-sheet and α-helix at the N-
terminus (residues 1±21) ending at the point denoted by * where the fold proper 
begins (taken from Sheehan et al., 2001).   
 
As mentioned before GSTs form an important line of defence protecting 
various cell components from reactive molecules by catalysing the nucleophilic 
attack of GSH on electrophilic substrates (Bladeren, 2000).   
GSTs have a high binding affinity for GSH (dissociation constants between 
10-200 µm and GSH concentrations of 1-10 mM), and the mechanism is likely to 
begin with GSH binding first before the electrophilic substrate, where the later can 
a) 
b) 
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have a carbon, nitrogen or sulphur atom as its electrophilic functional centre 
(Salinas et al., 1999; Eaton & Brammler, 1999). The formation of a thioether bond 
between the cysteine resudue of GSH and the electrophile (figure 1.2) generally 
results in a less reactive and more water-soluble product (Eaton & Brammler, 
1999). Low Km values for the electrophilic substrates are needed by the cell in order 
to keep their low intracellular levels, and the GSH binding site is always likely to be 
occupied as the intracellular GSH concentration varies from 1-10 mM (Salinas et 
al., 1999).  
GSH binds mostly to domain I residues. In solution the GSH thiol is 
protonated with a pKa of approximately 9, but when bound this drops to around 6, 
which indicates that the GST enzyme is binding the protonated GSH thiol and then 
deprotonation occurs at the G-site. According to kinetic and spectroscopic studies 
the thiolate form is the predominant form at the G-site (Salinas et al., 1999).  
When bound to the enzyme, GSH usually adopts an extended conformation, 
running anti-parallel to the loop connection α2-β3, which produces a pair of 
antiparallel β-strand H-bonds. Generally there are four types of interactions with 
GSH in the binding site (Salinas et al., 1999): 
1. Stabilisation and orientation of the y-Glu of GSH;  
2. Alignment of the glutathione peptide backbone; 
3. Stabilisation of the carboxylate of glycine; 
4. Interaction with the SH of cysteine for catalysis. 
 
 
Additionally to their function in catalysing the conjugation of electrophilic 
compounds to glutathione (GSH), GSTs also perform a number of other roles. They 
can serve as peroxidases, isomerases and thiol transferases, they can inhibit the 
Jun N-terminal kinase (protecting cells against H2O2-induced cell death); they are 
able to bind non-catalytically a wide range of endogenous and exogenous ligands 
and also to modulate signalling processes (Sheehan et al., 2001; Frova, 2006). 
 
1.1.2.2. Substrates and metabolism  
  
Glutathione conjugation is the first of four steps in mercapturic acid synthesis 
which leads to the elimination of toxic compounds (Townsend et al., 2003; Hayes et 
al., 2005). Subsequent reactions in this pathway comprise sequential removal of the 
 
 
27 
γ-glutamyl moiety and glycine from the glutathione conjugate, which is then 
succeeded by N-acetylation of the resulting cysteine conjugate. GSTs are part of an 
integrated defence strategy, and their success depends on the combined actions of 
several proteins. Firstly, they depend on glutamate cysteine ligase and glutathione 
synthase, which are the suppliers of GSH, and secondly, on the work of trans-
membrane multidrug resistance-associated proteins (MRPs) that actively excrete 
glutathione conjugates from the cell. As the glutathionylate moiety is hydrophilic, the 
conjugate cannot simply re-diffuse back into the cell (Hayes et al., 2005; 
McGoldrick et al., 2005).  Nine MRP proteins are known, and which are all 
members of the C family of ABC transporters. Among these, MRP1 and MRP2 can 
remove glutathione conjugates and compounds complexed with GSH (Hayes et al., 
2005). 
Figure 1.5 illustrates the roles of GSTs and related enzymes in the 
detoxification of exogenous and endogenous toxic compounds. Exogenous 
substrates for soluble GSTs include drugs, industrial intermediates, pesticides, 
herbicides, environmental chemicals and pollutants, and also carcinogens (Hayes 
et al., 2005). A number of exogenous substrates are listed in table 1.2 (Eaton & 
Brammer, 1999). GSTs can also participate in the metabolism of endogenous toxic 
compounds such as the detoxification of products of oxidative stress. The 
production of reactive oxygen species, such as the superoxide anion O2
–, hydrogen 
peroxide H2O2, and the hydroxyl radical HO*, from partially reduced O2 is an 
unavoidable consequence of aerobic respiration (Hayes et al., 2005; Sheehan et 
al., 2001). Primarily, they can interact with the antioxidant defences such as the 
superoxide dismutase, catalase, and glutathione peroxidase, and the non-
enzymatic α-tocopherol, ascorbic acid, GSH and bilirubin; however, they can still 
oxidise and inflict damage on membrane lipid, DNA, protein, and carbohydrate, 
which originate cytotoxic and mutagenic degradation products. Aldehyde 
dehydrogenase, alcohol dehydrogenase, aldo-keto reductase, GST, and Se-
dependent glutathione peroxidase are some of the enzyme systems that protect the 
cell against these by-products of oxidative stress (Hayes et al., 2005). A small 
number of endogenous compounds acting as GSTs substrates are also shown in 
table 1.3 (Eaton & Brammer, 1999).  
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Figure 1.5 - Glutathione S-transferases and related enzymes involved in the 
detoxification of exogenous and endogenous toxic compounds (taken from Masella 
et al., 2005).  
 
Table 1.3 – Substrates for Glutathione S-transferases (modified from Eaton & 
Brammer, 1999).  
Environmental 
carcinogens/toxicants 
Pesticides Drugs Endogenous molecules 
Benzo(a)pyrene 7,8-
duhydrodiol-9,10-
epoxide (BPDE) Lindane Cis-platin 4-Hydroxy-2-nonenal 
AFB-8,9-epoxide Alachlor Chlorambucil Cholesterol-5,6-oxide 
Styrene oxide Atrazine Cyclophosphamide Adenine propenal 
5-Hydroxymethyl(a)-
chrysene sulfate DDT 
BCNU (Bis-chloro-
methyl nitrosourea) 9-Hydroperoxy-linoleic acid 
7-Hydroxymethylbenz(a)-
anthracene sulfate Methyl parathion Thiotepa 
Dopaminochrome, 
aminochrome 
4-Nitroquinoline oxide 
EPN (O-ethyl-O-4 
nitrophenyl phenyl-
phosphonothioate) Fosfomycin 
Catechol estrogens (quinines 
derived from 2 and/or 4 
hydroxyestradiol) 
Acrolein  Ethacrynic acid Malelylacetoacetate 
Hexachlorobutadiene  Nitroglycerine  
Butadiene  Menadione  
Trichloroethylene  
Acetaminophen 
(NAPQI)  
Methylene chloride  Mitozantrone  
Ethylene oxide  Adriamycin  
Phip (2-amino-1-methyl-
6-phenylimidazo[4,5b]-
pyridine)    
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Generally GSTs are detoxification reactions leading to less reactive 
products. However, for certain xenobiotics GST-mediated conjugation with GSH 
may result in formation of more reactive glutathione conjugates (Hayes et al., 2005; 
Eaton et al., 1999). Examples of bioactivation are the formation of direct toxic 
conjugates from dialkyldihalides such as dihalomethanes and dihaloethanes, and 
the production of indirect toxic conjugates from halogenated alkenes and alkynes 
such as hexachloro-1,3-butadiene, trichloroethylene etc., which are nephrotoxic. 
These toxic conjugates are then metabolized by membrane bound GSTs. Also, the 
incomplete detoxification of certain ethers, esters and organic phosphates upon 
conjugation by the GST leads to cleavage of the substrate called thiolysis with only 
one of the two products being conjugated, which provides a chemical threat to the 
cell (Bladeren et al., 1979; Anders et al., 1990; Andersson et al., 1994; Keen et al., 
1978).  
In cancer chemotherapy, the ability of GST to produce reactive metabolites 
has been exploited with the objective of targeting tumours that over-express 
particular transferases. As an example, the cytotoxic drug TLK286 is activated by 
GST through a beta-elimination reaction in order to obtain an active analogue of 
cyclophosphamide (Hayes et al., 2005). 
 
1.1.2.3 Evolution 
 
Detoxification enzymes have existed in both prokaryotes and eukaryotes for 
more than 2.5 billion years, where GSTs constitute a very ancient protein 
superfamily and which is now considered to have evolved from a thioredoxin-like 
ancestor in response to the development of oxidative stress (Sheehan, 2001; 
Frova, 2006). 
Initially, Theta GSTs were thought to be the ancient progenitors of the family, 
because their evolution predates the prokaryote-eukaryote split, as a response to 
oxygen toxicity. Plant and mammalian specific GST classes would then have 
evolved from a Theta-class gene duplication that took place before the partition of 
fungi and animals. However, subsequent description of the overall structure of 
GSTs highlighted a prominent folding resemblance among all soluble GST classes, 
but also with other protein families, suggesting that GST evolution in a larger 
context is part of the evolution of the thioredoxin fold (TRX) superfamily (Pemble 
and Taylor, 1992; Martin, 1995; Copley et al., 2004). 
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Cytosolic GSTs evolution can be broadly divided into two phases: phase 1 
comprising the ancient events, and phase 2 covering the appearance and 
diversification of the multiplicity of GST classes.  
  
1.1.2.3.1 Phase 1 
 
 The main event of phase 1 is the recruitment of a second, all helical domain 
(domain II) either as C-terminal addition to (E. coli GRX2, CLICs, eEF1Bg, cytosolic 
GSTs) or as insertion into the thioredoxin fold (DsbA, HCCA, Kappa GSTs) (Frova, 
2006).  
 Considering the structural characteristics of cytosolic and Kappa GSTs, it 
has been proposed that they evolved independently from thioredoxin/glutaredoxin 
proteins via two parallel pathways, A and B (figure1.6a) (Ladner et al., 2004; 
Robinson et al., 2004). Model which substitutes two previous ones by Armstrong, 
(1997) and Sheehan et al., (2001), in which Kappa GSTs were located on the same 
evolutionary pathway as Theta enzymes, likely preceding them. 
Phases 1 and 2 are illustrated at the left and the right side of a hypothetical 
border line in figure 1.6. All left side enzymes comprise thiol transferase activity and 
feature a cysteine as essential active site residue. By contrast, on the right side, the 
cytosolic and Kappa GSTs have a serine as active site residue; do not form mixed 
disulphides with glutathione and act as conjugating enzymes instead of redox ones 
(Ladner et al., 2004).  
 
 
31 
 
Figure 1.6 – Model of the evolution of TRX proteins based on structural and 
functional data. The most ancient steps are illustrated in (a). (b) Phase 2 
differentiation of cytosolic GSTs. Thick arrows in (b) indicate the likely sequence of 
critical evolutionary steps, dimerization and changes in active site residues, these 
last represented by geometric symbols. Circle = Cys, diamond = Ser and triangle = 
Tyr (taken from Frova, 2006). 
 
1.1.2.3.2 Phase 2 
 
 A possible evolutionary model of cytosolic GSTs is shown in figure 1.5b, 
which suggests some general considerations. The ubiquitously distributed Theta, 
Zeta, Omega and Sigma classes are represented by a maximum of two to three 
members in each species, meaning that these genes have undergone a small 
number of duplications or that the duplicated copies were subsequently lost. A 
monophiletic origin of Zeta and Theta GSTs, preceding the plant-animal split, has 
been suggested, and is consistent with the conservation of intron number and 
position, active site residue and the function of these enzymes in all eukaryotes 
(Board et al., 1997; Dixon et al., 1998; Frova, 2003). 
 A modification in the crucial G-site residue, from serine to tyrosine, in the 
mammalian Alpha, Mu, Pi classes and in Sigma GSTs, characterizes another 
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evolutionary separation of the cytosolic GSTs, which is sustained by phylogenetic 
trees based on sequence data (Board et al., 1997).  
The taxon specific GSTs are much more abundant, showing that on one 
hand, the family as a whole is ancient; but on the other hand, the large expansion 
occurred more recently and independently in the diverse lineages (Soranzo et al., 
2004). 
The higher evolutionary rate of the specific GST classes possibly reflects an 
adaptive response to environmental insults, where specific GST classes are those 
usually involved in detoxification of xenobiotics, comprising the principal phase II 
enzymes in animals and plants. The adaptive advantages of these systems depend 
on their versatility, in other words, the capacity to detoxify a wide range of 
compounds, and on the rapidity by which new environmental challenges can be 
counteracted (Frova, 2006). 
 
1.2 Human GSTs 
 
 In humans, soluble GSTs are collectively expressed in large amounts, and 
each organ possesses a unique profile of them. For example, in the liver they 
constitute as much as 4% of total soluble protein (Eaton & Brammer, 1999; Aliya et 
al., 2003). GSTs exhibit sex, age, tissue and tumour specific patterns of variation, 
and they are induced by a number of different chemicals, which are naturally 
occurring and to which humans are exposed regularly (Aliya et al., 2003). 
 At the moment there are eight distinct gene families encoding human GSTs, 
Alpha on chromosome 6, Mu on chromosome 1, Theta on chromosome 22, Pi on 
chromosome 11, Zeta on chromosome 14, Sigma on chromosome 4, Omega on 
chromosome 10 and Kappa, for which the chromosomal location is not known and, 
while probably soluble, is expressed in the mitochondria (figure 1.7 and table 1.4) 
(Strange et al., 2001). As mentioned before, recent evidence suggests that this last 
GST, previously considered as just one class of the soluble GSTs, constitute a 
distinct subfamily instead (Frova, 2006).  
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Figure 1.7 – The glutathione S-transferase supergene family (taken from 
Strange et al., 2001). 
 
 
In humans, many genes in the cytosolic GSTs are know to contain several 
polymorphisms as shown in table 1.3, which produce significant interindividual 
differences in responses to xenobiotics, including carcinogens and 
chemotherapeutic agents (Hayes et al., 2005; Okcu et al., 2004). Polymorphisms 
are common alterations in a DNA sequence that may originate reduced or 
increased activity of the encoded gene. They are stable and heritable, and include 
single nucleotide polymorphisms (SNPs), micro- and minisatellites. An SNP 
corresponds to a single base exchange, which may or may not cause an amino 
acid exchange in the encoded protein. Microsatellites are multiple copies of 
repeated DNA sequences in a length of 0.1-10 kb and which consist of repeated 
small sequences up to 4 nucleotides (Efferth et al., 2005). The most studied 
polymorphisms in the human cytosolic GST family are the ones in the Mu, Theta 
and Pi classes (Strange et al., 2001). 
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Table 1.4 – Classification and nomenclature for human glutathione S-transferases 
(taken from Eaton & Brammer, 1999) 
 
 
1.2.1 Mu and Theta GSTs 
 
The human GST Mu crystal structure, according to Salinas et al. (1999), was 
determined in 1994 by Raghunathan and his collaborators with the inhibitor S-
dinitrobenzyl GSH bound to the active site of the protein. 
 The GST Mu class is encoded by a 100 kb gene cluster at 1q13.3 arranged 
as 5’-GSTM4-GSTM2-GSTM1-GSTM5-GSTM3-3’, and coding for an equal number 
of enzymes, as shown in figure 1.8 (Parl, 2005; Pavanello et al., 2000).  
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Figure 1.8 – The hGSTM1gene is part of the Mu-class GST gene cluster at 1p13.3, 
which is arranged as 50-GSTM4-GSTM2-GSTM1-GSTM5-GSTM3-30 (top of 
diagram). The hGSTM1gene (black box) consists of 8 exons, which range in size 
from 36 to 112 bp, while the introns vary from 87 to 2641 bp. hGSTM1is embedded 
in a region with extensive homologies and flanked by two almost identical 4.2-kb 
regions (grey boxes). The hGSTM1null allele arises by homologous recombination 
of the left and right 4.2-kb repeats, which results in a 16-kb deletion containing the 
entire hGSTM1gene (bottom of diagram). The point of deletion cannot be precisely 
localized because of the high sequence identity between the repeats (taken from 
Parl et al., 2005). 
 
 The gene coding for isoform hGSTM1is polymorphic and has four allele 
variants, hGSTM1-A, -B, -C and -0. In the first two a mis-sense single nucleotide 
polymorphism occurs, nucleotide 534GC (172LysAsn), which does not appear 
to affect enzyme functions or the type of substrate and allele C is very rare 
(Pavanello et al., 2000; Parl, 2005). The last variant corresponds to a deletion 
polymorphism, which results in a total lack of expression of a functional protein in 
the homozygous null (-/-) genotype, hGSTM1-0 (Tuimala et al., 2004; Parl, 2005; 
Hatagima et al., 2007). The frequency of the hGSTM1-/- is around 50-53% in 
Caucasians and Asians, but lower in Afro-Americans, 27% (Parl, 2005).  
 The hGSTM3 gene is significantly shorter than the other hGSTMs and 
oriented tail-to-tail in the cluster, in other words, in reverse orientation with respect 
to other members of the class (figure 1.7). In the hGSTM3 gene, the hGSTM3-A 
wild type and hGSTM3-B variant alleles differ from each other by a deletion of 3 bp 
in intron 6, resulting in a recognition sequence for the YY1 transcription factor in the 
latter. hGSTM4 shares 87% of amino acid sequence identity with hGSTM1, 83% 
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with hGSTM2 and 70% with hGSTM3 (Parl, 2005; Hayes et al., 2000; To-Figueras 
et al., 2002). 
The hGSTT class is comprised of two genes, hGSTT1 and hGSTT2, which 
are localised at 22q11.2 and separated by about 50 kb (figure 1.8). Both of them 
contain five exons with identical intron/exon boundaries, yet they only share around 
55% of amino acid sequence (Parl, 2005; Sheehan et al., 2001).  
Similar to hGSTM1, a homozygous null polymorphism for hGSTT1 has been 
described, hGSTT1-0, which results in lack of protein expression and is probably 
caused by a homologous recombination event involving the left and right 403 bp 
repeats (Carroll et al., 2005; Parl, 2005; Bladeren, 2000). This phenotype occurs in 
10-64% of several ethnic groups, being 16% in English populations, 38% in 
Nigerians, and with higher frequencie in Asians, ranging from 47 to 64% (Parl, 
2005; Pavanello et al., 2000; Bladeren, 2000). This deletion of the hGSTT1 gene 
does not include hGSTT2 (figure 1.9) (Parl, 2005).  
Polymorphisms that confer a modest disease risk can be a substantial public 
health burden if they are common to the same individual (Hashibe et al., 2003). An 
increased frequency of hGSTM1and hGSTT1 null genotypes has been associated 
with certain human malignancies (Zheng Ye et al., 2005). Affected individuals show 
decreased capacity to detoxify certain carcinogens and have been linked with an 
increased risk for several types of cancers including bladder, gastric, colorectal, and 
breast cancer, and acute lymphocytic leukaemia (Saadat et al., 2004) 
Granja et al. (2004) demonstrated that individuals lacking hGSTM1or 
hGSTT1 genes are more susceptible to the effects of a large series of carcinogens, 
and the combined null hGSTM1and hGSTT1 genotypes increase the risk for thyroid 
cancer 2.6 times.  
According to Zheng Ye et al. (2005) there is a significantly increased risk of 
acute lymphoblastic leukaemia associated with these two GST null genotypes, 
which may play a role in leukemogenesis.  
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Figure 1.9 – The hGSTT1 gene is part of the Theta-class GST gene cluster at 
22q11.2 (top of diagram). hGSTT1 and hGSTT2 are separated by approximately 50 
kb. GSTT2 lies head-to-head with a gene encoding the D-dopachrome tautomerase 
(DDCT). The hGSTT2 and DDCT genes have been duplicated in an inverted 
repeat. The duplicated hGSTT2 is a pseudogene (named hGSTT2P) because an 
abnormal exon 2/intron 2 splice site causes a premature translation stop. The 
hGSTT1 gene (black box) consists of five exons, which range in size from 88 to 195 
bp, while the introns vary from 205 to 2363 bp. The hGSTT1 gene is embedded in a 
region with extensive homologies and flanked by two 18 kb regions, HA3 and HA5 
(grey boxes), which are more than 90% homologous. In their central portions HA3 
and HA5 share a 403-bp sequence with 100% identity. The hGSTT1 null allele 
arises by homologous recombination of the left and right 403-bp repeats, which 
results in a 54-kb deletion containing the entire hGSTT1 gene (bottom of diagram). 
The point of deletion cannot be precisely localized because of the sequence identity 
between the 403-bp repeats (taken from Parl et al., 2005). 
 
 
The hGSTM1-0 has particularly been connected with an increased sensitivity 
to polyaromatic hydrocarbons and tobacco smoke. The deficiency of this enzyme 
was connected with a higher frequency of chromatid breaks and sister chromatid 
exchanges in smokers, and of chromosomal aberrations in bus drivers exposed to 
polyaromatic hydrocarbons (Tuimala et al., 2004). Also, alterations in the p53 and 
H-ras genes of smokers with lung cancer are more common in the hGSTM1-0 
genotype. An increase in p53 mutations correlated with the hGSTM1null allele was 
also obtained in ovarian cancer (Sanchez et al., 2001). 
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GSTT1-0 was correlated to an enlarged baseline frequency of sister 
chromatid exchanges and chromosomal aberrations, most likely through interaction 
with endogenous genotoxins (Tuimala et al., 2004).  
 Loss of hGSTM1and hGSTT1 genes can also increase susceptibility to 
inflammatory diseases, such as asthma and allergies, artherosclerosis, rheumatoid 
arthritis, and systemic sclerosis (Hayes, 2005).  
 
1.2.2 GST Pi 
 
Class pi GST, the most widely distributed isoform of the GSTs, was first 
prepared as an acidic enzyme from human placenta. It seems to be extremely 
conserved and not related to any other GST class in mammals (Lin et al., 2003; 
Aliya et al., 2003). Its single gene is located at 11q13, 2.8 kb long and consists of 
seven exons, as illustrated in figure 1.9. The open reading frame begins at the 3’ 
end of the first exon and is 630 bp long, encoding a protein of 210 amino acids, 
including the initiating methionine (Parl, 2005; Ali-Osman et al., 1997).  
A number of SNPs have been reported in the hGSTP1 gene, and two of 
them result in amino acid substitutions in codons 104 (IleVal) and 113 (AlaVal) 
in exons 5 and 6, respectively (figure 1.10) (Parl, 2005; Okcu et al., 2004). The 
combination of these two SNPs results in the four genotypes hGSTP1-A , -B, -C 
and -D. hGSTP1-A , also called the wild-type, is not affected by any nucleotide 
substitution, thus it presents a Ile at codon 104 and a Ala at codon 113 (Ali-Osman 
et al., 1997). hGSTP-A is the most common allele among the Caucasian 
population, with a frequency of around 44% (Okcu et al., 2004; Eaton & Brammer, 
1999). hGSTP1-B differ from hGSTP1-A  by having the following nucleotide 
substitution, 313AG (104IleVal); hGSTP1-C is characterised by two nucleotide 
transitions, the one observed in the hGSTP1-B isoform and the 341CT 
(113AlaVal), and finally the hGSTP1-D isoform, which is distinguished by only 
one nucleotide substitution at 341CT (113AlaVal) (Ali-Osman et al., 1997; 
Bladeren et al., 2000).    
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Figure 1.10 – Overview of hGSTP1 gene, mRNA and protein. The hGSTP1 gene at 
11q13 is about 2.8 kb long and contains seven exons. The open reading frame 
starts at the 30 end of the first exon and is 630 bp long, encoding a protein of 209 
amino acids with a relative molecular weight Mr 23,224. The arrows indicate 
polymorphic sites. Two of the polymorphisms result in amino acid substitutions in 
codons 104 (IleVal) and 113 (AlaVal) in exons 5 and 6, respectively (taken from 
Parl et al., 2005). 
 
 
 Both amino acids 104 and 113 affect substrate specificity to the point of 
distinguishing between planar and non-planar substrates, as the allelic alterations 
provoke a steric effect at the substrate-binding site (H-site) of the enzyme, without 
affecting the glutathione-binding site, but leading to a substrate-dependent 
functional modification when compared with wild-type enzyme (Parl, 2005; Okcu et 
al., 2004; Gaspar et al., 2004; Ali-Osman et al., 1997). The crystallographic 
structure of hGSTP1-A  revealed the key amino acid residues lining the alleged H-
site of human placental GST Pi to be Tyr7, Tyr108, Val10, Val35, Phe8, and 
Gly205.  
 The hGSTPs have been extracted and purified from many extra-hepatic 
organs, and their expression is easily detected in human placenta, lung, kidney, 
blood, breast and at certain developmental stages in other tissues like notochord 
(Hayes et al., 1995; Aliya et al., 2003). This class of enzymes has attracted the 
attention of epidemiologists with respect to cancer risk, as it is expressed in several 
tumours and it is the major GST isozyme in a large range of sensitive and resistant 
cancer cells. Its cellular level is associated with cell proliferation and related with the 
degree of de-differentiation (Aliya et al., 2003; Parl, 2005). The relation between 
hGSTP1 and cancer will be discussed in more detail in section 1.3.  
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 The hGSTP1 gene is involved in inflammatory diseases, such as asthma and 
allergies, artherosclerosis, rheumatoid arthritis, and systemic sclerosis (Hayes, 
2005). Due to the ability to modify the substrate specificity of the wild-type enzyme, 
the hGSTPi allelic variants also constitute a risk factor for Parkinson’s disease in 
individuals exposed to pesticides (Board et al., 2000). 
The hGSTP1 genotypes have, as well, been associated with atopic airway 
disease and related with the severity of airway dysfunction, as defined by bronchial 
hyperresponsiveness. The frequency of hGSTP1-A increases in parallel with the 
extent of airway reactivity/obstruction, while frequency of hGSTP1-B showed an 
inverse tendency (Hayes et al., 2000).   
Glutathione S-transferases have emerged as promising therapeutic targets 
because specific classes and subclasses are over-expressed in a broad variety of 
cancers, such as breast, lung, colon, brain; and they may participate in the etiology 
of other diseases, including neurodegenerative diseases, multiple sclerosis and 
asthma (Parl, 2005; Townsend et al., 2003). One of the therapeutic strategies used 
is the design of GST inhibitors, which perform as reasonably non-toxic modulatory 
agents, and function in circumstances where conventional anti-cancer drugs are 
detoxified by GSTs. Alternatively, drugs designed to break protein:protein 
interactions of GST with stress kinases also provide a possible therapeutic 
approach with relation to the modification of proliferative responses. Another 
strategy is to exploit the important expression of GST in tumours, predominantly 
hGSTPs, through design of GST-activated prodrugs (Townsend et al., 2003).  
 
1.3 hGST Pi and Cancer 
  
 Cancer research has been creating a rich and complex amount of 
knowledge, revealing cancer to be a malignancy involving dynamic variations in the 
genome. Those variations can be due to the detection of mutations that produce 
oncogenes with dominant gain of function and tumour suppressor genes with 
recessive loss of function. Together, these two classes of cancer genes have been 
identified through their modification in human and animal cancer cells and by their 
generation of cancer phenotypes in experimental models (Hanahan et al., 2000).   
 Cancer cells have defects in regulatory circuits that control normal cell 
proliferation and homeostasis. There are more than 100 distinct types of cancer, 
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and subtypes of tumours can be found within specific organs (Hanahan et al., 
2000). Hanahan et al. (2000) suggest that the extensive number of cancer cell 
genotypes is an expression of six fundamental alterations in cell physiology that 
collectively determine malignant growth: self-sufficiency in growth signals, 
insensitivity to antigrowth signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis. Every one of 
these physiologic changes corresponds to the successful rupture of an anti-cancer 
defence mechanism present into cells and tissues.   
 Although the hGSTPi enzyme works as a defence mechanism against 
cancer through the metabolism and detoxification of carcinogenic compounds, its 
expression or lack of it, seems to be correlated with several types of cancer. The 
hGSTPi over-expression has been associated with malignant transformation, such 
as, prostate cancer, squamous cell carcinoma of neck and head, gastric carcinoma, 
acute lymphoblastic leukaemia, and chronic lymphoid leukaemia, among others. 
The hGSTP1 over-expression is also associated with tumour drug resistance, and 
poor patient survival (Allen et al., 2007; Ali-Osman et al., 1997). Usually, in various 
human tumours and pre-neoplastic lesions, the hGSTP1 protein is over-expressed, 
while in the corresponding normal tissues the protein is not present or is expressed 
at very low levels (Ali-Osman et al., 1997; Schultz et al., 1997).  
 As mentioned before, the GST Pi gene is located in a relatively small region 
of chromosome 11q13 in which is situated a number of cancer-associated genes 
and proto-oncogenes, including bcl1/prad1, int2, hstf1, and sea. A few of them have 
been reported to be co-amplified with the GST Pi gene in some tumours (Ali-Osman 
et al., 1997). The Pi class is the predominant GST form in cancer cells (Aliya et al., 
2003). 
 
1.3.1. GST Pi polymorphisms and cancer risk  
 
Pharmacogenetics is the science that illustrates the impact of various genetic 
polymorphisms on the biological activities of drugs. Determination of genetic 
polymorphisms of drug metabolising enzymes has given drug metabolism scientists 
a powerful tool. Epidemiological studies have highlighted some polymorphic 
differences in individuals with genetic mutations in specific enzymes that confer 
altered kinetic properties. Phenotypically, changes in kinetic properties are often 
reflected by alterations in rates at which subjects metabolise drugs, with individuals 
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identified as “poor metabolisers” if they have enzymes with reduced catalytic 
capability or “extensive metabolisers” if mutated enzymes have unusually high 
catalytic activity, where the first case is the most common. Documented 
consequences of polymorphism in drug metabolising enzymes include enlarged 
susceptibility to cancer and increased toxicity or decreased effectiveness of drugs 
(Sanchez et al., 2001).  
Besides influencing susceptibility to carcinogenesis, hGSTP1 polymorphisms 
are modifiers of response to chemotherapy in patients with metastatic colorectal 
cancer and those with multiple myeloma. hGSTP1 polymorphisms also influence 
the risk of therapy-related acute myeloid leukaemia in patients successfully treated 
for breast cancer, non-Hodgkin’s lymphoma, ovarian cancer, and Hodgkin’s disease 
(Hayes, 2005).   
Harries et al. (1997) observed a highly significant increase in the frequency 
of the hGSTP1-B genotype in a cohort of bladder cancer patients. This research 
group also observed an increase in the proportion of individuals with this 
polymorphic genotype in lung cancer patients. These findings are also true for 
teratoma and seminoma cancers (Harries et al., 1997). Henderson et al. (1998) 
also reported increased frequency of hGSTP1-B variant in bladder and testicular 
cancer. The same study demonstrated that hGSTP1-A genotype was significantly 
reduced in cases of prostate cancer. 
According to Gaspar et al. (2004), in thyroid cancer the presence of 
hGSTP1-A  leads to a significantly later age of tumour onset when compared to 
hGSTP1-B, suggesting a possible association between hGSTP1-A  and the age of 
disease manifestation. In the same study it was also observed that the presence of 
three risk alleles, hGSTM1and hGSTT1 null genotypes and hGSTP1-A, lead to a 
significant increase in thyroid cancer, particularly for papillary tumours.    
Hashibe et al. (2003) observed an increasing risk of head and neck cancer 
related to hGSTP1-B when this polymorphism was combined with hGSTM1and 
hGSTT1 null genotypes.  
The hGSTM1 and hGSTT1 null, and hGSTP1-B or hGSTP1-C variants were 
associated with superior outcome in women with primary breast cancer. It has been 
also reported that in patients with metastatic colorectal carcinoma who were 
uniformly treated with 5-fluorouracil and oxaliplatin, those who had hGSTP1-B or 
hGSTP1-C had a significantly longer survival (Ocku et al., 2004). 
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According to Ocku et al. (2004) the combination of hGSTP1-A and 
hGSTM1null genotypes in individuals with anaplastic astrocytoma, anaplastic 
oligodendroglioma, and anaplastic oligoastrocytoma confers a survival advantage. 
The research group also concluded that individuals with this genotype also have an 
increased risk of adverse events secondary to chemotherapy that primarily 
comprised nitrosourea alkylating agents.      
 It has been found that the different hGSTP1 variants show different catalytic 
activities towards benzo[α]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE, a BP 
ultimate carcinogen from tobacco smoke), with the hGSTP1-B variant showing a 
higher in vitro activity towards BPDE when compared to the hGSTP1-A  isoform 
and a maximum protection against BPDE in HepG2 cells, which were transfected 
with different allelic variants of hGSTP1. In contrast to what might be expected, a 
case control study found an increased lung cancer risk associated with the 
hGSTP1-B allele (To-Figueras et al., 2002). However, the results obtained by To-
Figueras et al. (2002) were contradictory, as they reported that laryngeal cancer 
tended to concur with the in vitro observations. This suggested that those 
individuals with a combination of hGSTP1-A and high microsomal epoxide 
hydrolase (other detoxification enzyme) activity, when exposed to tobacco smoke, 
may be at high risk of forming BPDE-DNA adducts that induce critical mutations 
and trigger cancer initiation.   
 Parl et al. (2003) mentioned a number of contradictory studies involving 
hGSTP1 polymorphisms and breast cancer. A first study reported significantly 
increased risk for women with hGSTM1and hGSTT1 null genotypes together with 
the hGSTP1-B, while a second study did not observe any correlation with this 
genotype combination. A third case study found the lowest risk for women 
simultaneously carrying the hGSTM1and hGSTT1 null variants, and hGSTP1-B 
allele, whereas the same second study reported an increased risk in 
premenopausal women lacking the hGSTM1and hGSTT1, and carrying the 
hGSTP1-A  genotype; which may suggest that the differences can be due to the 
presence of different hGSTP1 isoform. Finally, a fifth study of breast cancer 
patients found no increase in risk related to any combination of hGSTM1, hGSTP1, 
and hGSTT1 genotypes when compared with the control individuals involved in the 
study.   
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1.3.2. Human GST Pi and drug resistance  
 
 
By means of gene transfection and pharmacokinetic studies, many 
chemotherapeutic agents, including melphalan, cyclophosphamide, vincristine, 
adriamycin, cisplatin, etoposide, thiotepa, chlorambucil, and busulphan have been 
shown to be substrates for hGSTP1 enzymes (Dasgupta et al., 2003).  However, 
the effectiveness of these chemotherapeutic agents can be severely limited by 
multiple drug resistance (Reinemer et al., 1991). 
Enzyme activity towards electrophilic compounds is significantly different for 
the particular alleles of different substrates (Okcu et al., 2004). The hGSTP1-B and 
hGSTP1-C variants are associated with a lower thermal stability and altered 
catalytic activity to a range of substrates compared with hGSTP1-A. The catalytic 
activity of hGSTP1-B and hGSTP1-C alleles towards thiotepa, chlorambucil, and 1-
chloro-2,4-dinitrobenzene is lower than that of hGSTP1-A. However, when cisplatin, 
carboplatin, 4-hydroxyfosfamide, and epoxides of benzo(α)pyrene represent the 
substrate, the hGSTP1-B and hGSTP1-C variants have a higher cytoprotective 
effect than hGSTP1-A  (Dasgupta et al., 2003; Okcu et al.,2004).   
Development of drug resistance is a key element in the failure of 
chemotherapy treatment. Exposure to anticancer drugs may originate the induction 
and expression of gene products that protect the cell, constituting a selective 
survival advantage. It is possible that GSTs serve two individual roles in the 
development of drug resistance via direct detoxification as well as acting as an 
inhibitor of the MAP kinase pathway. Consequently, it is not unexpected that 
elevated levels of GSTs have been described in a substantial number of tumour 
types (Townsend et al., 2003).  
Table 1.4 comprises a list of anticancer compounds to which resistance has 
been connected with high levels of GSTs. Some of these compounds are 
substrates of GSTs and can be directly inactivated through catalytic conjugation to 
GSH during formation of the thioether bond. Numerous anticancer drugs induce 
apoptosis via inactivation of the MAP kinase pathway, particularly via JNK and p38. 
The anticancer drugs that require JNK are also listed in table 1.5. Cisplatin is an 
example of a drug that requires JNK activity for maximal cytotoxicity. Thus, 
inhibition of the JNK signalling pathway leads to a decrease in cisplatin-induced 
apoptosis, while over-expression of c-jun increases the sensitivity of cells towards 
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cisplatin. High levels of GST expression, especially hGSTPi, are related with 
prevention of apoptosis, which is instigated by a number of stimuli. This fact is 
consistent with GSTs acting as inhibitors of the MAP kinase pathway (Townsend et 
al., 2003; Allen et al., 2007).  
Abnormal cellular signalling is also a cancer property, and thus high levels of 
hGSTPi in various tumours may be either a cause or effect of the transformation 
process. The pathology of prostate cancer strongly supports these conclusions. 
Hypermethylation of the hGSTPi regulatory region is the main somatic alteration 
identified in human prostate cancer, which results in loss of hGSTPi expression, 
and is proposed to happen during pathogenesis of the disease. Alteration of 
hGSTP1 expression can be originated through methylation of CpG islands, which 
have not been identified in other GST genes. The island in the 5’-flanking region of 
GSTP1 contains 82 CpG sites. Hypermethylation of the promoter region has been 
reported in practically all human prostatic carcinomas, but not in normal or benign 
tissues (Hayes et al., 2000). Aberrant hypermethylation has been observed in renal 
carcinoma, hepatocellular carcinoma and in one third of primary breast cancers. 
GST expression and/or activity of specific isoforms are lost in some individuals with 
allelic variations (Parl, 2005; Hayes et al., 2000; Zhang et al., 2005).  
The methyl-CpG-binding domain protein, which mediates hypermethylation 
of the GSTPi regulatory region, provides a possible target for restoration of GSTPi 
activity (Townsend et al., 2003). Studies on the influence of GSTP1 on disease 
susceptibility and outcome of therapy might consider the possibility of methylation 
(Hayes et al., 2000). 
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Table 1.5 – Anticancer agents associated with increased levels of GST and 
resistance (modified from Townsend et al., 2003). 
Substrates of GST 
Chlorambucil 
Melphalan 
Nitrogen mustard 
Phosphoramide mustard 
Acrolein 
Hydroxyalkenals 
Ethacrynic acid 
Steroids 
 
Not characterised as substrates 
Antimetabolites* 
Antimicrotubule drugs* 
Topoisomerase I & II inhibitors* 
Bleomycin 
Hepsulfam 
Mitomycin C* 
Adriamycin* 
Cisplatin 
Carboplatin 
*Require JNK activation for cytotoxicity 
 
1.3.3. hGST Pi inhibitors as therapeutic agents  
 
 
 A variety of GST inhibitors were shown to modulate multiple drug resistance 
by sensitizing tumour cells to anticancer drugs (Townsend et al., 2003). Potential 
inhibitors are listed in table 1.6. There is a vast number of both competitive and 
non-competitive inhibitors of GSTs, which have to be taken in serious consideration 
as therapeutic sensitizers to anticancer drugs due to the therapeutic limitations of 
anticancer drugs which include toxicity, carcinogenicity, or unsuitability as a drug for 
human use (Schultz et al., 1997).  
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 The best characterized GST inhibitors are the ethacrynic acid (EA) and the 
peptide analogues of glutathione (Schultz et al., 1997; Reinemer et al., 1991). EA 
inhibits GST Alpha, GST Mu and mainly GST Pi, by binding directly to the 
substrate-binding site of the enzyme, as well as by reducing its cofactor, GSH, via 
conjugation of the Michael addition intermediate to the thiol group of GSH. EA has 
been described to potentiate the cytotoxic effects of chlorambucil in human colon 
carcinoma cell lines and melphalan in human colon tumour xenografts in SCID 
mice. The therapeutic value of EA as a chemosensitizer has also been verified in 
patients. Since the clinical benefit of EA was firstly limited by its diuretic properties 
and severe side effects, and secondly by its lack of isozyme specificity, efforts were 
made to develop inhibitors with more optimal isozyme specificity and clinical 
application (Townsend et al., 2003; Schultz et al., 1997).   
TLK199 is a peptidomimetic glutathione analogue that is a low micromolar 
inhibitor of GST Pi. It acts as a chemosensitizer, and was shown to potentiate the 
toxicity of numerous anticancer agents in different tumour cell lines. In animal 
studies, sensitivity to melphalan was improved in xenograft models with elevated 
GST levels. This analogue has also been shown to be an inhibitor of the multidrug 
resistance-associated protein-1 (MRP-1), reversing the resistance to a variety of 
agents in NIH3T3 cells transfected with MRP-1 (Townsend et al., 2003). 
 
            Table 1.6 – Agents observed to inhibit GST activity (modified from Schultz 
et al., 1997). 
Agent Class of drug 
1. Clofibrate Antihyperlipidemic drug 
2. Ethacrynic acid Diuretic 
3. GSH analogues GST inhibitors 
4. Gossypol Antifertility drug 
5. Indomethacin NSAID 
6. Misonidazole Antifungal drug 
7. Piriprost NSAID 
8. Sulfasalazine Antibiotic 
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1.4 Aims  
 
 
 According to Okcu et al. (2004) no published study has examined the 
differential activity of the hGSTP1 alleles for nitrosourea anticancer drugs which are 
DNA alkylating antineoplastic agents. Carmustine, lomustine, semustine, 
streptozocin and ethylnitrosourea were the nitrosourea drugs used in this project. 
They act non-specifically through directly attacking DNA by crosslinking the guanine 
nucleotide bases which subsequently prevents the DNA strands from separating 
which is required for replication. Due to their lipophilic properties they are 
particularly useful drugs for the treatment of brain tumours as they have the ability 
to cross the blood-brain membrane.  
 When obtained, these data could be used as a pharmacogenetics tool, as 
genotyping of individuals before undergoing chemotherapy could in the near future, 
lead to the prescription of the right drug and optimisation of therapeutic doses on a 
case-by-case basis (Sanchez et al., 2001). 
 Consequently, the aims of this project included: 
 Cloning of the four hGSTP1 coding sequences into a suitable expression 
vector; 
 Over-expression and purification of the four hGSTP1 isoforms; 
 Enzymatic assays of the hGSTP1 enzymes towards nitrosourea anticancer 
drugs; 
 Co-crystallisation of the hGSTP1-D variant with the nitrosourea anticancer 
drugs for structure determination; 
 Transfection of the four hGSTP1 constructs into a suitable human cell line 
and application of the nitrosourea anticancer drugs for measurement of cell 
death.  
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Chapter 2 – Molecular cloning, over-expression and purification of 
the four hGSTP1 enzymes 
 
 
2.1 Introduction 
 
 The development of gene cloning techniques has allowed scientists over the 
years to clone and optimise the over-expression of many proteins and enzymes of 
medical interest. Techniques like the polymerase chain reaction (PCR), restriction 
enzyme reactions and transformation of bacteria with vectors containing genes of 
interest, enable the expression of high amounts of recombinant protein by easily 
grown bacteria such as E. coli. These techniques have been important for the 
biochemical study of proteins and to obtain information about their structure by 
protein crystallography.     
 The human GST class Pi gene has two single nucleotide polymorphisms that 
result in amino acid substitutions in the proteins, giving rise to four different 
genotypes: hGSTP1-A, -B, -C and -D. In order to obtain these four variants, the 
hGSTP1-B cDNA coding sequence was acquired in the form of an Image Clone 
from Open Biosystems (NCBI accession number is BC010915) (figure 2.1) with the 
objective of cloning the GST protein and mutating the gene to generate the other 
three observed variants and to then over-express the corresponding proteins.    
 
 Figure 2.1 – hGSTP1-B cDNA coding sequence inserted into the Image Clone 
from Open Biosystems (NCBI accession number is BC010915.) 
 
 Legend: atg – Initiation codon 
gtc – SNP in amino acid 104  valine instead of alanine 
tga – Stop codon  
 
1 gggggctgga gtttcgccgc cgcagtcttc gccaccatgc cgccctacac cgtggtctat 
61 ttcccagttc gaggccgctg cgcggccctg cgcatgctgc tggcagatca gggccagagc 
121 tggaaggagg aggtggtgac cgtggagacg tggcaggagg gctcactcaa agcctcctgc 
181 ctatacgggc agctccccaa gttccaggac ggagacctca ccctgtacca gtccaatacc 
241 atcctgcgtc acctgggccg cacccttggg ctctatggga aggaccagca ggaggcagcc 
301 ctggtggaca tggtgaatga cggcgtggag gacctccgct gcaaatacgt ctccctcatc 
361 tacaccaact atgaggcggg caaggatgac tatgtgaagg cactgcccgg gcaactgaag 
421 ccttttgaga ccctgctgtc ccagaaccag ggaggcaaga ccttcattgt gggagaccag 
481 atctccttcg ctgactacaa cctgctggac ttgctgctga tccatgaggt cctagcccct 
541 ggctgcctgg atgcgttccc cctgctctca gcatatgtgg ggcgcctcag cgcccggccc 
601 aagctcaagg ccttcctggc ctcccctgag tacgtgaacc tccccatcaa tggcaacggg 
661 aaacagtgag ggttgggggg actctgagcg ggaggcagag tttgccttcc tttctccagg 
721 accaataaaa tttctaagag agttaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 
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 Over-expression of proteins and their subsequent purification are essential 
tools to study and understand protein functionality in both cells and organisms. 
These techniques have been used throughout the last decade to produce large 
quantities of a protein of interest in order to study its function, structure and 
interactions with other proteins. This has been used to assist in the discovery of 
medical treatments, to determine enzymatic mechanisms and in the production of 
new drugs.  
 Recombinant DNA techniques have allowed scientists to not only produce 
large quantities of proteins, but also to produce them in forms which enable their 
easy and subsequent chromatographic purification from complex protein mixtures. 
For example, the addition of a small number of amino acids on the N or C-terminus 
of the protein of interest, commonly called a "tag", has been used as an effective 
purification tool. In this study a histidine tag (His-tag) was used to purify the four 
variants of the human GSTP-1 enzyme. This tag is composed of six histidine amino 
acids, which are added to the N-terminus of the proteins. The His-tag protein has 
binding affinity to the chromatography column containing chelated Ni2
+. Untagged 
proteins do not usually bind to this column and after washing the bound His-tagged 
protein is eluted using a buffer containing imidazole which competes and displaces 
the His-tagged protein from the chelated Ni2
+. 
 Proteins of interest can also be separated and purified from a mixture of 
proteins according to an array of different properties, such as size, charge and 
hydrophobicity.  
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2.2 Materials and Methods  
 
All reagents, unless otherwise stated were obtained from Sigma Aldrich 
(Poole, UK) and were of the highest grade available. Reagents used in the 
molecular biology experiments were obtained from Promega Ltd (Southampton, 
UK). Filtered Purite water of double distilled quality (ddH2O) was used to prepare all 
of the solutions.  
 
2.2.1 Stock solutions 
 
The following stock solutions were filter sterilised using Sartorius ministart 
0.2 μm syringe filters and then stored at –20oC: 
 Ampicillin (100 mg/ml) 
 Kanamycin (30 mg/ml) 
 X-Gal 20 mg/ml in dimethylformamide (stored in an opaque 
container due to light sensitivity) 
 IPTG (1M) 
  
2.2.2 Growth media 
 
2.2.2.1 Luria-Bertani (LB) broth 
 
25 g of LB broth was added to 1 L of ddH2O, and sterilised by autoclaving at 
121oC, 15psi for 20 minutes. Prior to use, the appropriate selective antibiotic was 
added to the media, using a Minisart filter (Sartorius Stedim biotech). 
 
2.2.2.2 LB plates 
 
 Prior to autoclaving, 1% w/v bacteriological agar was added to 1 L of LB 
broth. When the media cooled to approximately 50oC, stock antibiotic was added to 
a final concentration of 100 μg/ml for ampicillin or 30 μg/ml for kanamycin plates 
using a Minisart filter (Sartorius Stedim biotech). The solution was then poured into 
Petri dishes and left to set in a laminar flow hood before storage at 4oC.  
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2.2.3 Glycerol Stocks 
 
In order to preserve the bacterial strains of interest, 200 μl of 40% v/v sterile 
glycerol solution was added to 200 μl aliquots of the overnight cultures and flash 
frozen in liquid nitrogen. Stocks were then stored at -80oC. 
 
 
2.2.4 Plasmid preparation   
 
2.2.4.1 Miniprep 
 
The extraction of plasmids from 10 ml overnight cultures was performed with 
the QiaprepTM miniprep kit (Qiagen Ltd) by following the manufacturer's instructions. 
The extraction is based on the method developed by Birnboim & Doly (1979). 
Bacterial cells were ruptured by an alkaline lysis buffer allowing proteins and cell 
debris to be separated by centrifugation. The cleared lysate in the presence of high 
salt conditions was passed through a spin column containing a silica membrane 
enabling the plasmid DNA to bind to it, and to be purified by several washes. The 
plasmid DNA was finally eluted with ddH2O.    
 
2.2.4.2 Maxiprep 
 
 
The extraction of plasmids from 1 L overnight cultures was performed with 
the GenEluteTM HP Plasmid Maxiprep Kit (Sigma-Aldrich) by following the 
manufacturer's instructions. The kit is based on the alkaline lysis method developed 
by Birnboim & Doly (1979) described previously in section 2.4.1. 
 
 
2.2.5 DNA gel electrophoresis 
 
 The separation of DNA fragments according to their size was performed by 
agarose gel electrophoresis.  
 
2.2.5.1 (X 50) TAE buffer stock solution: 
 
 900 ml ddH2O 
 242 g Tris-base  
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 57.1 ml glacial acetic acid 
 18.6 g EDTA (pH 8.0) 
 
2.2.5.2 Agarose gels 
 
 Agarose gels were run using a Bio-Rad mini-sub cell GT horizontal gel 
apparatus with a Shandon Vokam 500-500 power supply. 0.6 g of electrophoresis 
grade agarose was dissolved in 60 ml of 1 x TAE buffer by heating in a microwave 
on full power for 2 minutes. The mixture was left to cool and 1 μl of concentrated 
ethidium bromide (EtBr) (10 mg/ml) was added. The gel was poured into a 
horizontal gel bed-casting tray containing combs, and left to set at room 
temperature. The combs were removed, and the gel was placed into the 
electrophoresis tank and completely covered with 1 x TAE buffer.   
 
2.2.5.3 Running agarose gels 
 
5 μl of DNA hyperladder 1 (Bioline, UK) (appendix 1) and DNA samples 
mixed with DNA loading buffer 6x concentrate (10 mM Tris-HCl, pH 7.5, 50 mM 
EDTA, 0.25% Bromophenol blue, 0.25% Xylene Cyanol FF+, 10% Ficoll, 0.4% 
Orange G) were loaded into the wells of the gel. Finally electrophoresis was carried 
out at 100 V for approximately 45 minutes and the results visualised under a UV 
transilluminator at 312 nm.  
 
2.2.6 DNA purification 
 
DNA was either purified by gel extraction or by using the SureClean method 
from Bioline (Bioline, UK). 
 
2.2.6.1 Gel extraction 
 
Using a clean scalpel the DNA band of interest was cut out from the agarose 
gel during visualization at 312 nm on a transilluminator and its weight recorded. The 
extraction was performed using a Qiagen gel extraction kit (Qiagen Ltd, Crawley, 
UK) according to the manufacturer's instructions. In the presence of a high salt 
buffer the agarose was dissolved which enabled the DNA to bind to the silica 
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membrane of a spin column. The DNA was purified from agarose and EtBr through 
several washes, and finally eluted with ddH2O.   
  
2.2.6.2 SureClean  
 
SureClean Plus kit (Bioline, UK) provided a column-free method for nucleic 
acid purification, and when used the manufacturer's instructions were followed. This 
method was used to purify or concentrate DNA from PCR reactions or enzymatic 
digestions, and for applications such as cloning and sequencing. The SureClean 
solution removes enzymes, primers/primers-dimers and dNTPs through the 
precipitation of nucleic acids > 100 bp without using organic solvents or spin 
columns. After precipitation, the nucleic acid pellet was washed with 70% ethanol 
and resuspended in the desired volume of ddH2O.    
 
2.2.7 Genomic DNA  
 
 The hGSTP1-B cDNA coding sequence was obtained in the form of an 
Image clone from Open Biosystems and (NCBI accession number: BC010915). 
 A 10 ml universal flask containing LB media and 10 μl of chloramphenicol 
(25μg/ml) was inoculated, and incubated at 37oC, with shaking at 200 rpm 
overnight. From this overnight culture plasmid extractions were performed using a 
QiaprepTM miniprep kit (Qiagen Ltd) as described in section 2.4.1. 
 
2.2.8 PCR reactions 
 
2.2.8.1 Primer design 
 
2.2.8.1.1 Incorporation of restriction sites 
 
To determine which restriction enzymes should be used in the cloning 
experiments, the hGSTP1-B human gene sequence was imported into the online 
program www.restrictionmapper.org to identify the restriction sites present in the 
gene. Restriction sites that were not present in the gene but were in the multiple 
cloning site of the pET-28a vector were suitable. The restriction sites NheI (3’) and 
HindIII (5’) were chosen for incorporation into the primers.   
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2.2.8.1.2 Primers 
 
Based on the gene sequence, forward and reverse primers were designed 
incorporating the restriction sites chosen. The forward primer contains the NheI 
restriction site (gctagc) and the reverse primer contains the HindIII restriction site 
(aagctt). 
 
 Forward primer – 5’  3’  
 
Gene sequence:                 ATG CCG CCC TAC ACC GTG 
 
Primer sequence:   gctagc   ATG CCG CCC TAC ACC GTG 
 
Length = 24 bp       GC content = 66.7%  Tm = 69.6oC  
 
 
 
 Reverse primer – 3’  5’ 
 
 
Gene sequence:                 AGT GAC AAA GGG CAA CGG TAA C 
 
Primer sequence:   aagctt   TCA CTG TTT CCC GTT GCC ATT G 
 
Length = 28 bp       GC content = 46.4%  Tm = 65.1oC  
 
  
 Primers were obtained from MWG as 10 nM lyophilised salt free pellets and 
resuspended in ddH2O to a concentration of 100 pmol/μl. The solution was stored 
at -20oC according to the manufacturer's instructions.   
 
2.2.8.2 Reaction components 
 
The 30 μl PCR reactions contained: 
 
 
 1 μl Deep Vent DNA polymerase 
 5 μl 10x Thermopol buffer (200 mM Tris-HCl, 100 mM (NH4)2SO4, 100 
mM KCl, 20 mM MgSO4, 1% Triton X-100, pH 8.8) 
 2 μl MgSO4 (2 mM) 
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 5 μl dNTPs (1/10 dilution) 
 1 μl of each primer (0.1 nM)  
 1 μl of DNA template  
 15 μl ddH2O 
 
2.2.8.3 PCR program  
 
 In order to determine the optimal annealing temperature to amplify the 
human hGSTP1-B sequence a gradient PCR was performed. The annealing 
temperatures used in the eight different reactions were 59, 60.1, 60.9, 61.8, 62.7, 
64.4, 65.1 and 65.9oC. The PCR program was carried out in a minicycler (M J 
Research, UK) as shown in table 2.1. 
 
 
Table 2.1 – PCR program used for the isolation and amplification of the human 
HGSTP1-Bgene.   
Step Temperature (oC) Time 
 Initial denaturation 94 3 min 
 25 cycles of   
     - Denaturation 94 20 sec 
     - Annealing 59 – 65.9* 30 sec 
     - Extension 72 1 min 
 Final extention 72 7 min 
 Hold 4 N 
* Gradient PCR annealing temperatures: 59, 60.1, 60.9, 61.8, 62.7, 64.4, 65.1 and 
65.9oC. 
 
2.2.8.4 Poly-A tailing 
 
For ligation into a cloning vector (such as pGEM-T), the amplified PCR 
products were single-A-tailed. To the finished PCR reactions, 10 μl of the non-proof 
reading JumpStart RedTaq DNA polymerase was added and the reaction incubated 
at 72oC for 20 minutes. Agarose gel electrophoresis was used to visualise the PCR 
products and to ensure that the amplified DNA fragments were the correct size 
(section 2.5). 
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The poly A-tailed DNA was then purified using the SureClean Plus kit 
(section 2.6.2).  
 
2.2.9 Competent cells manufacture 
 
 The E. coli cell lines NovaBlue (Novagen) and BL21-codonPlus (DE3)-RIPL 
(Stratagene) were made chemically competent using the method described by 
Hanahan et al. (1983). 1 ml of a 10 ml overnight culture was used to inoculate 100 
ml of LB media. This culture was incubated at 37oC and at 150 rpm until mid log 
phase was reached which corresponded to an OD595 of 0.5-0.6. The cells were 
harvested by centrifugation at 6,000 g for 10 minutes at 4oC. The supernatant was 
discarded and 15 ml of ice cold 1x RbCa TXN salts was used to resuspend the cell 
pellet. The cell suspension was incubated on ice for 15 minutes and then 
centrifuged at 4,000 g for 10 minutes at 4oC. The supernatant was discarded and 
the cell pellet carefully resuspended in 4 ml of 1x RbCa TXN salts. The suspension 
of competent cells was incubated at 4oC overnight, after which glycerol stocks were 
made (section 2.3).    
 
2.2.10 Cloning into pGEM-T vector 
 
2.2.10.1 Ligation 
 
 The cloning vector pGEM-T (Promega) (Appendix 2) is a high copy number 
vector which contains single 3´-T overhangs at the insertion site. This avoids re-
circularisation of the plasmid and enables PCR products to bind to its overhangs. 
  
 The following ligation mixture to insert the gene into the pGEM-T vector was 
incubated at 4oC overnight: 
 1 μl pGEM-T vector 
 2 μl poly A-tailed DNA  
 5 μl 2x rapid ligation buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 
10 mM dithiothreitol, 1mM ATP, 25 μg/ml bovine serum albumin 
(BSA)) 
 1 μl T4 DNA ligase  
 1 μl ddH2O  
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The positive control contained 2 μl of control insert supplied with the pGEM-
T system and to the negative control no insert was added.  
 
2.2.10.2 Transformation into E. coli NovaBlue cells 
 
 Transformation of the pGEM-T vector containing the appropriate insert into 
the E. coli NovaBlue cells was performed by heat shock. 2 μl of the ligation reaction 
was added to 50 μl of cells, previously thawed on ice. The mixture was incubated 
on ice for 20 minutes followed by heat shock for precisely 45 seconds at 42oC, and 
then cooled on ice for 5 minutes. 175 μl of pre-warmed LB media (section 2.2.2.1) 
was added and the final mixture incubated at 37oC for 1 hour with shaking at 200 
rpm. The culture was spread onto an LB ampicillin/IPTG/X-Gal plate (X-Gal to a 
final concentration of 30 μg/ml and IPTG to a final concentration of 0.5 mM), and 
incubated overnight at 37oC in a static incubator. 
 After the overnight incubation the plate was checked for blue/white colonies. 
White colonies were streaked onto a LB ampicillin/IPTG/X-Gal plate which was 
incubated overnight at 37oC. The same colonies were also used to inoculate four 10 
ml universals flasks containing LB media and ampicillin, which were incubated at 
37oC overnight at 200 rpm. From these overnight cultures plasmid extractions were 
performed using a QiaprepTM miniprep kit (Qiagen Ltd) (section 2.4.1).  
 
2.2.10.3 Digestions 
 
To check for successful transformants, double digest reactions were 
performed in order to free the insert from the pGEM-T vector. Each reaction 
contained:  
 10 μl of DNA from plasmid miniprep 
 1 μl FastDigest NheI (Fermentas) 
 1 μl FastDigest HindIII (Fermentas) 
 2 μl 10x FastDigest buffer  (Fermentas)  
 6 μl ddH2O  
 
 All reactions were mixed by gentle pipetting and incubated at 37oC for a 
minimum of 15 minutes. 
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2.2.10.4 Sequencing 
 
 Plasmid miniprep samples were sent to Geneservice (London) for dye 
terminator sequencing using the T7 and Sp6 primers which are specific for the 
vector. Sequencing was used to ensure that the gene of interest was successfully 
cloned into the vector without mutations.  
 
2.2.11 Cloning into pET-28a vector 
 
2.2.11.1 Plasmid preparation 
  
The pET-28a vector (Novagen) (appendix 3) is a protein expression vector 
which incorporates a N-terminal poly-histidine tag onto the expressed protein. 
1L flask of LB media containing 30 μg/ml of kanamycin was inoculated with 
BL21(DE3) cells (Stratagene) containing the pET28a vector. The culture was 
incubated overnight at 37oC with shaking at 200 rpm. From this overnight culture, 
plasmid extractions were performed using a GenEluteTM HP Plasmid Maxiprep Kit 
(section 2.4.2). 150 μl of the Maxiprep solution was concentrated using SureClean 
(section 2.6.2) to approximately 750 μg/ml in a final volume of 20 μl.  
 
2.2.11.2 Digestions 
 
In order to linearise and prepare the vector for gene insertion a double digest 
was carried out with the restriction enzymes NheI and HindIII.  
A 25 μl reaction contained: 
 2.5 μl pET-28a vector 
 1.2 μl NheI 
 1.2 μl HindIII 
 3 μl 10x buffer B (50 mM NaCl, 6 mM Tris-HCl, 6 mM MgCl2, 1 mM 
dithiothreitol, pH 7.5) 
 3 μl BSA  
 14.1 μl ddH2O 
 
The reaction was mixed by gentle pipetting and incubated at 37oC for 3 
hours. 
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 The pGEM-T vector was digested to liberate the insert (section 2.2.10.3), 
which was then excised and extracted from an agarose gel (section 2.2.6.1). 
 
2.2.11.3 SAP treatment 
 
 
After the double digest the pET-28a vector was treated with Shrimp Alkaline 
Phosphatase (SAP) to avoid its recircularisation and self-annealing, by removing 
phosphate groups from both 5´-termini. SAP is active on 5´ overhangs, 5´ recessed 
and blunt ends (Sambrook et al., 1989).  
The reaction contained: 
 25 μl restriction digest mixture 
 0.5 μl SAP (Roche Ltd) 
 2.5 μl 10x SAP buffer (0.5M Tris-HCl, 100 mM MgCl2, pH 9.0)  
 
The reaction was mixed by gentle pipetting and incubated at 37oC for 20 
minutes, followed by inactivation of SAP at 65oC for 15 minutes. The digest was 
then run on an agarose gel and the DNA band corresponding to the linear vector 
was excised and extracted using the Qiagen gel extraction kit (section 2.6.1). 
 
2.2.11.4 Ligation 
 
 To ligate the insert into the expression vector pET28a, the following ligation 
mixture was incubated at room temperature overnight, and stored at 4oC before 
transformation: 
 3 μl insert DNA 
 1 μl pET28a vector (50 ng/ml) 
 2 μl DTT 
 2 μl 10x reaction buffer 
 1 μl ATP (10 mM) 
 1 μl T4 DNA ligase 
 5 μl ddH2O   
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2.2.11.5 Transformation 
 
Transformation of the pET-28a vector containing the appropriate insert into 
E. coli NovaBlue singles cells and BL21-codonPlus (DE3)-RIPL cells was 
performed by heat shock. 1 μl of the ligation reaction was added to 50 μl of cells, 
previously thawed on ice. The mixture was incubated on ice for 20 minutes followed 
by heat shock for precisely 30 seconds at 42oC, and then cooled on ice for 2 
minutes. 175 μl of pre-warmed LB media (section 2.2.2.1) was added and the final 
mixture incubated at 37oC for 1 hour at 200 rpm. The culture was then spread onto 
a LB kanamycin plate (section 2.2.1), and incubated overnight at 37oC in a static 
incubator. 
 A few colonies from each plate were then selected and grown overnight in 10 
ml universal flasks containing LB kanamycin media at 37oC and shaken at 200 rpm. 
Plasmid mini-preps (section 2.4.1) and restriction enzyme digestions (section 
2.11.2) were performed to confirm the presence of the 630 bp hGSTP1-B gene. To 
ensure the gene has been cloned without mutations, positive miniprep samples 
were sent for sequencing (section 2.10.4), and the T7 forward and reverse primers 
which are specific for the pET-28a vector were used. 
 
2.2.12 Site-Directed Mutagenesis 
 
Site-directed mutagenesis was performed to alter amino acids 104 and 113. 
Variants A and C were generated from variant B by mutagenesis of codon 104, and 
finally variant D was generated from variant A by mutagenesis of codon 113.  
To perform the desired mutagenesis the QuikChange Lightning® Site-
Directed Mutagenesis Kit (Stratagene) was used and the manufacturer's 
instructions were followed. The method used the supercoiled double-stranded DNA 
(dsDNA) pET-28a vector containing the hGSTP1-B insert and two synthetic 
oligonucleotide primers, both containing the desired mutation. The oligonucleotide 
primers, each complementary to opposite strands of the vector, were extended 
during temperature cycling by PfuUltra high-fidelity DNA polymerase, without primer 
displacement. Extension of the oligonucleotide primers generated a mutated 
plasmid containing staggered nicks. Following temperature cycling, the product was 
treated with DpnI endonuclease (target sequence: 5´-Gm6ATC-3´), which is specific 
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for methylated and hemimethylated DNA. The endonuclease was used to digest the 
parental DNA template and select for mutation-containing synthesized DNA (Nelson 
& McClelland, 1992). This is possible because DNA isolated from almost all E. coli 
strains is dam methylated and therefore susceptible to DpnI digestion.  
 
2.2.12.1 Primer design 
 
Primers for mutagenesis were designed by the online program PrimerX 
(www.bioinformatics.org/primerx). They were designed to be 34 and 37 bp long with 
a melting temperature (Tm) of >78°C. 
 
Mutation of codon 104 (Val  Ile) 
 
 Forward primer – 5’  3’:      CCTCCGCTGCAAATAC ATC 
TCCCTCATCTACACC 
 
 Reverse primer – 3’  5’:      GGTGTAGATGAGGGA GAT 
GTATTTGCAGCGGAG 
    
Mutation of codon 113 (Ala  Val) 
 
 Forward primer – 5’  3’:    CTACACCAACTATGAG GTG 
GGCAAGGATGACTATGT  
 
 
 Reverse primer – 3’  5’:    CACATAGTCATCCTTGCC CAC 
CTCATAGTTGGTGTAG 
 
 
 Primers were obtained from MWG as 10 nM lyophilised salt free pellets and 
resuspended in ddH2O to a concentration of 100 pmol/μl. The solution was stored 
at     -20oC according to the manufacturer's instructions.   
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2.2.12.2 Reaction components 
 
The PCR reactions contained: 
 14 μl pET-28a vector containing the hGSTP1-B gene  
 5 μl 10x reaction buffer  
 1 μl dNTP mix 
 1 μl of each primer (125 ng) 
 1.5 μl Quik Solution Reagent  
 ddH2O to 50 μl 
+ 
  1 μl PfuUltra high-fidelity DNA polymerase  
 
2.2.12.3 PCR program  
 
 The PCR program used for mutagenesis, described in table 2.2, was carried 
out in a minicycler (MJ Research, UK): 
 
Table 2.2 – PCR program used for site-directed mutagenesis of the hGSTP1-B 
gene into the hGSTP1-A, -C and -D genes.   
Step Temperature (oC) Time 
 Initial denaturation 95 2 min 
 18 cycles of:   
         - Denaturation 95 20 sec 
         - Annealing 60 10 sec 
         - Extension 68 2 min 51 sec 
 Final extention 68 5 min 
 Hold 4 n 
 
 
 Post PCR, 2 μl of DpnI restriction enzyme was added to the PCR product. 
The reactions were gently mixed by pipetting, briefly spun down in a microfuge and 
incubated at 37oC for 5 minutes in order to digest the parental supercoiled dsDNA.  
 
   
 
 
64 
2.2.12.4 Transformation 
 
  Using a heat shock protocol the different DpnI-treated DNA plasmids were 
transformed into XL10-GOLD Ultracompetent cells, supplied with the kit. 2 μl of 
XL10-Gold β-mercaptoethanol mix was added to 45 μl of cells, previously thawed 
on ice. The cells were left to incubate on ice for 2 minutes and 2 μl of DpnI-treated 
DNA was added before the mixture was incubated on ice for 30 minutes. The 
transformation reactions were heat shocked for precisely 30 seconds at 42oC, and 
cooled on ice for 2 minutes. 500 μl of pre-warmed LB media (section 2.2.2.1) was 
added and the final mixture incubated at 37oC for 1 hour at 250 rpm. Each culture 
was divided equally and spread onto three LB kanamycin plates (section 2.2.1), and 
incubated overnight at 37oC in a static incubator. 
 Several single colonies from each plate were then selected and grown 
overnight in 10 ml universal flasks containing LB kanamycin media at 37oC and 200 
rpm. Plasmids were extracted using a Qiagen miniprep kit (section 2.2.4.1), and 
sent for sequencing to confirm mutagenesis was successful (section 2.2.10.4).  
 
2.2.13 Protein over-expression  
 
2.2.13.1 Induction of protein over-expression 
 
 To express the four recombinant proteins, 20 μl of glycerol stocks of BL21-
codonPlus (DE3)-RIPL cells, containing the pET-28a vector with the human GSTP1 
genes, were used to inoculate 10 ml LB universal flasks containing 30 μg/ml 
kanamycin and 30 μg/ml chloramphenicol. The cultures were incubated at 37oC 
overnight at 200 rpm. Four 100 ml flasks containing LB and the same antibiotics 
were inoculated with 1 ml of the overnight culture and used in expression studies. 
After expression had been optimised the 10 ml overnight cultures were used to 
inoculate 1 L flasks of LB medium containing antibiotics. 
Expression studies were carried out to determine the optimal conditions to induce 
soluble over-expression of the four proteins. All cultures were incubated at 37oC 
until a set OD595 of 0.6, 0.8, 1.0 and 1.2 was reached, at which point 1 mM of IPTG 
was added to the cultures to induce expression. To determine the best post-
induction growth time cultures were either incubated for four hours or overnight at 
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37oC. The optimal induction conditions were determined and were subsequently 
used in future protein expression experiments. 
 
2.2.13.2 Cell lysis 
 
 After induction, cultures were kept at 4oC overnight and then cells were 
harvested by centrifugation at 13,000 g for 20 min at 4oC. For 1 L cultures the pellet 
was divided into 4 portions and their weight recorded before storage at -20oC until 
needed.  
 
2.2.13.2.1 Bugbuster 
 
 BugBuster protein extraction reagent (Novagen, UK) was only used during 
the expression studies. BugBuster was formulated to gently disrupt the cell wall of 
E. coli cells and consequently free soluble protein. Its composition uses a mixture of 
non-ionic detergents to perforate the cell wall while avoiding denaturing of soluble 
protein. The cell pellet from 1 ml culture was resuspended in 200 μl of BugBuster 
reagent, previously diluted 1/10 in 20 mM sodium phosphate buffer (pH 8.0). To 
digest nucleic acids, 1 μl of Benzonase® nuclease (Novagen) was added to the 
mixture. The cell suspension was incubated for 20 min on a shaking platform at 
room temperature, and the insoluble cell debris separated by centrifugation at 
16,000 g for 20 min at 4oC. Finally the supernatant was transferred to a fresh tube 
and both fractions run and analysed on a SDS-PAGE gel (section 3.2.2). 
 
2.2.13.2.2 Sonication 
 
 Cell pellets were resuspended in 10% w/v of 20 mM sodium phosphate 
buffer (pH 8.0) and, 1 μl of Benzonase® nuclease per ml of buffer was added to the 
cell suspension. The solution was incubated for 20 min on a shaking platform at 
room temperature. The cell suspension was placed on ice and sonication was 
performed using a Soniprep 150 Sonicator (Sanyo) in eight 15 seconds blasts at 10 
microns, with eight 15 seconds breaks in between to avoid overheating. The cell 
extract was finally centrifuged at 13,000 g for 20 minutes at 4oC to pellet the 
insoluble fraction.   
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2.2.13.3 SDS-PAGE gel electrophoresis 
 
 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
widely used method for separating proteins based on their molecular weight, 
described by Laemmli (1970). When SDS detergent is added to a mixture of 
proteins, they lose their secondary, tertiary and quaternary structures, and become 
negatively charged, allowing them to migrate towards the positive electrode. The 
concentrations of the acrylamide and crosslinker (bisacrylamide) in the gel can be 
varied to best suit the separation of proteins of interest according to their size. In 
this project all gels were prepared with 6% stacking and 12.5% separating gels, 
which were then run on a Bio-Rad mini-protean-tetra cell (Bio-Rad Laboratories 
Ltd). 
 
2.2.13.3.1 Stock solutions and buffers 
 
SDS-PAGE loading buffer: 
 100 mM Tris-HCl, pH 8.0 
 0.2% bromophenol blue (w/v) 
 2% β-mercaptoethanol (v/v) 
 4% SDS (w/v) 
 20% glycerol (v/v) 
 
SDS solution A: 
  30% Acrylamide/bisacrylamide (29:1) 
SDS solution B: 
 1.5 M Tris-HCl, pH 8.6 
 
SDS solution C: 
 0.5 M Tris-HCl, pH 6.8 
 
SDS solution D: 
 10% SDS (w/v) 
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SDS-PAGE running buffer: 
 18 g/L Tris-HCl, pH 8.8 
 6g/L SDS 
 86.4 g/L glycine 
 
SDS-PAGE microwave stain: 
 
 1 g Coomassie brilliant blue (G250) 
 1 L methanol 
 800 ml ddH2O 
 200 ml glacial acetic acid 
 
2.2.13.3.2 Preparation of SDS-PAGE gels 
 
 SDS-PAGE gels were comprised of a layer of stacking gel and another of 
separating gel.  
 
Stacking gel (6.0%): 
 2 ml SDS solution A 
 2.5 ml SDS solution C 
 1 ml SDS solution D 
 4.5 ml ddH2O 
 
Separating gel (12.5%): 
 4.2 ml SDS solution A 
 2.5 ml SDS solution B 
 1 ml SDS solution D 
 2.3 ml ddH2O 
 
 The apparatus to cast the gel was assembled according to the 
manufacturer's instructions. To initiate polymerisation of the gels, 100 µl of APS 
(10% w/v) and 10 µl of TEMED were added to the mixtures, and the gel formed in 
between two glass plates, with 1 mm integrated spacers. The separating gel was 
poured up to 2/3rds of the depth of the plates and to prevent it from drying out, the 
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top was filled with water. After the gel was set, the water was poured out and the 
top of the gel dried with blotting paper. The water was poured out and the top of the 
gel which was then dried with blotting paper. The stacking gel was prepared and 
added to the top of the separating gel. Gels were stored in the fridge until needed or 
used immediately.  
 
 2.2.13.3.3 Sample preparation 
 
 Equal volumes of protein sample and SDS-PAGE loading buffer (section 
3.2.2.1) were mixed together, and incubated at 100oC for 10 min to ensure the 
protein was denatured before it was loaded into the wells. 
 
2.2.13.3.4 SDS-PAGE gel running  
 
 After polymerisation, gels were placed into the electrophoresis tank which 
was filled with 1 x SDS-PAGE running buffer (section 3.2.2.1). 20 µl of different 
protein samples and in one well 10 µl of the Bio-Rad precision plus ladder (for 
accurate molecular weight measurement) (appendix 4) were loaded into the wells 
with a 50 µl Hamilton syringe. Finally, the gel was run at 200 V for 45 to 55 minutes. 
 
2.2.13.3.5 SDS-PAGE gel staining 
 
 The SDS-PAGE gel was removed from the cast and placed into a plastic 
container. The SDS-PAGE microwave stain was added until the gel was 
submerged and this was ‘microwaved’ for 3 minutes on full power. The stain was 
removed and the gel rinsed with water. The container was filled with water and 
‘microwaved’ for a further 20 min on full power. Finally, the hot water was discarded 
and the gel placed in fresh water for further visualisation using a light box. 
 
2.2.13.4 Protein purification 
 
 Protein mixtures originated from the cell extracts (section 3.2.1.2.2) were 
filtered using Sartorius ministart 0.2 μm syringe filters (Sartorius Stedim Biotech, 
Germany) and purification buffers were vacuum filtered using 0.2 µm membrane 
filters (Whatman) and stored at 4oC. Purifications were performed at 4oC using an 
AKTA system (GE Healthcare). All columns when not in use were stored at 4oC. 
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2.2.13.4.1 Protein purification buffers 
 
Nickel affinity (NA) chromatography:  
 Buffer A - 20 mM sodium phosphate, pH 8.0  
 Buffer B - 20 mM sodium phosphate, 500 mM Imidazole, pH 8.0 
 
Gel filtration (GF) chromatography: 
 Buffer C - 50 mM sodium phosphate, 150 mM NaCl, 1 mM DTT, 
pH 7.0 
 
2.2.13.4.2 Nickel affinity chromatography 
 
 A 10 ml or 50 ml nickel affinity chromatography column (GE Healthcare), 
packed with HIS-SelectTM Nickel Affinity Gel, was equilibrated with 3 column 
volumes of buffer A prior to loading the protein mixture into the column using a 
superloop (GE Healthcare). Proteins with no affinity to the Nickel were washed off 
with 3 column volumes of buffer A, followed by a 3 column volume gradient to 100% 
of buffer B, and 1 column volume of buffer B to elute all bound protein. 5 ml 
fractions were collected throughout purification and protein detected by absorbance 
at 280 nm. Fractions showing absorbance peaks were analysed by SDS-PAGE to 
identify those containing the protein of interest. These fractions were pooled 
together and concentrated to approximately 1 ml (section 3.2.5).  
 
2.2.13.4.3 Gel filtration chromatography 
 
 The concentrated 1 ml protein sample was injected into a Superdex75 or 200 
gel filtration column (GE Healthcare), which was pre-equilibrated with 1 column 
volume of buffer C.  The protein of interest was eluted from the column with 1 
column volume of the same buffer. 1 ml fractions were collected over the entire 
elution volume and protein detected by absorbance at 280 nm. Fractions showing 
absorbance peaks were analysed by SDS-PAGE to identify those containing the 
protein of interest, which were pooled together for protein quantification by 
measuring the absorbance at 280 nm. 
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 2.2.13.5 Protein quantification 
 
 A simple method to determine the concentration of a purified protein in 
solution is to measure the absorbance at 280 nm and then use the Beer-Lambert 
law, where the absorbance is a linear function of the concentration:  
 
A = Ɛ l C  (1) 
 
 A - Absorbance 
 Ɛ - Extinction coefficient (ƐGSTP1 = 29130 M
-1cm-1) 
 l - Path length  
 C - Concentration 
 
 Absorbance was measured using either a Shimadzu UV-VIS 2100 or a 
Biotech Photometer UV 1101 spectrophotometers with a quartz cuvette of 1cm path 
length. 200µl of both protein sample and buffer, for a blank reading, were used. 
One absorbance unit corresponds to 1.247 g/L of GSTP1 protein.  
 
2.2.13.6 Concentration of protein 
 
 Protein was concentrated using either Vivaspin 6 or 20 concentrators 
(Sartorius Stedim Biotech, Germany), which are disposable ultrafiltration devices 
with a 10 kDa cut off polyethersulfone membrane. Protein concentration was 
performed by centrifugation at 4,000 g in the cold room until the desired volume 
was achieved. 
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2.3 Results and Discussion  
 
2.3.1 Cloning of hGSTP1-B 
 
 In order to achieve protein over-expression the cloning stategy involved TA 
cloning of the PCR products into the pGEM-T cloning vector and subsequent 
cloning into the pET-28a expression vector. 
The hGSTP1-B cDNA coding sequence obtained in the form of an image 
clone was used as a template for gradient PCR. The PCR products were run on a 
1% agarose gel (figure 2.2). This showed that all eight annealing temperatures in 
the gradient PCR, varying from 59.0 to 65.9oC, successfully resulted in a PCR 
product of approximately 630 bp corresponding to that of the hGSTP1-B coding 
sequence (633bp). 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 – 1% agarose gel of the gradient PCR products. Lane 1 is the DNA 
marker Hyperladder I (Bioline). Lanes 2 – 9 contain the PCR products from each of 
the 8 annealing temperatures (59, 60.1, 60.9, 61.8, 62.7, 64.4, 65.1 and 65.9oC 
respectively) used in the gradient PCR. The DNA migrated to a position equivalent 
to 630 bp corresponding to the hGSTP1-B coding sequence.    
 
The optimal annealing temperature was then set at 65.5oC as illustrated on 
figure 2.3, and the indentity of the PCR product confirmed by sequencing.  
 
 
1      2  3  4  5  6  7  8  9  
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Figure 2.3 – 1% agarose gel of PCR products. Lane 1 is the DNA marker 
Hyperladder I (Bioline). Lanes 2 and 3 contain the PCR products of a reaction 
performed with the annealing temperature of 65.5oC. The DNA migrated to a 
position equivalent to 630 bp corresponding to the hGSTP1-B coding sequence. 
 
 After the PCR, the product was treated with Taq DNA polymerase, which 
added a single 3’ poly-A overhang to the amplified sequence due to its terminal 
transferase activity. The hGSTP1-B gene was then purified and ligated into the 
cloning vector pGEM-T, which was already linearised by the manufacturer and has 
a single poly-T 3’ overhang allowing easy ligation of poly-A tailed inserts.  
 The pGEM-T vector possesses ampicillin resistance genes, meaning that 
only cells containing the plasmid will grow on LB plates with ampicillin. In addition to 
this, the pGEM-T vector also possesses the β-galactosidase gene, which allows the 
cells to metabolise X-Gal, resulting in blue coloured colonies. If an insert has been 
incorporated into the vector the β-galactosidase gene will be disrupted and 
consequently the X-Gal will not be metabolised, producing white colonies. Positive 
colonies from the pGEM-T ligation were selected through antibiotic resistance and 
blue/white selection, where about 60% of the colonies were white. Several white 
colonies were selected and a double restriction digestion, with NheI and HindIII, 
used to confirm the presence of the inserts (figure 2.4).   
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Figure 2.4 – 1% agarose gel of a double restriction digestion of pGEM-T and insert 
with NheI and HindIII. Lane 1 is the DNA marker Hyperladder I (Bioline). Lanes 2 to 
5 contain the double restriction digestion products.  
 
 Lanes 3 and 5 in figure 2.4 showed that a fragment of approximately 630 bp, 
was released from the vector (3000 bp). This indicated that the insert was probably 
cloned into the pGEM-T vector. In order to confirm this, the plasmids used in lanes 
3 and 5 were sequenced. Using the program BLAST, the sequencing results were 
compared with the hGSTP1-B gene, which allowed confirmation that the correct 
sequence had been isolated with no mutations.  
  The hGSTP1-B gene was ligated into pET-28a vector to allow a tightly 
controlled, high level of protein expression under the control of the inducer IPTG. 
The pGEM-T vector was double digested with NheI and HindIII in order to release 
the hGSTP1-B gene. 
 The pET-28a vector was linearised with the same restriction enzymes and 
SAP treated to avoid recircularisation. The gene was ligated into the pET-28a 
vector through their compatible overhangs. Colonies from both BL21-CodonPlus 
(DE3)-RIPL and NovaBlue cells transformation plates were selected and single 
digests performed to confirm the presence of the hGSTP1-B gene. NovaBlue cells 
were used to store the pET-28a vector containing the hGSTP1-B sequence and 
BL21-CodonPlus (DE3)-RIPL cells used for hGSTP1-B over-expression. Figure 2.5 
shows an agarose gel of single digests with HindIII of the extracted pET-28a vector. 
The comparison of the DNA band resulting from the single digest of pET-28a vector 
(5369bp) without an insert to the DNA bands resulting from the single digests of the 
15 samples (≈6000bp), indicates that the inserts were cloned into the pET-28a 
vector. Plasmids from the positive digestions were sequenced to confirm that the 
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gene was intact and without mutations. The extra two bands on lanes 4 to 9 are the 
result of restriction digests of HindIII on the BL21-CodonPlus (DE3)-RIPL cells 
plasmids.  
 
 
 
Figure 2.5 – 1% agarose gel of single restriction digestions of the pET-28a vector 
with HindIII. lanes 1 and 19 are the DNA marker, lane 2 is uncut pET-28a vector, 
lane 3 is pET-28a vector cut with HindIII, lanes 4 to 9 represent single digests of 
pET-28a vector with HindIII, extracted from several BL21-CodonPlus (DE3)-RIPL 
cells colonies, and lanes 10 to 18 represent single digests of pET-28a vector with 
HindIII, extracted from several NovaBlue cells colonies.  
 
2.3.2 - Site Directed Mutagenesis of hGSTP1-B to obtain hGSTP1-A, -C and -D  
 
 Site directed mutagenesis was used in this project as a technique to 
construct the four different variants of hGSTP1. The over-expressed proteins could 
then be studied to understand any differences in their protein structure and activity 
towards a variety of nitrosourea anticancer drugs. Using this approach, variants A 
and C were obtained from variant B, and subsequently variant D from variant A. 
hGSTP1-A and -D contain an isoleucine, and hGSTP1-B and -C a valine at codon 
104; whereas at codon 113 hGSTP1-A and -B contain an alanine, and hGSTP1-C 
and -D contain a valine.     
 As with variant B, the other three variants were then transformed into 
NovaBlues singles cells for plasmid storage and E. coli BL21-CodonPlus (DE3)-
RIPL competent cells for potential protein over-expression.    
 
 
 
 
 1  2   3   4  5  6 7 8  9 10 11 12 1314 15 16 
1718 19 
6000bp 
 
5000bp 
 
 
 
75 
2.3.3 Expression studies on hGSTP1 enzymes 
 
 To over-express the four hGSTP1 proteins, the pET-28a vector containing 
the four different inserts was transformed into E. coli BL21-CodonPlus (DE3)-RIPL 
competent cells. These cells were chosen because they constitute an all-purpose 
E. coli strain ideal for performing high-level protein expression and easy induction in 
T7 expression systems. They also contain extra copies of the argU, ileY, and leuW 
as well as the proL tRNA genes. As this cell line efficiently over-expressed the four 
variants of hGSTP1 protein, no other expression cell lines were tested and used for 
this purpose.   
 Different induction conditions were studied. These included varying the 
OD595 at which the cells were induced (0.6, 0.8, 1.0 and 1.2) and the post-induction 
incubation time of the cultures (4 hours and overnight). SDS-PAGE gels revealed 
that the optimal conditions to obtain high levels of hGSTP1 proteins were achieved 
when the cultures were induced with 1 mM IPTG at an OD595 of 1.2 and left to 
incubate for 4 hours at 37oC.  
 Figure 2.6 shows the over-expression of soluble hGSTP1 proteins, which 
were extracted from the cells with the BugBuster reagent. All four over-expressed 
proteins appear to have a molecular weight of approximately 23 kDa which is 
consistent with the size of each hGSTP1 protein monomer. 
 
 
                               
Figure 2.6 – SDS-PAGE electrophoresis gel showing soluble protein over-
expressed in E. coli BL21-CodonPlus (DE3)-RIPL. Lanes a1, b1 and c1 are the 
protein ladder, lanes a2, b2, c2 and c4 represent the pre-induction proteins 
expressed by the strains containing the hGSTP1-A, B, C and D genes, respectively. 
Lanes a3, b3, c3 and c5 represent the post-induction proteins expressed by the 
strains containing the hGSTP1-A, B, C and D genes, respectively. 
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2.3.4 Purification of hGSTP1 enzymes 
 
2.3.4.1 Nickel affinity chromatography 
 
 Conventionally, most researchers use glutathione affinity chromatography to 
purify GST enzymes or GST fusion proteins (Simons & Vander Jagt, 1977; Smith & 
Johnson, 1988; Chen et al., 1999; Ralat & Colman, 2004). This technique allows 
purification of GST tagged proteins by using glutathione immobilized to a matrix 
such as Sepharose. When injected into the column, GST proteins bind to the 
ligand, and impurities are removed by washing with resuspension buffer. Proteins 
can then be eluted using reduced glutathione. However, GST mutants may have 
their glutathione binding affinity affected by the mutations leading to different 
purification yields (Ali-Osman et al., 1996; Chen et al., 1999); and glutathione used 
as an eluting agent can covalently modify superficial cysteine residues through S-
thiolation or thiol-disulfide exchange, which could have an effect on enzyme activity 
or stability. For these reasons, nickel affinity chromatography constitutes a more 
efficient chromatographic method to purify this family of enzymes using a His-tag 
(Chen et al., 1999). Nickel affinity chromatography also avoids the purification of 
GSTs expressed naturally by E. coli.  
  A 10 ml nickel affinity column was run as previously described in section 
3.2.3.2 to purify hGSTP1-A protein and the resulting absorbance trace is seen in 
figure 2.7, where fractions B4 to B10 were found to contain the desired protein. This 
was confirmed by running an SDS-PAGE electrophoresis gel (figure 2.8) where 
bands of approximately 23 kDa are visible. The hGSTP1-A containing fractions 
were concentrated to approximately 1 ml for further purification by gel filtration 
chromatography. Purification of the other three hGSTP1 variants produced similar 
traces and electrophoresis gels.    
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Figure 2.7 – Elution profile of hGSTP1-A protein from a 10 ml nickel affinity column. 
The A280 trace is seen in blue, the concentration of buffer B in green and fractions 
containing hGSTP1-A marked by the black bar. 
 
 
 
Figure 2.8 – SDS-PAGE electrophoresis gel of HGSTP1-A protein from a 10 ml 
nickel affinity column. Lane 1 is the protein marker, and lanes 2 to 8 represent the 
elution fractions from B4 to B10.   
  
2.3.4.2 Gel filtration chromatography 
 
 Gel filtration chromatography was used as the final purification step for the 
four hGSTP1 proteins. This chromatographic method separates proteins based on 
their size, ensuring homogeneity of the sample and the proteins quaternary 
structure. It is based on the principle that larger proteins cannot diffuse into the 
pores of the resin and pass through the fluid volume of the column faster than 
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smaller proteins, which allows bigger proteins to be eluted first and smaller ones 
last.  
 Concentrated protein from nickel affinity chromatography was applied to the 
equilibrated gel filtration column and run as previously described in section 3.2.3.3. 
As the hGSTP1 protein in solution constitutes a dimer of approximately 46 kDa, 
they can be purified by both Superdex 75 (molecular weight range of 3 – 50 kDa) 
and Superdex 200 (molecular weight range of 12.4 – 2000 kDa) gel filtration 
columns. The elution profile of the hGSTP1-D protein from a Superdex 75 column is 
seen in figure 2.9, and fractions C10 to D9 were found to contain this protein. These 
fractions were analysed by SDS-PAGE (figure 2.10). Gel filtration chromatography 
was a good thecnique to separate possible hGSTP monomers that did not dimerise. 
The 23 KDa monomers would have eluted later on in the chromatographic run as 
they would have taken longer to be removed from the pores of the resin due to their 
smaller size in comparison to the dimers. Purification of the other three hGSTP1 
variants produced similar traces and electrophoresis gels.      
 
 
 
 
Figure 2.9 – Elution profile of hGSTP1-D from the Superdex75 gel filtration column. 
The A280 trace is seen in blue and fractions containing hGSTP1-D protein marked 
by the black bar. 
 
 
 
46 KDa 
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Figure 3.5 – SDS-PAGE electrophoresis gel for the elution of hGSTP1-D from the 
Superdex 75 gel filtration column. Lanes 10 and 17 are the protein marker, and 
lanes 1 to 9 and 11 to 16 represent the elution fractions from C10 to D9.   
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2.4 Summary  
 
 The hGSTP1-B cDNA coding sequence was amplified by polymerase chain 
reaction, and inserted into the pGEM-T cloning vector with restriction sites 
incorporated for further subcloning into the pET-28a expression vector. Finally it 
was then possible to create the other three variants (hGSTP1-A, -C and -D) by site 
directed mutagenesis.     
 Protein expression studies were carried out with E. coli BL21-CodonPlus 
(DE3)-RIPL competent cells after cloning the four hGSTP1 genes into the pET-28a 
vector. The best conditions to over-express these proteins were found to be 
induction at an OD595 of 1.2 with 1mM IPTG and a further 4 hours of incubation at 
37oC. 
 All four proteins were successfully purified through two purification steps. 
The first step involved nickel affinity chromatography which was possible due to the 
incorporation of a His-tag on the N-terminus of the proteins. Gel filtration 
chromatography was the second purification step and it was used to ensure 
homogeneity of the recombinant protein samples.  
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Chapter 3 - Enzymatic studies on the four hGSTP1 isozymes 
 
3.1 Introduction 
  
 Enzymatic assays are designed, developed and carried out in order to study 
enzymatic activity and kinetics, and to understand enzyme functionality. 
Spectrophotometry, fluorometry, and chromatography are examples of techniques 
used in enzymatic studies. Substrate concentration, pH, temperature and salt 
concentration are factors to be controlled and studied, which can affect the 
enzymatic activity during the assay.   
  As mentioned in the introduction, glutathione S-transferases (GST) are a 
family of enzymes involved in catalysing the addition of the tripeptide glutathione 
(GSH) to a wide range of exogenous and endogenous compounds (Ralat & 
Colman, 2004; Parl, 2005; Frova, 2006).  
 Many studies have been carried out on hGSTP1 enzymes as their over-
expression appears to be heavily connected and related to cancer. Their 
involvement in several inflammatory diseases and Parkinson's disease has also 
been identified. The human GSTP1 enzymes contain 210 amino acids, including 
the initiating methionine, have a molecular weight of approximately 23.3 kDa and an 
isoelectric point of 5.5.   
 This study is focused on the relationship of the four hGSTP1 isozymes and 
nitrosourea chemotherapeutic drugs carmustine, lomustine, semustine, streptozocin 
and ethylnitrosourea which are DNA alkylating antineoplastic agents.  
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3.2 Materials and Methods 
 
3.2.1 Activity assays with hGSTP1 enzymes 
 
 Purification of the four recombinant hGSTP1 isoforms by nickel affinity 
chromatography and gel filtration chromatography (section 2.2.13.4) was followed 
by 5 washes with assay buffer D (100 mM potassium phosphate, pH 6.5). After the 
fifth wash proteins were concentrated to approximately 1.25 mg/ml.  
 The spectrophotometric GST activity assay was based on the method 
developed by Habig et al. (1974). It measures a direct change in the absorbance of 
the substrate 1-chloro-2,4-dinitrobenzene (CDNB) when it is conjugated with 
reduced L-glutathione (GSH). The GS-DNB conjugate absorbs at 340 nm (Habig et 
al., 1974; Habib & Jakoby, 1981). The assays were conducted in triplicate and 
performed using a Spectra MR™(Dynex, USA) plate reader and 96-well plates 
(Greiner Bio-One, Germany). Each reaction well contained 199 µl of master-mix 
and 1 µl of hGSTP1 enzyme. The assay blanks contained 200 µl of master-mix and 
readings were taken every minute for 25 minutes. 
 
 10 ml of master-mix consisted of: 
 9.87 ml of buffer D 
 100 µl of 200 mM GSH in water 
 30 µl of 200 mM CDNB in 95% ethanol 
 
 GST specific activity was calculated with the following equation: 
 
(ΔA340)/min x V (ml) x dil  = μmol/ml/min            (2) 
                                    Ɛ mM x Venz (ml) 
                           
 
ΔA340/min - Change in absorbance 
Ɛ mM (mM
-1cm-1) - Extinction coefficient for the CDNB conjugate at 340 nm (5.3 mM-
1 for a 96 well plate) 
dil - Dilution factor of the original sample 
V - Reaction volume 
Venz - Volume of enzyme sample tested 
The result was then converted into μm/mg/min. 
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3.2.2 Inhibition assays with hGSTP1 enzymes  
 
 Inhibition of the activity assays was carried out with the nitrosourea drugs 
carmustine, lomustine, semustine, streptozocin and ethylnitrosourea, and 
conducted for each GSTP1 variant (figure 3.1). These assays were performed to 
investigate the difference in product formation when compared to the activity 
assays at 340 nm. Streptozocin was diluted in water and all other drugs in dimethyl 
sulphoxide (DMSO). 
       
 
      
 
 
 
Figure 3.1- Structure of the five nitrosourea anticancer drugs used in this study: a) 
carmustine, b) lomustine, c) semustine, d) streptozocin and e) ethylnitrosourea.  
   
a) b) 
c) 
d) 
e) 
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 Each reaction well contained the relevant drug at a final concentration of 13 
mM, 195.5 µl of master-mix (193.75 µl for semustine) and 1 µl of GSTP1 enzyme. 
Each blank contained drug at a final concentration of 13 mM and 196.5 µl of 
master-mix (194.75 µl for semustine). Readings were taken every minute for 25 
minutes.  
 10 ml of master-mix consisted of: 
 9.87 ml of buffer D 
 100 µl of 200 mM GSH in water 
 30 µl of 200 mM CDNB in 95% ethanol 
 
3.2.2.1 Statistical analysis  
 
 The differences between control reactions and inhibition assays were 
analysed by the standard deviation bars and the p-value. The p value was 
produced by the Mann-Whitney-U test (SPSS, version 19).  
 
3.2.3 Wavelength scans 
 
 Wavelength scans of the nitrosourea drugs dissolved in 95% ethanol and 
enzymatic reactions containing the drugs were performed with the objective of 
assaying the GSTP1 proteins for glutathione conjugation activity towards the 
nitrosourea compounds using high performance liquid chromatography (HPLC) 
assays. The drugs were dissolved in 95% ethanol to the final concentrations of 0.5, 
1 and 2 µM and the enzymatic reactions made up as in the inhibitions assays but 
without the CDNB. The wavelength scans were then performed on a 
spectrophotometer.  
 Test reactions with the drugs and enzymes were measured at 250 nm using 
a quartz cuvette.  
 
3.2.4 Mass spectrometry 
 
 Purified hGSTP1-A enzyme was washed 5 times with buffer E (10 mM 
sodium phosphate, 140 mM sodium chloride, pH 7.0) and then concentrated to 
approximately 1.25 mg/ml. Prior to the enzymatic reaction with the nirosourea 
drugs, HGSTP1-A was assayed for activity as in section 4.2.1. The reactions were 
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carried out with the drugs carmustine, lomustine, semustine, streptozocin and 
ethylnitrosourea. The anticancer drug chlorambucil, a nitrogen mustard compound 
and a known substrate for hGSTP1 was used as a positive control.  
  
 Each 1 ml reaction contained (final concentrations): 
 50 µM HGSTP1-A enzyme 
 2 µM drug 
 5 mM GSH  
 buffer E up to 1 ml  
 
  Each 1 ml blank reaction contained (final concentrations): 
 2 µM drug 
 5 mM GSH  
 buffer E up to 1 ml  
 
 The reactions were carried out at 37oC with light shaking for 60 minutes and 
then terminated with 1 ml of 10% (v/v) perchloric acid. A Q-TOF 6520 (Agilent) 
coupled to a HPLC-Chip 1200 interface mass spectrometry system was used to 
analyse the possible reaction products (appendix 5). The samples were loaded onto 
a micro C18 reverse phase analytical column (75µm x 150mm, Agilent Protein 
Identification Chip) and eluted over 12 min using a methanol/water gradient with 
0.1% formic acid solution. The extracted ion chromatograms (EIC) were obtained 
from the monoisotopic masses of the anticancer drugs and possible products, in 
order to determine their presence in the control and reaction samples. The EIC 
were obtained from the monoisotopic masses of the anticancer drugs and possible 
products, in order to determine their presence in control and reaction samples.  
  
 A second experiment using an Agilent Triple Quadrupole (QQQ) mass 
spectrometer online with a 1200 series Rapid Resolution HPLC (Agilent) was used 
to double check the results of the above method (appendix 5). Fresh samples were 
prepared as above and run from 5% acetonitrile (containing 0.1% formic acid) to 
95% acetonitrile (containing 0.1% formic acid) over 12 minutes. The samples were 
loaded onto a Zorbax Eclipse Plus C18 reverse phase analytical column (2.1 x 150 
mm, 3.5 µm, Agilent Technologies, Palo Alto, USA) and its temperature was 
maintained at 35oC for the duration of the assay. 
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3.2.5 Denitrosation assays of hGSTP1 enzymes  
 
 Possible denitrosation of the nitrosourea compounds by the hGSTP1 variant 
proteins was assayed by measuring the amount of nitrite formed. 
 The denitrosation assay was based and adapted on the method described 
by Talcott and Levin (1983). Each hGSTP1 was assayed with each nitrosourea 
drug, and each set of assays was divided into 5 reactions for 0, 5, 10, 20 and 30 
minutes of incubation with the drug. The reactions contained a total volume of 750 
µl and were started by adding 2 mM of the drug (final concentration) to a master 
mix comprised of: 
 5 mM of reduced glutathione (final concentration)  
 300 µg/ml of hGSTP1 (final concentration) in buffer C  
 Buffer F (100 mM sodium phosphate buffer, pH 7.4) 
 
 The reactions were incubated at 37oC with light shaking and stopped after 
the incubation time by adding 750 µl of chloroform. The reactions were vortexed to 
remove the intact drug and denatured enzyme. The tubes were centrifuged at 
13000 g for 8 minutes and the aqueous phase removed, which was followed by the 
addition of 750 µl of chloroform. The mixture was vortexed and centrifuged again at 
13000 g for 8 minutes to remove any traces of drug. The aqueous phase was 
removed and added to a tube containing 400 µl of 50 mM sulfanilamide and 0.5 mM 
N-(1-napthyl)ethylenediamine dihydrochloride dissolved in 3 M HCl. Finally the 
mixtures were vortexed and incubated for 20 minutes at 55oC with light shaking. 
After the samples had cooled to room temperature they were measured at 540 nm 
on a Spectra MR™(Dynex, USA) plate reader. Blank reactions and a nitrite 
standard curve without the enzymes were also performed. The standard curve was 
generated by adding increasing amounts of sodium nitrite (0 - 40 µM) to the above 
master mix.   
  
 3.2.6 Thermofluor shift assays on hGSTP1 enzymes 
 
 Pantoliano et al., (2001) developed the thermofluor shift assay or also called 
fluorescence-based thermal stability assay as a cross-target drug discovery 
method, allowing a fast screening of possible ligands that may increase protein 
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stability on binding. These ligands can be substrates, co-factors, metal ions, 
inhibitors, other proteins and also man-made analogues of natural ligands.   
 The assay measures the changes in protein thermal stability produced by 
ligand binding when compared to protein in the absence of ligand. The melting 
temperature (Tm) constitutes the midpoint of the protein unfolding transition. The 
Tm will most likely increase when a ligand binds to the protein, and the consequent 
temperature shift (ΔTm) is the direct result of the ligand concentration and its affinity 
to bind to the protein (Pantoliano et al., 2001).  
 Folded and unfolded proteins can be differentiated when in contact with a 
hydrophobic fluorescent dye. The dye quenches when in aqueous solution, 
however as the assay temperature increases and the protein unfolds, the dye binds 
to the exposed protein hydrophobic interior leading to a rapid and increasing 
fluorescence emission (Ericsson et al., 2006).  
 All four hGSTP1 enzymes were purified and concentrated to approximately 
1.25 mg/ml in buffer C and activity assays were performed prior to the thermal shift 
assays with the same 200 mM reduced L-glutathione stock (section 2.2.13.4). 
Nitrosourea drugs were carmustine, lomustine, semustine, streptozocin and 
ethylnitrosourea. Chlorambucil was also studied.  
 
 3.2.6.1 Assays with nitrosourea drugs 
 
 Each assay reaction contained: 
 5 µl buffer F (25 mM Potassium phosphate buffer, pH 7.8) 
 3 µl hGSTP1 enzyme (A, B, C or D) 
 10 µl 200 µM nitrosourea drug (final concentration) 
 
  Each assay blank contained: 
 5 µl buffer F  
 3 µl hGSTP1 enzyme (A, B, C or D) 
 10 µl ddH2O 
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3.2.6.2 Assays with glutathione and nitrosourea drugs 
 
 Each assay reaction contained: 
 5 µl buffer F 
 2 µl hGSTP1 enzyme (A, B, C or D) 
 1 µl 500 µM GSH (final concentration) 
 10 µl 500 µM nitrosourea drug (final concentration) 
 
  Each assay blank contained: 
 5 µl buffer F  
 2 µl hGSTP1 enzyme (A, B, C or D) 
 1 µl 500 µM GSH (final concentration) 
 10 µl ddH2O 
 
 Control reactions were carried out with DMSO. 
 
3.2.6.4 Assays with MES buffer 
 
 Assays with MES buffer were performed by varying its concentration (25 
mM, 100 mM and 500 mM) and pH (5.5 to 6.7), and also by varying the addition of 
glutathione to the reaction mixtures.  
 
 Each assay reaction contained: 
 5 µl MES buffer   
 2 µl hGSTP1-D enzyme 
 11 µl ddH2O 
 
 Control reactions were performed as above, although buffer E replaced the 
MES buffer. 
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3.2.6.5 Assays with a range of buffers 
  
 Each assay contained: 
 5 µl buffer   
 2 µl hGSTP1-D enzyme 
 11 µl ddH2O 
 
 The buffers studied were as follows: 
1 - ddH2O (control) 
2 - 100 mM Bis-Tris-HCl, pH 6, 150 mM NaCl 
3 - 100 mM MES-NaOH, pH 6, 150 mM NaCl 
4 - 100 mM Imidazole-HCl, pH 7, 150 mM NaCl 
5 - 100 mM PIPES-NaOH, pH 7, 150 mM NaCl  
6 - 100 mM MOPS-NaOH, pH 7.2, 150 mM NaCl  
7 - 100 mM HEPES-NaOH, pH 7.5, 150 mM NaCl 
8 - 100 mM Bicine-NaOH, pH 8.3, 150 mM NaCl 
9 - 100 mM Glycine-NaOH, pH 9, 150 mM NaCl 
10 - 100 mM Boric acid-NaOH, pH 9, 150 mM NaCl 
11 - 100 mM CHES-NaOH, pH 9.5, 150 mM NaCl 
12 - 100 mM Ethanolamine-HCl, pH 9.5, 150 mM NaCl 
13 - 100 mM CAPS-NaOH, pH 10, 150 mM NaCl 
14 - 25 mM Potassium phosphate buffer, pH 7.8 
 
 The assays were prepared in triplicate and 2 µl of 40 x fluorescent dye 
Sypro® Orange (Invitrogen, USA) solution was added to each assay well. A sticky 
lid was glued to the top of the plates before centrifuging them for a few seconds at 
800 g. The plates were placed into a StepOne™ Real-Time PCR machine (Applied 
Biosystems) and heated from 25oC to 99oC at a rate of 0.74oC/min. The excitation 
and emission wavelengths were 490 nm and 580 nm, respectively. The 
fluorescence measurements were taken and analysed by the software package 
supplied within the PCR machine.   
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3.3 Results and Discussion 
 
 The four hGSTP1 variants were successfully purified by nickel affinity 
chromatography and gel filtration chromatography, and then buffer exchanged into 
the appropriate assay buffer as necessary.  
 
3.3.1 Activity assays of hGSTP1 enzymes 
 
 The activity assays were carried out using the universal GST substrate 
CDNB and the protocol followed the principles described by Habig & Jakoby (1981). 
It is a very convenient method to measure thioether formation as it depends on the 
direct change of absorbance at 340 nm of CDNB when conjugated with glutathione. 
The main disadvantage of this method is that this reaction is also catalysed at a 
finite rate non-enzymatically. However, to minimise the reaction in the absence of 
any of the hGSTP1 variants, the pH of the potassium phosphate buffer (buffer D) 
used in the assay was lowered to 6.5 and the master mix was used within 60 
minutes of its preparation (Habig & Jakoby, 1981). 
 Several trials were performed in order to adjust the assay conditions and 
obtain usable progress curves (figure 3.2). The assays were performed in triplicate 
in 96 well plates with a maximum reaction volume of 200 µl, and the assay 
conditions were set to be 6.25 µg/ml of enzyme, 0.3 mM of CDNB and 2 mM of 
GSH (final concentrations).  
 The specific activity of the enzymes is easily obtained as it is directly 
proportional to the increase in absorption (table 3.1). The initial velocity rates were 
calculated from the linear range of the reactions (figure 3.2) and used in equation 
(2) in order to obtain the specific activities of the four variants. There is a certain 
degree of variation among the isozymes. The hGSTP1-A appeared to be more 
active than the other variants, having a specific activity of 13.88 μmol/mg/min. This 
variant was shown to be 2.12 times more active than hGSTP1-B (6.54 
μmol/mg/min), 2.28 times more active than hGSTP1-C (6.08 μmol/mg/min) and 
1.13 times more active than hGSTP1-D (12.25 μmol/mg/min). 
 Variant A was found to be more active than B and C which supports the 
studies of Ali-Osman et al. (1997) and Parker et al. (2008) studies, where hGSTP1-
A  was shown to have a much lower Km for CDNB and have a higher specific 
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activity than variants B and C. However, both of these studies report a higher 
specific activity for variant C than variant B, which does not correlate with this study 
as variant B was approximately 1 fold more active than variant C. hGSTP1-A was 
also more active than variant D by roughly 1.1 times, which is not supported by 
Parker et al. (2008) who found both variants A and D to have the same activity.    
 
 
 
Figure 3.2 - Activity assays for hGSTP1-A (a), hGSTP1-B (b), hGSTP1-C (c), and 
hGSTP1-D (d). The progress curves show the formation of the yellow coloured GS-
DNB conjugate over 25 minutes at 25oC, which is measured by absorbance at 340 
nm. Error bars show the maximum and minimum values for each point. 
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Table 3.1 - Specific activities for each hGSTP1 isozyme obtained from the change 
in absorbance at 340 nm during the linear range of the activity assay with the 
standard substrate CDNB.   
hGSTP1 Variant Linear Range (min) ∆A340 /min 
Specific Activity 
(μmol/mg/min) 
A 2 0.44 13.88 ± 0.161 
B 2 0.21 6.54 ± 0.069 
C 3 0.19 6.08 ± 0.111 
D 2 0.39 12.25 ± 0.143 
  
 
 The effect of the polymorphisms might differ according to the substrate used 
and the type of catalytic mechanism. Amino acid 104 is located in helix 4 and forms 
part of the active site of the enzyme (H site). Variants B and C have in common this 
amino acid where isoleucine is substituted by a valine. Both variants were found to 
have the lowest specific activities with CDNB in comparison to variants A and D. 
However, Parker et al. (2008) found that when ethacrynic acid (EA) is used as a 
substrate, variants C and B had higher specific activities. Zimniak et al. (1994) 
reported the same results for both substrates when comparing variant A against 
variant B. These suggest that due to its position in the active site, polymorphism 
I104V produces functionally different enzymes according to the substrate used. On 
the other hand, the second polymorphism located in amino acid 113 is present at 
the N-terminal end of helix 5 and removed from the active site by approximately 18 
Å. This means that any difference in enzyme activity cannot be due to active site 
modifications by this amino acid (Hu, 1997; Parker, 2008). Hu et al. (1997) based 
on his results, proposed that amino acids Val113 and His114 by facing their 
corresponding amino acids on subunit B, form a "clamp" with hydrophobic tips 
across the solvent channel. This would lead to a higher hydrophobicity of the clamp, 
and decrease the distance between the tips, which in turn enables bulky and 
hydrophobic substrates to tightly interact with the clamp. However, if the substrates 
are small and of hydrophilic nature this interaction will be weak or even absent. Hu 
et al. (1997) also found out that this interaction is only possible when V104 is 
present (variant C), leading to lower a Km value.   
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 3.3.2 Inhibition assays 
 
 Currently, increasing numbers of oncogenes and cancer related genes are 
being screened in individuals at risk of developing cancer, and malignant cells are 
analysed and genotyped in order to diagnose and treat the disease. The functional 
differences between the hGSTP1 variants can play a big role in cancer risk, 
diagnosis, treatment and even drug development. Less active variants when 
exposed to carcinogens may potentially lead to a higher risk of malignancy due to 
oxidative stress in the cells. Many cases where the hGSTP1 polymorphisms, 
especially variants B and C, are associated with the increasing risk of individuals 
developing a wide variety of types of cancer are described in the introduction 
(section 1.3). However, this disadvantage may be used in favour of the patients 
who express these variants by administering a personalised treatment based on 
their genetic makeup. This personalised approach is referred to as 
pharmacogenetics.  Drugs can then be chosen according to their degree of affinity 
to the specific hGSTP1 variant and the patient survival rates can theoretically be 
increased.  
 Inhibition of the activity assays was carried out with the nitrosourea drugs 
carmustine, lomustine, semustine, streptozocin and ethylnitrosourea, and 
conducted for each GSTP1 variant. These assays aimed to investigate the 
difference in the formation of the GSH-DNB conjugate when compared to the 
standard activity assays monitored at 340 nm.  
 The activity data were tested for normality using the Shapiro-Wilk test of 
normality (table 3.2), which was found to be non-normally distributed at p ≤ 0.01. 
Consequently the non-parametric Mann-Whitney-U test of variance was used to 
analyze the independent inhibition assay samples in comparison to the respective 
activity assays (controls). 
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Table 3.2 - Shapiro-Wilk test of normality for the activity assays (SPSS, version 19). 
  Shapiro-Wilk 
  Statistic df Sig. 
Activity_A 0.480 26 0.000 
Activity_B 0.830 26 0.001 
Activity_C 0.821 26 0.000 
Activity_D 0.540 26 0.000 
 
 
 This inhibition assay could potentially be used in the future as a screen to 
investigate the activity of hGSTP enzymes or other GST classes against a high 
number of possible substrates such as newly designed drugs, and to quickly access 
their viability to be used as treatment against cancer or other diseases. The 
advantage of this method in comparison to calculating the IC50 value is that the 
results are based on the statistical analysis (p-value) of one high substrate 
concentration instead of a gradient of several concentrations. This will save time 
and money. However, the substrate concentration used should not be so high to the 
point of affecting enzymatic activity. If inhibition is not observed with a certain 
compound then this can be disregarded with no further studies, but on the other 
hand if inhibition is visible, then IC50 values should be calculated to allow for a 
more detailed study of the enzymatic reaction and type of inhibition.     
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3.3.2.1 Carmustine  
   
 The formation of the GS-DNB conjugate is visibly inhibited by carmustine, 
within 25 minutes, when catalysed by variants B, C and D; which is statistically 
significant as the p values are lower than 0.05 when the Mann-Whitney-U test is 
applied (SPSS, version 19). However, there is no apparent inhibition by carmustine 
when the reaction is catalysed by variant A (figure 3.3). 
 
  
 
Figure 3.3 - Inhibition assays with carmustine and a) hGSTP1-A (p=0.293), b) 
hGSTP1-B (p=0), c) hGSTP1-C (p=0) and d) hGSTP1-D (p=0) in the presence of 
GSH and CDNB.  
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3.3.2.2 Lomustine 
 
 When lomustine is present in the reaction with hGSTP1-B, the formation of 
the GS-DNB conjugate is not inhibited. However, the opposite is true and 
statistically significant when this drug is in the presence of the other hGSTP1 
variants (p≤0.05) (figure 3.4). 
 
 
Figure 3.4 - Inhibition assays with lomustine and a) hGSTP1-A (p=0), b) hGSTP1-B 
(p=0.949), c) hGSTP1-C (p=0) and d) hGSTP1-D (p=0) in the presence of GSH and 
CDNB. 
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3.3.2.3 Semustine 
 
 In regards to the anticancer drug semustine, all S-glutathionylation reactions 
appeared to be inhibited by this drug. This inhibition is the highest amongst the five 
drugs tested and considered to be statistically significant as all four p values are ≤ 
0.05 and equal to zero (figure 3.5). 
 
 
 
Figure 3.5 - Inhibition assays with semustine and a) hGSTP1-A (p=0), b) hGSTP1-
B (p=0), c) hGSTP1-C (p=0) and d) hGSTP1-D (p=0) in the presence of GSH and 
CDNB. 
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3.3.2.4 Streptozocin 
 
 The Mann-Whitney-U test shows that the anticancer drug streptozocin has 
no significant affinity to any of the four hGSTP1 variants (p>0.05) (figure 4.6). 
  
 
 
Figure 3.6 - Inhibition assays with streptozocin and a) hGSTP1-A (p=0.058), b) 
hGSTP1-B (p=0.06), c) hGSTP1-C (p=0.087) and d) hGSTP1-D (p=0.348) in the 
presence of GSH and CDNB. 
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3.3.2.5 Ethylnitrosourea 
 
 Finally, the inhibition assays with ethylnitrosourea show the same trend as 
the assays with semustine. All S-glutathionylation reactions appeared to be 
inhibited by this drug and to be statistically significant as all four p values are equal 
to zero (figure 3.7). 
 
  
 
Figure 3.7 - Inhibition assays with ethylnitrosourea and a) hGSTP1-A (p=0), b) 
hGSTP1-B (p=0), c) hGSTP1-C (p=0) and d) hGSTP1-D (p=0) in the presence of 
GSH and CDNB.  
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of product observed on the controls reactions. To be certain of this, however, it 
would be benefitial for the project to calculate IC50 values in order to identify the 
level of inhibition of each drug but also kinetic studies to identify the type of 
inhibition. These drugs could either be considered to be substrates or inhibitors. 
Among the two polymorphisms, residue 104 is the one that seems to play the 
important role in the catalytic mechanism of the enzymes as variants A and D, and 
B and C appear to show the same behaviour, respectively. However, there are two 
instances where this was not the case. These are reactions with carmustine 
involving variants A and D, and reactions with lomustine involving variants B and C. 
These differences are difficult to explain, but they could be the result of the 
combination of both polymorphisms of residues 104 and 113 by altering the side 
chain interactions and making the binding of these drugs weak or unfavourable.   
 Statistically the anticancer drug streptozocin does not show affinity towards 
any of the hGSTP1 variants, which means that when administered to a cancer 
patient it will be metabolised by another enzyme or enzymes present in the cytosol.        
 According to the above results and the number of nitrosourea drugs used in 
this study, the best drugs to treat cancer patients expressing: hGSTP1-A are 
carmustine and ethylnitrosourea, hGSTP1-B is ethylnitrosourea, hGSTP1-C 
carmustine and ethylnitrosourea, and hGSTP1-D is ethylnitrosourea. These 
combinations appear to have the least affinity to each other and therefore when 
administered to the patients, the drugs would be active for longer as their 
metabolism would be slower. Semustine and lomustine appear to show the highest 
degree of affinity to the enzymes and so, theoretically, they are inappropriate drugs 
to administer in patients who have tumours over-expressing this class of GSTs. 
 According to several studies on the hGSTP1 genotypes, polymorphism 
Val104 has been associated with reduced enzymatic activity when compared to 
polymorphism Ile104. Due to this fact, polymorphism Val104 has also been 
associated with favourable prognosis after treatment with drugs known to be class 
Pi substrates. This has been found to be true in a wide number of cancers, which 
means that the effect that these two mutations have is not specific to a cancer type 
but is most probably related to the metabolism of the drugs (Sweeney et al., 2000; 
Stoehlmacher et al., 2002; Hohaus et al., 2005). Therefore, patients expressing 
variants B and C present a reduced capability to detoxify anticancer drugs, and 
consequently the effectiveness of the dosage within the cell is higher when 
compared to patients expressing variants A and D. 
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 Since polymorphism Ile104 is the most common in the population, more 
research is needed in order to increase survival rates amongst patients expressing 
hGSTP1-A  or -D isoforms. Therefore, it is essential to find or design anticancer 
drugs that are substrates to this class of GSTs but which show a lower affinity 
towards these two variants.  
 
3.3.3 Wavelength scans  
 
 The aim of the wavelength scans was to find out the wavelength at which the 
reaction products absorbed. After incubation during the enzyme assay the reaction 
products were hoped to be analysed by HPLC with UV-VIS detection and then 
mass spectrometry would have been used to confirm the glutathione-conjugated 
products. Figure 3.8 shows the trace for the wavelength scan of the reaction with 
hGSTP1-A and carmustine. Both the drugs dissolved in ethanol and the reaction 
solutions produced similar traces and absorbed at the same wavelength of 
approximately 225 nm, which meant that spectroscopic detection could not be used 
with the HPLC conditions available.  
 
 
Figure 3.8 - Trace for the wavelength scan of the reaction with hGSTP1-A and 
carmustine. 
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 Kinetic assays with enzyme and the drugs were also monitored and 
measured at 250 nm in order to see if there was either formation of product or a 
decrease in the amount of drug. The results showed neither as all that was 
observed was a graph with lots of interference.     
 Due to this fact it was then decided to analyse the reaction products by mass 
spectrometry in order to confirm or not the presence of glutathione-conjugated 
products.  
 
3.3.4 Mass spectroscopy assays 
 
 The mass spectrometry data was used to look for the possible glutathione 
conjugates. The aim was to define the conjugates using accurate mass extracted 
ion chromatograms. The unused free glutathione was easily detected in all the 
samples, and as it is highly polar, it elute at the solvent front (figure 3.9).  
 There were several occasions where the amount of GSH in the reaction (R) 
was lower than the amount of GSH in the respective control (C) sample. However, 
as no complex was detected one cannot rule out ion suppression being the cause 
or the fact that glutathione binds to the enzyme free active sites. 
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Figure 3.9 - Mass spectra of free glutathione present in the control and reaction 
samples being eluted at the solvent front produced by the Q-TOF mass 
spectrometer.  
All 
samples 
 
a 
b 
+ESI  EIC(308.0911)  MS(all)  Rita_semustineR.d 
+ESI  EIC(308.0911)  MS(all)  Rita_semustineC.d 
+ESI  EIC(308.0911)  MS(all)  Rita_lomustineR.d 
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 In order to check that the mass spectrometry assay was working well a 
positive control was performed with the anticancer drug chlorambucil (CMB) (figure 
3.10), which is a known substrate for class Pi enzymes. This was confirmed by the 
mass spectrum for chlorambucil (figure 3.11). 
 
 
 
Figure 3.10 - Structure of the anticancer drug chlorambucil. 
 
 
 
 
Figure 3.11 - Mass spectra of control and reaction samples carried out with 
chlorambucil produced by the Q-TOF mass spectrometer. In blue is free 
chlorambucil, in green is the monoglutathionyl-CMB (CHBSG) conjugate and in pink 
is the diglutathionyl-CMB (CHBSG2) conjugate. 
 
 
 
(304.0866) Chlorambucil    R C 
(575.1937) Chlorambucil-GSH    R C 
(846.3008) Chlorambucil-2GSH  R C 
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 The glutathionilation of chlorambucil is a reaction that happens 
spontaneously in the absence of GSTs. However, when the enzyme is present in 
the reaction there is an increase in the amount of the products formed. Different 
classes of GSTs have different affinities to this drug (Ciaccio et al., 1990; Meyer et 
al., 1992). In blue is the free chlorambucil that was not transformed in either of the 
reactions.  Two products were visible in the mass spectra (figure 3.11). The first 
product and the most abundant was the monoglutathionyl-CMB (CHBSG) conjugate 
(in green), formed when a GSH molecule replaced one of the chlorine atoms. This 
first product then becomes the substrate for the second reaction where the 
diglutathionyl-CMB (CHBSG2) conjugate is formed (in pink). This second reaction 
happens when a second GHS molecule replaces the other chlorine atom. By 
looking at the spectrum it was visible that the amount of free chlorambucil in 
solution decreased in the reaction sample and that both products were present in 
higher amounts when compared to the control sample. 
 The hGSTP1-A enzyme was used in these mass spectrometry assays since 
according to Parker et al. (2008) this variant is the one that more efficiently 
conjugates the anticancer drug chlorambucil, and the same is true for the majority 
of anticancer drugs that are substrates of this class of GST. However, hGSTP1-D 
was used in the reaction with carmustine due to the lack of inhibition observed 
earlier with hGSTP1-A (figure 3.3). The mass spectra for the nitrosourea drugs 
carmustine (figure 3.12), lomustine (figure 3.13), semustine (figure 3.14), 
streptozocin (figure 3.15) and ethylnitrosourea (figure 3.16) all showed the same 
trend. Both control and reaction samples originally had the same trace, and there 
was no peak visible for any of the possible products in the respective reaction 
samples. 
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Figure 3.12 - Mass spectra of control and reaction samples carried out with 
carmustine produced by the Q-TOF mass spectrometer.  
 
 
 
 
Figure 3.13 - Mass spectra of control and reaction samples carried out with 
lomustine produced by the Q-TOF mass spectrometer.  
 
 
(214.0145) Carmustine             R C  
(484.1138) Carmustine-GSH   R C 
(233.0926) Lomustine            R C  
(503.1924) Lomustine-GSH   R C 
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Figure 3.14 - Mass spectra of control and reaction samples carried out with 
semustine produced by the Q-TOF mass spectrometer.  
  
 
 
Figure 3.15 - Mass spectra of control and reaction samples carried out with 
streptozocin produced by the Q-TOF mass spectrometer. 
(248.116) Semustine              R C  
(519.2232) Semustine-GSH   R C 
(266.0983) Streptozocin           R C  
(555.1715) Streptozocin-GSH  R C  
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Figure 3.16 - Mass spectra of control and reaction samples carried out with 
ethylnitrosourea produced by the Q-TOF mass spectrometer.  
  
 The assays analysed in the QQQ mass spectrometer produced the same 
results as above. 
 The analysis of the results obtained from these mass spectrometry assays 
suggests that the drugs used do not constitute viable substrates for hGSTP1 as the 
conversion of drugs into products was not detected. However, taking into account 
these results and the inhibition assays, it could be suggested that the drugs may act 
as inhibitors of the hGSTP1 enzymes, although further experiments would need to 
be carried out to confirm this. 
 
3.3.5 Denitrosation assays  
 
 The denitrosation assays were performed in order to find out if the reaction 
of the enzymes with the drugs resulted in nitrite formation. All the assays showed 
the same tendency (figure 3.17). None of the hGSTP1 variants possessed 
detectable activity towards the five drugs. Since there was no rate of nitrite 
formation in any of the reactions, the specific activity of the four variants against the 
five drugs could not be calculated.  
(118.0611) Ethylnitrosourea            R C  
(425.1449) Ethylnitrosourea-GSH   R C 
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 The denitrosation results for carmustine presented here confirm the findings 
of both Berhane et al., (1993) and Lien et al., (2002). The first study did not detect 
activity towards this drug with variant A, and the second did not detect activity with 
both variants A and B. The results from these denitrosation assays confirmed the 
mass spectrometry results discussed above. The nitrosourea drugs studied here do 
not constitute substrates for hGSTP1 enzymes as there was no nitrite formation in 
any of the reactions. 
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Figure 3.17 - Results of the denitrosation assays: a) carmustine, b) lomustine, c) 
semustine, d) streptozocin, e) ethylnitrosourea and f) nitrite standard curve. 
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 Figure 3.18 illustrates a possible reaction scheme for glutathione (GSH) 
conjugation and denitrosation of the nitrosourea drug carmustine (BCNU) catalysed 
by GSTs in general (Lien et al., 2002).  
 
 
Figure 3.18 - Proposed reaction scheme for glutathione (GSH) conjugation and 
denitrosation of the nitrosourea drug carmustine (BCNU) catalysed by GSTs in 
general (modified from Lien et al., 2002). 
 
 
 Denitrosation is thought to happen after S-glutathionilation of carmustine, 
when its glutathione conjugate reacts with water. A similar mechanism might be 
true for the other nitrosourea drugs. Denitrosation studies to measure enzyme 
activity towards these drugs would have to be carried out in order to find out if they 
could be substrates for any of the other human GST classes. The human GST 
enzymes that have been shown to have activity towards carmustine are hGSTM2-2, 
hGSTM3-3 and hGSTT1-1 (Berhane et al., 1993; Lien et al., 2002). The hGSTT1-1 
enzyme appeared to have the highest activity amongst the three, with a 14 fold 
greater specific activity than the other two (Lien et al., 2002). 
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3.3.6 Thermofluor shift assays 
 
 The thermofluor shift assays were carried out in order to assess the stability 
of the four hGSTP1 variants in the presence of the drugs, glutathione, MES buffer 
and a variety of different buffers, over a temperature range of 25oC to 99oC.    
 
3.3.6.1 Thermofluor shift assays with nitrosourea drugs 
 
 Figure 3.19 illustrate the results of the assay with all four variants in buffer F. 
Variant A was the most stable as it melted at 50.80oC, followed by variants B (TmB - 
49.99oC), D (TmD - 49.61
oC) and C (TmC - 48.60
oC), in this order.  
 
 
 
Figure 3.19 - Thermal denaturation curves of the four hGSTP1 allelic variants in 
buffer F. Assay temperature ranged from 25oC to 99oC. Melting temperatures were: 
TmA - 50.80
oC, TmB - 49.99
oC, TmC - 48.60
oC and TmD - 49.61
oC. 
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 The assays with the four variants and the five drugs were performed with 
and without glutathione. Figures 3.20, 3.22, 3.24 and 3.26 show the results for 
variants A, B, C and D, respectively, in the absence of glutathione. Whereas figures 
3.21, 3.23, 3.25 and 3.27 illustrate the results for variants A, B, C and D, 
respectively, and in the presence of glutathione. 
 
 
 
 
Figure 3.20 - Thermal denaturation curves of hGSTP1-A in buffer F, in the 
presence of the drugs and absence of GSH. Assay temperature ranged from 25oC 
to 99oC. Melting temperatures were: Tmcontrol - 50.80
oC Tmcarmustine - 48.54
oC, 
Tmlomustine - 49.34
oC, Tmsemustine - 48.52
oC, Tmstreptozocin - 50.73
oC and Tmethylnitrosourea 
- 50.46oC. 
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Figure 3.21 - Thermal denaturation curves of hGSTP1-A  in buffer F, in the 
presence of the drugs and GSH. Assay temperature ranged from 25oC to 99oC. 
Tmcontrol - 51.80
oC Tmcarmustine - 51.19
oC, Tmlomustine - 49.82
oC, Tmsemustine - 50.10
oC, 
Tmstreptozocin - 51.80
oC and Tmethylnitrosourea - 51.53
oC. 
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Figure 3.22 - Thermal denaturation curves of hGSTP1-B in buffer F, in the 
presence of the drugs and absence of GSH. Assay temperature ranged from 25oC 
to 99oC. Tmcontrol - 49.99
oC Tmcarmustine - 48.58
oC, Tmlomustine - 48.52
oC, Tmsemustine - 
48.22oC, Tmstreptozocin - 49.99
oC and Tmethylnitrosourea - 49.96
oC. 
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Figure 3.23 - Thermal denaturation curves of hGSTP1-B in buffer F, in the 
presence of the drugs and GSH. Assay temperature ranged from 25oC to 99oC. 
Tmcontrol - 51.05
oC Tmcarmustine - 50.92
oC, Tmlomustine - 49.10
oC, Tmsemustine - 49.80
oC, 
Tmstreptozocin - 51.01
oC and Tmethylnitrosourea - 51.03
oC. 
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Figure 3.24 - Thermal denaturation curves of hGSTP1-C in buffer F, in the 
presence of the drugs and absence of GSH. Assay temperature ranged from 25oC 
to 99oC. Tmcontrol - 48.60
oC Tmcarmustine - 47.93
oC, Tmlomustine - 47.10
oC, Tmsemustine - 
46.81oC, Tmstreptozocin - 48.60
oC and Tmethylnitrosourea - 48.55
oC. 
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Figure 3.25 - Thermal denaturation curves of hGSTP1-C in buffer F, in the 
presence of the drugs and GSH. Assay temperature ranged from 25oC to 99oC. 
Tmcontrol - 49.92
oC Tmcarmustine - 49.82
oC, Tmlomustine - 48.46
oC, Tmsemustine - 48.93
oC, 
Tmstreptozocin - 49.92
oC and Tmethylnitrosourea - 49.65
oC. 
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Figure 3.26 - Thermal denaturation curves of hGSTP1-D in buffer F, in the 
presence of the drugs and absence of GSH. Assay temperature ranged from 25oC 
to 99oC. Tmcontrol - 49.61
oC Tmcarmustine - 48.39
oC, Tmlomustine - 47.88
oC, Tmsemustine - 
47.80oC, Tmstreptozocin - 49.40
oC and Tmethylnitrosourea - 49.37
oC. 
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Figure 3.27 - Thermal denaturation curves of hGSTP1-D in buffer F, in the 
presence of the drugs and GSH. Assay temperature ranged from 25oC to 99oC. 
Tmcontrol - 50.73
oC Tmcarmustine - 50.12
oC, Tmlomustine - 48.70
oC, Tmsemustine - 49.35
oC, 
Tmstreptozocin - 50.71
oC and Tmethylnitrosourea - 50.44
oC. 
 
 The results give some indication that polymorphism 113 might be related to 
the thermal stability of class Pi GSTs. Variants A and B, which have amino acid 
Ala113 in common, appear to be more stable than variants C and D (Val113) as 
their melting temperatures were higher (figure 3.19). This small difference was also 
visible throughout the assays with the drugs, independently of glutathione being 
present or not. 
 Even though all assays where glutathione was present appeared to show a 
higher melting temperature compared to the assays without it, this increase was 
only higher by an average of 1.46oC. This is in the range expected for the specific 
binding of this tripeptide to the protein. Most human enzymes unfold above 
temperatures of 40°C.The hGSTP1 enzymes are relatively stable to temperature as 
their melting temperatures, ranged from 48.60 to 50.8°C. Caccuri et al., (1999) 
demonstrated that this class of human GSTs displayed practically unchanged 
affinity for glutathione at concentrations of 1-3 mM (human skin GSH concentration) 
in a wide range of temperatures, varying from 5°C to 43°C. This, together with the 
fact that mice lacking class Pi GSTs had a higher incidence of skin cancer, 
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illustrates the relevant role that these enzymes play in cancer prevention 
(Henderson et al., 1998).   
 The presence of the drugs tested did not increase the stability of the 
hGSTP1 enzymes. In fact, it decreased as protein in the assays melted at slightly 
lower temperatures in comparison to the controls. This suggests that drugs tested 
do not act as specific inhibitors of the hGSTP1 enzymes. Since some of the drugs 
were dissolved in DMSO the addition of the small amount of this solvent could 
destabilise the enzymes. A control with the addition of the same amount of DMSO 
to enzyme in the absence of the drug showed this to be the case. 
 In addition to their catalytic role as type II detoxification enzymes, hGSTP1s 
are also involved in the non catalytic intracellular storage and transport of various 
large hydrophobic planar aromatic nonsubstrate ligands, such as 
bromosulfopthalein (Prade et al., 1997; Oakley et al., 1999; Lu & Atkins, 2004). It 
appears that these enzymes possess several ligandin binding sites whose location 
is still unclear (Prade et al., 1997; Lu & Atkins, 2004). This ligand binding has been 
characterised as non-competitive inhibition towards CDNB, the standard substrate 
used to assay GSTs for activity (Oakley et al., 1999). However, none of the drugs 
tested in this study have the characteristics of the ligands that bind to the ligandin 
binding sites, ruling out the possibility that they could be non-substrate ligands for 
hGSTP1 enzymes.   
 Co-crystallisation and docking studies should be carried out to determine 
whether or not the nitrosourea drugs tested in this study have some affinity for 
hGSTP1 enzymes. 
  
4.3.6.2 Thermofluor shift assays with MES buffer 
 
 After solving the structure of the hGSTP1-D protein (chapter 5) it was noted 
the presence of two MES molecules within the structure which were bound to what 
is called the buffer binding site. These MES molecules were also present in the 
structure of variant A in complex with the chlorambucil-GSH conjugate (PDB ID: 
3CSH) by Parker et al., (2008); and according to Prade et al., (1997), they bind to 
the GSTP protein in its crystallised form as well as in solution. This was confirmed 
through fluorescence measurements which were possible due to the proximity of 
residue Trp28 to the MES molecule. Another study by Oakley et al., (1997) 
identified a third binding site for MES located at the bottom of the dimer interface, 
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where it binds between the two symmetry-related Tyr79 residues. The electron 
density of this third MES molecule was found to be weaker than the other two which 
may suggest that the site is only partially occupied, or that the MES molecule is 
highly mobile, or in fact both. The structure of hGSTP1-D enzyme contains both 
amino acid residues Trp28 and Tyr79. It was therefore decided to carry out thermal 
shift assays with MES buffer to see its effect on the stability of the hGSTP1-D 
isoform.   
 Two different assays were performed with MES buffer. The first one was to 
analyse the stability of the enzyme in the presence of different concentrations of 
buffer 25 mM, 100 mM and 500 mM, but keeping its pH at 5.5 (figure 3.28). The 
second one intended to evaluate the effect that the change in buffer pH had over 
the enzymes stability, but keeping buffer concentration at 100 mM (figure 3.29). 
 From the results presented in figure 4.26 it is visible that as the buffer 
concentration increases, protein stability decreases. At a concentration of 25 mM 
the enzymes melting temperature was 49.84oC which was only 0.36oC lower than 
the control. On the other hand, when the concentration increased to 500 mM the 
melting temperature was 45.5oC which was a considerable 4.7oC different. It should 
be noted that the pH of the reaction would vary due to the buffering effect of the 
different concentrations of MES in solution, meaning that the variations in melting 
temperatures may be due to the alteration in pH of the reactions.  
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Figure 3.28 - Thermal denaturation curves of hGSTP1-D in different concentrations 
of MES buffer at pH 5.5: Control potassium phosphate, pH 7.8 (Tm - 50.2
oC); 25 mM MES 
(Tm - 49.84oC); 100 mM MES (Tm - 47.67oC) and 500 mM MES (Tm - 45.5oC). 
 
 
 The assay illustrated by figure 3.29 shows the effect of the buffer at different 
pHs. The tendency here was that as the pH decreased the stability of the enzyme 
also decreased. The melting temperature at the higher pH of 6.7 was 49.9oC, 
exactly the same melting temperature as the control. However, at the lower pH of 
5.5 the melting temperature was 47.7oC and 2.2oC lower than the control.  
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Figure 3.29 - Thermal denaturation curves of hGSTP1-D in MES buffer (100 mM) 
at different pHs: Control potassium phosphate (Tm - 49.9
oC); MES, pH 5.5 (Tm - 47.7oC); 
MES, pH 5.8 (Tm - 48.8oC); MES, pH 6.1 (Tm - 49.5oC); MES, pH 6.4 (Tm - 49.6oC) 
and MES, pH 6.7 (Tm - 49.9oC). 
  
  These results might suggest that the lower pH offers an advantageous or 
favourable environment for the binding of the MES molecule to the site located in 
between the two subunits. This, in turn, may destabilise intersubunit interactions 
between important amino acid residues in this region of the protein. The MES 
molecules that bind to the buffer binding site are unlikely to destabilise the enzyme.  
  
4.3.6.1 Thermofluor shift assays with different buffers 
 
 A small variety of buffers described in section 3.2.6.5 was also tested against 
variant D in order to observe its stability in different environments and conditions. 
From the results presented in figure 3.30 it is clear that buffer ethanolamine-HCl 
(Tm - 40.1oC), was the most destabilising buffer for hGSTP1-D. Two other buffers 
that induced a destabilising effect were CAPS-NaOH (Tm - 43.4oC) and boric acid-
NaOH (Tm - 45.6oC). 
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Figure 3.30 - Thermal denaturation curves of hGSTP1-D in different buffers: Water 
(Tm - 50.0oC), Bis-Tris-HCl (Tm - 47.8oC), MES-NaOH (Tm - 48.6oC), Imidazole-
HCl (Tm - 48.6oC), PIPES-NaOH (Tm - 49.3oC), MOPS-NaOH (Tm - 49.7oC), 
HEPES-NaOH (Tm - 49.7oC), Bicine-NaOH (Tm - 50.4oC), Glycine-NaOH (Tm - 
49.3oC), Boric acid-NaOH (Tm - 45.6oC), CHES-NaOH (Tm - 50.4oC), 
Ethanolamine-HCl (Tm - 40.1oC), CAPS-NaOH (Tm - 43.4oC) and Potassium 
Phosphate (Tm - 49.9oC). 
  
 None of the buffers tested here significantly increased the stability of variant 
D. Both Bicine-NaOH (Tm - 50.4oC) and CHES-NaOH (Tm - 50.4oC) buffers 
appeared to be the best buffers for this enzyme.  However, the melting 
temperatures were only 0.4oC higher when compared to water (Tm - 50.0oC). The 
majority of the other buffers did not have a destabilising or a stabilising effect on the 
enzyme as the melting temperatures were between 49 and 50oC which as seen 
above is expected for this variant. These included potassium phosphate buffer (Tm 
- 49.9oC) which was used in this study and throughout the literature with GST 
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enzymes, especially to carry out activity assays. These results show that it was a 
good choice of buffer to use. Similar results can be assumed for the other three 
variants however these were not tested due to time limitations.   
 
 After analysing the results of the assays as a whole there are two 
assumptions that can be made. The first is that certain drugs may act as inhibitors 
of certain hGSTP1 variants. However, due to their low levels of inhibition they could 
not be used as an effective medical treatment since they would be readily 
metabolised by other enzymes present in the cell. The second assumption is that 
the nitrosourea drugs do not constitute substrates for the human GSTPi class of 
enzymes as it was confirmed by the mass spectrometry and denitrosation assays. 
The presence of the drugs in the inhibition assays could interfere with the normal 
formation of the GSH-DNB conjugate by blocking the entrance of the CDNB 
molecules in the active site channel. Nevertheless, one cannot rule out the 
possibility that these drugs might be S-glutathionylated by other GST classes and 
that the respective conjugates might constitute substrates to the hGSTP1 variants. 
The second hypothesis may be more credible since the results from the thermal 
shift assays in the presence of the drugs did not show an increase in the stability of 
the variants when compared to the control reactions indicating that the drugs had 
no specific binding to the enzymes. Furthermore, in spite of the fact that over-
expression of these hGSTP1 enzymes in tumours is associated with multidrug-
resistance, is the fact that hGSTP1 enzymes have a weak affinity for a wide range 
of anticancer drugs (Laborde, 2010). This can possibly be explained by the role that 
this class of enzymes play on the signalling pathway responsible for cell apoptosis 
and survival. In other words, GSTs appear to be linked to members of the mitogen 
activated protein kinase (MAPK) pathways which are involved in death signalling 
and cell survival. In this case, GSTs role is to sequester the kinase in a complex 
which consequently stops it from acting on downstream targets, resulting in a 
change in the regulation of pathways responsible for apoptosis and cell 
proliferation. The c-Jun N-terminal kinase (JNK), a MAP kinase involved in stress 
response, inflammation, cellular differentiation, proliferation and apoptosis, was 
found to be inhibited by hGSTP1 through direct protein–protein interactions. JNK 
can be activated by a variety of stress stimuli, such as protein synthesis inhibitors 
and UV radiation, which consequently phosphorylates c-Jun, a component of the 
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activator protein-1 (AP-1) transcription factor. This, in turn, induces AP-1-dependent 
target genes involved in cell death and proliferation (Adler et al., 1999; Tew, 2007; 
Laborde, 2010). The inhibition of the JNK activation by hGSTP1 is highly important 
for drug resistant tumours that over-express this enzyme. In fact, over-expression of 
hGSTP1 during chemotherapy may change the balance in the regulation of 
signalling pathways responsible for cell proliferation and apoptosis, and so, giving 
cancer cells the opportunity to escape death. This may explain the wide number of 
drug resistance cases that associate hGSTP1 high levels of expression with drugs 
that are either weak substrates or not substrates at all (Laborde, 2010). 
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3.4 Summary 
 
 Different assays were performed to assess the relationship of the four 
hGSTP1 variants against five nitrosourea compounds (carmustine, lomustine, 
semustine, streptozocin and ethylnitrosourea) which are used in chemotherapy and 
are especially important for the treatment of brain tumours since they can cross the 
brain membrane.  
 After the activity assays it was found that variants A and D were the most 
active towards CDNB. They share residue Ile104 which has been shown to 
influence the catalytic affinity of this class of enzymes towards different substrates. 
 The results of the mass spectrometry assays show that none of the drugs 
are substrates of the enzymes as no glutathione conjugate was identified, and the 
fact that no nitrite production resulted from the denitrosation assays confirms the 
mass spectrometry results. After these, the results from the inhibition assays can 
lead to the interpretation that four of the drugs may be weak inhibitors of the 
variants. However, this theory was not readily confirmed by the results of the 
thermofluor shift assays. More research is needed to verify this suggestion.   
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 Chapter 4 - Crystallisation and X-ray diffraction studies on 
hGSTP1-D  
 
 
4.1 Introduction 
 
 The structure of a protein or enzyme contains important information required 
to understand its function, activity, interactions and involvement in biological and 
chemical processes, which may promote the design of drug targeting, or engineer 
enzymes for particular industrial processes. Protein crystallisation is the first step 
used to achieve this goal as it enables scientists to visualize protein structures 
accurately close to their atomic level.  
 A protein crystal is a three-dimensional array of ordered macromolecules in 
which the electrons diffract the X-rays in certain directions defined by the crystal 
lattice. Measurement of intensities of diffracted X-rays allows the calculation of a 
map where the distribution of the electrons in the structure is visible. Crystals are 
formed in conditions specific to each different protein. Each crystallisation condition 
results from a particular combination of protein concentration, pH, temperature, 
precipitant and buffer. The higher the degree of homogeneity of a protein in 
solution, the higher is the probability of a protein crystal to be formed.  
 There are two stages involved in protein crystallisation. The first and 
essential stage is nucleation and the second is crystal growth. Nucleation or 
formation of a nucleus is the microscopic agglomeration of protein molecules. In the 
second stage, the protein concentration in the solute decreases, leading the system 
to crystal growth but without further nucleation (Asherie, 2004; Chayen & Saridakis, 
2008).  
 In figure 4.1, a crystallisation phase diagram illustrates the relationship 
between protein concentration and precipitant concentration. As the precipitant 
concentration increases, protein solubility decreases. The phase diagram is divided 
into undersaturated and supersaturated areas. In the undersaturated area, protein 
is completely dissolved and will not crystallise. The supersaturated area is 
composed of three zones: the precipitation zone where supersaturation is very high 
and protein precipitates; the labile or crystallisation zone where supersaturation is 
moderate and spontaneous nucleation happens; and finally, the metastable zone 
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where supersaturation is low and protein crystals are stable and likely to grow large 
and well ordered (Asherie, 2004; Chayen & Saridakis, 2008).    
 
 
Figure 4.1 - Illustration of a schematic crystallisation phase diagram. As the 
precipitant concentration increases, protein solubility decreases. Crystals dissolve 
in the undersaturated area as the concentration is lower than the protein solubility, 
and grow in the supersaturated area (taken from Asherie, 2004).   
  
 There are different methods to obtain protein crystals. Vapour diffusion is 
one of the most common methods used, where crystals can be formed by sitting 
drop or hanging drop techniques (figure 4.2A and B). These techniques differ in the 
orientation of the droplet containing the mixture of purified protein, precipitant and 
buffer. Where the droplet on the hanging drop technique has a vertical orientation 
by hanging from the coverslip, the droplet on the sitting drop technique has a 
horizontal orientation by sitting on a support fitted in the well, allowing for the use of 
higher volumes of droplet. For vapour diffusion to work it is necessary to have a 
sealed system from the outside environment, which can be achieved by using 
vacuum grease between the cover slip and the reservoir. Both techniques aim for 
the equilibrium between the droplet and the reservoir containing a volume of either 
lower or higher concentrations of crystallising agents present in the droplet. As the 
water in the droplet starts vaporising and shifts to the reservoir, the concentration of 
precipitants increases in the droplet to a level that favours crystal formation and 
growth.   
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Figure 4.2 - Three techniques of crystallising protein for X-ray diffraction: A) Sitting 
Drop; B) Hanging Drop; C) Microbatch (www.genengnews.com/gen-
articles/automation-of-protein-crystallography/1855/).  
 
 Another popular method to crystallise protein is illustrated by figure 4.2C and 
is called microbatch or microscale batch experiments. This method allows for the 
testing of multiple sets of crystallisation conditions in a very short period of time 
through the utilisation of robots designed for the purpose. Several commercial 
companies supply different kits which contain a multitude of prepared crystallisation 
conditions ready to be used in the crystallisation experiments. The microbatch 
method has the advantage of using smaller amounts of chemicals which is less 
expensive and at the same time leading to faster crystallisations. The method 
involves dispensing and mixing the concentrated protein solution and the 
crystallisation condition in the well. Once all droplets are dispensed the plate it is 
then covered with Al's oil, a mixture of paraffin and silicon oils, allowing for slow 
evaporation and droplet precipitation condition to increase. Contrary to the vapour 
diffusion method, here supersaturation is achieved as soon as protein and 
crystallisation reagents are mixed together.  
 Both vapour diffusion and microbatch methods were used in this study with 
the objective of crystallising hGSTP1-D, which has never been crystallised before.  
 The three dimensional structure of a protein is essential for a detailed look 
into the mechanism of the enzyme. This information can be obtained through X-ray 
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crystallography, a technique that consists on striking a protein crystal with a beam 
of X-rays which diffract into various specific directions determined by the 
arrangement of the atoms within the crystal. This is possible due to the fact that X-
rays and inter atomic distances (chemical bonds) of proteins have similar 
wavelengths. A diffraction experiment results in the measurement a wide number of 
reflection intensities, and each one of these reflections (spots) is characterised by 
its amplitude and phase (determined separately). The reflection amplitudes and 
phases are represented by the structure factors. This allows one to obtain the 
distribution of electrons in the asymmetric part of the crystal unit cell with the 
mathematical Fourier transform method.  
 From diffraction images of a protein crystal it is possible to determine the unit 
cell dimensions, the crystal system and also the space group. The smallest 
repeating unit that makes up a protein crystal is called the unit cell, which is defined 
by its three lengths (a, b, c) and its three angles (α, β, γ). The spot spacing on the 
diffraction image is determined by the dimensions of the unit cell. The crystal 
system is determined by its shape and there are seven crystal systems: triclinic, 
monoclinic, orthorhombic, tetragonal, trigonal, hexagonal and cubic. The symmetry 
of the diffraction pattern provides the space group which allows determination of the 
packing of the molecules in the crystal lattice.  
   An X-ray that is reflected from one plane of atoms of a protein crystal 
travels a smaller distance when compared to an X-ray that is reflected from 
neighbouring plane of atoms inside the crystal. Only X-rays which are diffracted in 
phase with each other in the directions which satisfy Bragg’s Law add up and can 
be registered by detectors. The distance travelled by the X-ray is dependent on the 
separation of the layers and the angle at which it penetrates the crystal. In order for 
this wave to be in phase with the wave that is reflected from another plane of atoms 
it needs to travel a whole number of wavelengths. This diffraction pattern is 
explained by Bragg's Law (equation 3):   
 
    nλ=2dsinθ   (3) 
 
n - Integer number of wavelengths  
λ - Wavelength of the X-rays 
d - Spacing between the layers of atoms (lattice planes) 
θ - Angle between the incident X-rays and the surface of the crystal 
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  The waves that are reflected from different layers are completely in phase 
with each other when n is an integer number which will amplify and can be 
registered as spots (figure 4.3). On the other hand, when the waves are not in 
phase they dissipate and no spots are observed. The shorter the d value, the 
greater θ value is.    
  
 
 
Figure 4.3 - Illustration of the conditions that satisfy Bragg’s law. 
 
 Miller indices (h, k, l) define the diffraction spots by describing the several 
lattice planes and directions that divide the protein crystal across its three-
dimensional coordinates (a, b, c). The spacing between the lattice planes (dhkl) 
which is determined from the λ and θ values, which allow the calculation of the 
dimensions that define the unit cell of the crystal.          
 The Ewald's sphere illustrates Bragg's law in three dimensions (figure 4.4).  
The sphere of radius 1/λ is centered on the X-ray beam and represents the 
radiation of the wavelength λ. The crystal is located at the origin of the Ewald's 
sphere and is represented by the reciprocal lattice. All reciprocal lattice points are 
situated at the end of a vector which is perpendicular to the corresponding family of 
crystal planes. The length of this vector is inversely proportional to the distance 
between the lattice planes (d). Only a few reflections or reciprocal-lattice points in 
any one crystal orientation can be in the diffracting position of the Ewald's sphere, 
and therefore satisfy Bragg's law (equation 3). The majority of the reflections will 
not lie on the surface of the sphere. Therefore, the crystal needs to be rotated to 
bring successive reflections into diffraction. 
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Figure 4.4 - The Ewald construction. The trigonometric condition 1/d=(2/λ)sinθ is 
fulfilled when a reciprocal lattice point crosses the surface of the Ewald's sphere 
(taken from Dauter, 1999).   
 
 The primary result of crystallographic experiments is the electron density 
map for every atom within the unit cell. In order for this to be achieved it is 
necessary to determine the amplitudes and phases for the diffracted X-rays. The 
amplitudes are easily determined by a variety of existing computer programs 
through the calculation of the square root of the intensity, where negative values 
are set to zero. In the case of protein crystals, the phases have to be determined 
through indirect methods. Isomorphous replacement and molecular replacement 
are the two most used methods.  
 The isomorphous replacement method is usually used when a closely 
related structure is not available and it requires at least two data sets. A native set 
from the protein crystal alone and a derivative set with heavy atoms specifically 
interacting with specific amino acids in the protein. Heavy atoms, such as mercury, 
platinum or gold can be incorporated and attached to the protein molecules through 
soaking or co-crystallisation experiments. The incorporated heavy atoms modify the 
scattering of the diffracted X-rays, and the differences between the two data sets 
are due to the presence of the heavy atoms. This allows one to determine their 
positions in the protein molecules. The protein phase angles can then be calculated 
from computer refinement of the heavy atom parameters. 
 The molecular replacement method is most frequently used when a related 
protein structure is available. The known structure is used as a model. In this 
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method the crystallographic calculation is done in reverse. The structure factors and 
phases from the known model are applied to the new data set in order to determine 
the new structure factor. This will always produce some bias towards the model in 
the preliminary structure factors determinations, which would be avoided if the 
previous method was used. The structure of the model needs to be placed into the 
unit cell in precisely the same position and orientation as the new protein molecule 
before the phases can be applied. Firstly, this is performed by a rotation function 
which rotates the model data to accurately fit the new structure, and secondly by a 
translation function that moves the reoriented data through the unit cell to as 
precisely as possible to fit the position of the molecule. After rotation and 
translation, the position and orientation of the model can be improved through 
refinement cycles. Finally, the phases from the model structure factors are applied, 
and by using the new amplitudes it is possible to calculate and refine a new set of 
structure factors.              
 After determining the amplitudes and phases, the structure factors can be 
calculated through the Fourier transform method. After determining the amplitudes 
and phases for all of the Miller indices (h, k, l) they can be combined to originate the 
structure factor. The sum of all atomic structure factors for specific Miler indices is 
defined by the total structure factor equation (equation 4). 
  
                                               (4) 
 
 (4) Structure factor equation. 
 
 Consequently, the electron density for all the points in the unit cell is then 
obtained from the inverse Fourier transform of all the structure factors from each of 
the Miler indices.     
 
         
 
 
                                    (5) 
 
 (5) Calculation of the electron density in a protein crystal. 
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 The observed experimental amplitudes Fobs and their phases can be used to 
calculate a basic electron density map with the Fourier transformation. This map 
represents an approximation of the true protein structure and it depends on the 
accuracy of the calculated phases. In turn, the (Fobs – Fcalc, φcalc) electron density 
map is calculated with the differences between the observed and calculated 
amplitudes and also the calculated phases. It demonstrates the difference between 
the true and the modelled structures. However, more often the (2Fobs – Fcalc, φcalc) 
electron density map is used, and corresponds to a superposition of the two above 
maps to demonstrate the model electron density as well as the features in need of 
corrections. This last map is calculated with the differences between the multiple 
number of observed amplitudes and calculated structure factor amplitudes 
(equation 6).   
 
         
 
 
                                         (6) 
 
 (6) The 2Fo-Fc electron map summation. 
 
 All data (amplitudes and phases) used to calculate the electron density maps 
contain a certain degree of error, consequently the maps also have a level of noise. 
A good cut-off level for the (2Fobs – Fcalc, φcalc) map ≈ 1σ, and for the (Fobs – Fcalc, 
φcalc) map is ± 3σ, where σ is the root-mean-square deviation of all map points from 
the average value. 
 Refinement of the structure may improve the quality of the electron density 
map. Every time the structure is refined, R-factors are calculated. The R-factor is 
used to compare the observed structure amplitudes │Fobs│ with the structure 
amplitudes calculated from the model │Fcalc│ determined over a group of reflections 
(h). In other words, it represents a measure of how good the refined structure fits 
the observed data and it is defined by equation 7.     
 
  
                  
        
   (7) 
  
 (7) The R-factor equation. 
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 Another R-factor is the R-free which contrarily to the R-factor mentioned 
above, is unbiased and indicates the quality of the newly determined structure. Its 
value is obtained from a fraction of the data that is not used in the refinement, 
approximately 5% of the data, and which should be free of the effects of overfitting. 
 The refinement converges when the R-factors stop improving, and then the 
new structure is validated.  
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4.2 Materials and Methods 
 
 Microbatch crystallisation screens were performed using Hampton 96 well 
plates and carried out on an Oryx6 crystallisation robot (Douglas Instruments Ltd). 
The manufacturer's instructions were followed. 
 Hanging drop experiments were carried out with 24 well ComboPlateTM 
plates (Greiner Bio-One) and CrystalCleneTM cover slips (Molecular Dimensions, 
UK). 
 
4.2.1 Microbatch screens with hGSTP1-D  
 
 Screen A: Two crystallisation kits were used to screen for protein 
crystallisation: MDL-01 and JCSG-plus (Molecular Dimensions, UK). 10 mg/ml of 
pure hGSTP1-D in buffer C (50 mM sodium phosphate, 150 mM NaCl, 1 mM DTT, 
pH 7.0) was mixed with 100 mM of the drug streptozocin. 1µl droplets composed of 
0.5 µl of protein solution and 0.5 µl of crystallisation condition were dispensed in 96 
well plates. The wells were then covered with Al's oil (1:1 (v/v) paraffin oil and 
silicon oil). Plates were incubated at 4oC and 18oC, and checked weekly for crystals 
for two to three weeks under a light microscope. 
 
 Screen B: Two crystallisation kits were used to screen for potential protein 
crystallisation: Crystallisation Basic Kit for Proteins 82009 (Sigma, UK) and 
Crystallisation Extension Kit for Proteins (Sigma, UK). Pure HGSTP1-D was 
concentrated to 10 mg/ml in gel filtration buffer as before. 1µl droplets composed of 
0.5 µl of protein and 0.5 µl of crystallisation condition were dispensed in 96 well 
plates. The wells were then covered with Al's oil (1:1 (v/v) paraffin oil and silicon 
oil). Plates were incubated at 4oC and checked weekly for crystals for two to three 
weeks under a light microscope. 
 
4.2.2 Optimisation with hGSTP1-D  
 
4.2.2.1 Microbatch  
 
 Optimisation of the crystallisation condition in well G10 on the MDL-01 plate 
(200 mM calcium chloride dihydrate, 100 mM Na HEPES (pH 7.5), and 28 % v/v 
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PEG 400) was carried out as illustrated on table 4.1. 1 µl droplets composed of 0.5 
µl of protein solution and 0.5 µl of crystallisation condition were dispensed in 96 well 
plates. The wells were then covered with Al's oil (1:1 (v/v) paraffin oil and silicon 
oil). The plate was incubated at 4oC and 18 oC, and then checked for crystals two to 
three weeks later under a light microscope. 
 
Table 4.1 – Microbatch optimisation of crystallisation condition on plate MDL-01: 
200 mM calcium chloride dihydrate, 100 mM Na HEPES (pH 7.5), and 28 % v/v 
PEG 400. 
1 2 3 4 5 6 7 
 
A 
50mM  
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
100mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
150mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
200mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
250mM 
CaCl2 
28%  
PEG400 
100mM 
NaHEPES 
pH 7.5 
300mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
 
 
B 
200mM 
CaCl2 
15% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
200mM 
CaCl2 
20% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
200mM 
CaCl2 
25% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
200mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
200mM 
CaCl2 
30%  
PEG400 
100mM 
NaHEPES 
pH 7.5 
200mM 
CaCl2 
35% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
 
 
C 
200mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 6.8 
200mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.0 
200mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.3 
200mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 7.5 
200mM 
CaCl2 
28%  
PEG400 
100mM 
NaHEPES 
pH 7.8 
200mM 
CaCl2  
28% 
PEG400 
100mM 
NaHEPES 
pH 8 
200mM 
CaCl2 
28% 
PEG400 
100mM 
NaHEPES 
pH 8.2 
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4.2.2.1 Crystal Seeding Using Vapour Diffusion  
 
 Crystal seeding experiments were prepared by diluting small crystals that 
grew in well A4 (table 4.1). Dilutions of 1/50, 1/100 and 1/1000 were carried out in 
mother liquor (0.2 M calcium chloride dihydrate, 0.1 M Na HEPES (pH 7.5), and 28 
% v/v PEG 400). The hanging drop technique was used to set up the crystal dishes, 
and each droplet contained: 1 µl seeds; 5 µl of protein solution (10 mg/ml of 
hGSTP1-D in gel filtration buffer and 100 mM streptozocin drug); and 4 µl of mother 
liquor. The reservoir contained mother liquor with varying concentrations of 
PEG400: 20%, 25% or 28%. Controls were also performed containing 5 µl of buffer 
C and 5 µl of 20%, 25% or 28% of PEG400. Plates were incubated at 4oC and 
checked for crystals two weeks later under a light microscope.  
 
4.2.2 Vapour Diffusion Trials with hGSTP1-D 
 
 These vapour diffusion trials were performed using the hanging drop 
technique. They were adapted and based on the following publications, where 
crystallisation of hGSTP1-A has been successful: Oakley et al., 1997; Oakley et al., 
1998 and Parker et al., 2008. The difference between Variants A and D, lies in 
amino acid 113, where variant A contains an alanine, variant D contains a valine.  
 
 Trail A: The hGSTP1-D enzyme was purified and concentrated to 10 mg/ml 
in 10 mM phosphate buffer (pH 7.0), 1 mM EDTA and 60 mM DTT. The reservoir 
solution contained 16 – 31% (w/v) ammonium sulphate, 100 mM MES buffer (pH 
5.5) and 10% (v/v) glycerol. Each condition was assembled by pipetting 1 ml of 
reservoir solution into the reservoir and by mixing 2 µl of protein solution with 2 µl of 
reservoir solution on the cover slip, which was then inverted and sealed with 
vacuum grease. Plates were incubated at 4oC and checked for crystals two to three 
weeks later under a light microscope. 
 
 Trial B: After purification of hGSTP1-D by gel filtration chromatography, 5 
units of thrombin per mg of fusion protein (GE Healthcare, UK) was used to cleave 
the His tag from the protein. This was carried out overnight at room temperature 
and with gentle stirring. Cleaved protein was then separated from the uncleaved 
protein by nickel affinity chromatography and then purified by gel filtration 
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chromatography (section 2.2.13.4). The untagged hGSTP1-D protein was 
concentrated to approximately 20 mg/ml in 10 mM phosphate buffer (pH 7.0), 1 mM 
EDTA and 60 mM DTT. Finally, trial B was assembled using the same conditions 
and techniques of the trial A above.     
 
 Trial C: This trial was carried out in the same way as trial B, with the 
difference that the protein was kept in the gel filtration buffer (50 mM sodium 
phosphate, 150 mM NaCl, 1 mM DTT, pH 7.0).  
 
 The successful condition in screen C was repeated several times with 
different hGSTP1-D protein batches. Potential crystals would then be soaked in the 
nitrosourea drugs and also in chlorambucil, used as a control, just before being 
frozen in liquid nitrogen. 
 
 Hanging drop co-crystallisation experiments using the same conditions as in 
trial C were also attempted by adding 100 mM of the nitrosourea drugs and 100 mM 
of chlorambucil, used as a control, to the protein solution.   
 
4.2.3 Preparation of crystals for data collection 
 
 Two crystals grew in one of the crystallisation conditions of screen C (section 
5.2.2). They were split into nine crystals. All nine crystals were picked up by a nylon 
loop and flash frozen in liquid nitrogen after being placed in the following 
cryoprotectant to mimic conditions in the crystal dish: 40% ammonium sulphate, 
50mM phosphate buffer (pH 7.0), 150 mM NaCl, 100mM MES buffer (pH 5.5), and 
30% glycerol. One of the crystals was used for data collection "in house" to confirm 
the crystals were protein. The crystals were then used for data collection at the 
Diamond Synchrotron Source in Oxford.    
 
4.2.4 X-ray data collection 
 
 The X-ray data were collected at beamline I03 using the Pilatus 6M-F 
detector at the Diamond Synchrotron Source (www.diamond.ac.uk). The X-ray data 
collection conditions are displayed in table 4.2. 
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Table 4.2 - X-ray data collection conditions for the best hGSTP1-D crystal. 
Crystal hGSTP1-D 
Cryo-protectant 
40% ammonium sulphate, 50 mM 
phosphate buffer (pH 7.0), 150 mM NaCl, 
100 mM MES buffer (pH 5.5), 30% glycerol 
Beam line I03 
Wavelenth (Å) 0.9763 
No of frames 360 
Oscilation in degrees 0.5 
 
 
4.2.5 Structure determination 
 
4.2.5.1 Data processing 
 
 The program Xia2, version 0.3.3.0 (Winter, 2010), was used to process the 
data. It uses the following data reduction software programs: XDS (Kabsch, 1993), 
MOSFLM (Leslie, 1992), Labelit (Sauter et al., 2004), Pointless (Evans, 2005) and 
CCP4 (Collaborative Computational Project, Number 4, 1994).   
 
4.2.5.2 Phase determination 
 
 Molecular replacement was carried out using the automated program 
MOLREP, version 10.2 (Vagin & Teplyakov, 1997). The structure of the human 
HGSTP1-A in complex with glutathione (PDB ID: 5GSS), which is one amino acid 
different, was used as a model. The program outputs a list of rotational and 
translational function solutions in order to place the model structure into the target 
unit cell.   
 
4.2.5.3 Model building and refinement 
 
 The electron density map was calculated and the hGSTP1-D structure was 
built to give the best fit. The program REFMAC, version 5.6 (Murshudov et al., 
1997), was used for maximum likelihood refinement, and the model was manually 
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rebuilt in COOT (Emsley & Cowtan, 2004). Solvent molecules were added to the 
structure manually.   
 
4.2.5.4 Structure validation 
 
 The program PROCHECK, version 3.3 (Laskowski et al., 1993), was used 
after refinement to verify the quality of the model.  
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4.3 Results and Discussion 
 
4.3.1 Microbatch screens with hGSTP1-D 
 
 Screen A: Pure and concentrated hGSTP-D enzyme was mixed with the 
drug streptozocin, and the resulting protein solution used to screen the 
crystallisation conditions in MDL-01 and JCSG-plus kits, both at 4oC and 18oC. 
After an incubation time of two to three weeks small crystals were formed in two 
different conditions. Figure 4.5a shows the crystals formed in the following 
crystallisation condition of the MDL-01 plate: 0.2 M calcium chloride dihydrate, 0.1 
M Na HEPES pH 7.5, 28 % v/v PEG 400; and figure 4.5b shows the crystals formed 
in the JCSG-plus plate with the following crystallisation conditions: 0.2 M calcium 
acetate, 0.1 M sodium cacodylate pH 6.5, 40 % v/v PEG 300. Both plates were 
incubated at 4 oC. 
 
 
Figure 4.5 – Crystals grown from the screening conditions: a) 0.2 M calcium 
chloride dihydrate, 0.1 M Na HEPES pH 7.5, 28 % v/v PEG 400 (MDL-01 plate); b) 
0.2 M calcium acetate, 0.1 M sodium cacodylate  pH 6.5, 40 % v/v PEG 300 
(JCSG-plus plate). 
 
 The crystals formed in both conditions were very small and of insufficient 
quality to use for X-ray diffraction experiments. Alternatively, a needle test was 
used to roughly assess the origin of the crystals. The crystals in figure 4.5a 
appeared to be soft by crushing with a needle which was considered as a probable 
indication of protein crystals, whereas crystals in figure 4.5b were harder and 
considered to be salt crystals.  
 Optimisation of the crystallisation condition from the MDL-01 plate (200 mM 
calcium chloride dihydrate, 100 mM Na HEPES (pH 7.5), and 28 % v/v PEG 400) 
a b 
250 µm 250 µm 
 
 
145 
was carried out as illustrated in table 4.1. The droplets present in the plate stored at 
18oC turned dark brown and the protein appeared denatured. Two to three weeks 
after setting the experiment crystals were visible in wells A2, A4, B3, C1, C2 and C3 
(table 4.1) of the plate stored at 4oC. As these crystals were again small, irregular 
and of poor quality it was decided to seed the crystals present in well A4 (figure 
4.6). This well contained the original crystallisation condition and the highest 
number of small crystals.    
 
 
Figure 4.6 – Crystals formed in well A4 (crystallisation condition: 0.2 M calcium 
chloride dihydrate, 0.1 M Na HEPES pH 7.5, 28 % v/v PEG 400). 
  
 
 As the microbatch optimisation did not work as expected, it was decided to 
carry on the optimisation experiments by performing crystal seeding through the 
hanging drop technique as explained in section 4.2.2.1. Crystal seeding offers a 
higher protein concentration in the droplet which enables a point of nucleation for 
the crystals (Giacovazzo et al., 2002). After two to three weeks of incubation at 4oC, 
crystals were visible in several droplets including the control wells containing no 
protein, which allowed the conclusion that the crystals formed were salt crystals. 
These optimisation experiments were not continued further.    
 
 Screen B: Pure and concentrated hGSTP1-D enzyme was used to screen 
the crystallisation conditions in the following two plates: Basic Kit for Proteins 82009 
and Crystallisation Extension Kit for Proteins. After two to three weeks of incubation 
at 4oC no crystal growth was visible in any of the wells of both plates. As protein 
was seen to denature in the above experiments at 18oC, screen B was only 
performed at 4oC where protein appeared to be more stable.    
200 µm 
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4.3.2 Vapour diffusion screens with hGSTP1-D  
 
 Trial A: Based on the publications mentioned in section 4.2.2 the following 
crystallisation conditions were tested using the hanging drop technique: 
 Protein solution: 10 mg/ml in 10 mM phosphate buffer (pH 7.0), 1 mM EDTA 
and 60 mM DTT; 
 Reservoir solution: 16 – 31% (w/v) ammonium sulphate, 100 mM MES buffer 
(pH 5.5) and 10% (v/v) glycerol. 
 Three weeks after setting up the plates no crystal formation was visible in 
any of the droplets. As hGSTP1-A enzyme was reported to have been successfully 
crystallised without having a His tag incorporated (Oakley et al., 1997; Oakley et al., 
1998 and Parker et al., 2008), it was decided to test the same crystallisation 
conditions after removing the tag.     
 
 Trial B: In order to cleave the His tag from purified hGSTP1-D enzyme, 5 
units of thrombin per mg of fusion protein was used. After incubation with this 
protease enzyme, cleaved protein was separated from uncleaved by nickel affinity 
chromatography. Figure 4.7 illustrates a typical trace for this protein separation, 
where protein without the His tag eluted in the first fractions due to the lack of 
affinity to the column, whereas uncut hGSTP1-D was eluted as normally, during the 
imidazole gradient. Protein was then further purified by gel filtration chromatography 
and buffer exchanged into 10 mM phosphate buffer (pH 7.0), 1 mM EDTA and 60 
mM DTT. With the objective of increasing the probability of crystallisation, hGSTP1-
D was concentrated to approximately 20 mg/ml. In spite of these changes, no 
crystal growth was observed after the incubation time and a last alteration to the 
original conditions was attempted.  
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Figure 4.7 – Elution profile of hGSTP1-D without the His tag from a 50 ml nickel 
affinity column. The A280 trace is seen in blue, the concentration of buffer B in green 
and fractions containing hGSTP1-D marked by the black bar. 
 
 Trial C: In this trial 20 mg/ml of protein was kept in gel filtration buffer (50 
mM sodium phosphate, 150 mM NaCl, 1 mM DTT, pH 7.0) and the reservoir 
solutions were maintained as for trials A and B. Approximately three weeks after 
setting up the plates, 2 big colourless plate shaped crystals (figure 4.8) with several 
layers were formed in the crystallisation condition containing 31% (w/v) ammonium 
sulphate, 100 mM MES buffer and 10% (v/v) glycerol. The two crystals were split 
into nine smaller ones and one of them was checked by X-ray diffraction using the 
“in house” system. The crystal diffracted to 2Ǻ resolution and proved to be protein. 
  
 The crystals were soaked in cryoprotectant (40% ammonium sulphate, 
50mM phosphate buffer – pH7.0, 150mM NaCl, 100mM MES buffer – pH 5.4, and 
30% glycerol) and frozen in liquid nitrogen in order to collect data at the Diamond 
Light Synchrotron Radiation Source.  
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Figure 4.8 - hGSTP1-D plate shaped crystals grown from vapour diffusion 
experiments. The crystallisation conditions were: 10 mg/ml of protein in 50 mM 
sodium phosphate, 150 mM NaCl and 1 mM DTT (pH 7.0). The reservoir solution 
contained 16 – 31% (w/v) ammonium sulphate, 100 mM MES buffer (pH 5.5) and 
10% (v/v) glycerol.  
 
 
   The successful crystallisation condition was replicated several times 
with the objective of soaking the crystals in the nitrosourea anticancer drugs and in 
chlorambucil which is a well known GSTP1 substrate (Parker et al., 2008). This 
would have lead to information about the mechanism and interaction of different 
substrates with amino acid 113 (Val). However, there was no growth of new crystals 
and as demonstrated by enzymatic assays discussed in chapter 3, the nitrosourea 
anticancer drugs do not seem to constitute either substrates or inhibitors to the 
human class Pi of enzymes. The co-crystallisation experiments also carried out with 
the same objective were not successful as no crystals were formed in any of the 
droplets.   
 
4.3.3 hGSTP1-D structure determination  
 
 
 X-ray data were collected as previously described in table 4.2. Table 4.3 
shows the data processing statistics for the hGSTP1-D crystal used for structure 
determination which belonged to the space group P1211.  
 
 
 
 
300 µm 
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Table 4.3 - Data processing statistics for the hGSTP1-D protein. In brackets are the 
values for the outer resolution shell. Rmerge = ΣhΣjǀ<Ih>-Ij(h) ǀ/ΣhΣjI(h), where I(h) is 
the intensity of the reflections h, Σh is the sum over all the reflections and ΣJ is the 
sum over J measurements of the reflections.  
Crystal hGSTP1-D 
Resolution (Å) 54.3 - 1.57 (1.62 - 1.57) 
Cell dimensions  
P1211 
a, b, c = 54.4 Å, 69.0 Å, 68.2 Å 
No of protomers 2 
Solvent content 
(%) 
VM (Å
3 Da-1) 
54.77 (2.7) 
No of measured 
reflections 
242721 
No of unique 
reflections 
70355 
Completeness 99.1 (99) 
(I)/ δ (I) 8.7 (2.2) 
Rmerge †  0.078 (0.49) 
 
 
 The program MOLREP, version 10.2 (Vagin & Teplyakov, 1997) was used 
for molecular replacement where hGSTP1-A in complex with glutathione (PDB ID: 
5GSS) was used as a model.  
 Table 4.4 illustrates the final refinement statistics for the hGSTP1-D enzyme. 
The electron density allowed the positioning of 425 amino acid residues, five of 
which belonged to the pET-28a vector and were left after removing the His tag with 
thrombin. The final model contains 534 water molecules, 1 sulphate ion, 1 glycerol 
molecule and 2 MES molecules. The final module was refined to an R-factor of 
21.5% in the resolution range of 54.3 - 1.6 Å, excluding the 5.1% of randomly 
distributed reflections assigned to calculate Rfree at 25.8. The program PROCHECK, 
version 3.3 (Laskowski et al., 1993), allowed to calculate the G-factor at 0.1. This 
value confirms the stereochemical properties of the hGSTP1-D structure as normal.     
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Table 4.4 - The final refinement statistics for the hGSTP1-D structure. In brackets 
are the target values.   
Crystal No 4 
Resolution (Å) 54.3 - 1.6 
Overall R-factor (%) 21.5 
Rfree (5.1% total data) 25.8 
No of residues 425 
No of waters modelled 534 
No of sulphate ions modelled 1 
No of glycerol molecules modelled 1 
No of MES molecules modelled 2 
RMSD bond length (Å) 0.014 (0.022) 
RMSD bond (˚) 1.507 (2.00) 
Wilson B factor (Å2) 26.5 
Average B factor: 
 
      Protein (Å2) 19.9 
      Water (Å2) 31.3 
      Ligands (Å2) 34.0 
REFMAC RMS error (Å2) 0.103 
Ramachandran analysis (% of residues): 
 
      Most favoured 93.4 
      Additionally allowed 0.1 
      Generously allowed 0.6 
      Disallowed 0 
G-factor 0.1 
 
 
 
4.3.4 hGSTP1-D structure  
 
 The non-allosteric human glutathione S-transferase Pi enzyme is a 
homodimer (figure 4.9). Each subunit has an approximate molecular weight of 23 
kDa, containing two binding sites. The G-site or glutathione binding site, and the H-
site or substrate binding site. Together they form the active site. Each subunit is 
also composed of two domains. The N-terminal domain or domain I includes amino 
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acids 1 to 74, and most of these residues form the G-site. This domain comprises 
approximately one third of the protein and is part of the thioredoxin superfamily fold 
with a βαβαββα sequence (figure 1.4). The C-terminal domain or domain II includes 
residues 81 to 209, and most of these amino acids form the H-site. This domain 
forms two thirds of the protein and consists of a bundle of alpha helices (Armstrong, 
1997; Sheehan et al., 2001; Aliya et al., 2003; Frova, 2006). 
  The G-site is common to all GST subunits and contains specific residues for 
glutathione binding and catalytic activity (figure 4.10). Residues Arg13, Lys44, 
Gln51, Gln64, Tyr7 and Asp98 are part of the glutathione binding site and are 
conserved in other mammalian class Pi GSTs. Residue Arg13 interacts with the α-
carboxylate group of the glutamyl moiety of GSH. Amino acid Lys44 interacts with 
the carboxylate group of the glycine residue of GSH. Residues Gln51, Gln64 and 
Asp98 are in the surrounding area of the zwitterionic part of the γ-glutamyl group of 
GSH (Widersten et al., 1992). Amino acid residues Trp38 and Ser65 are also 
involved in the binding of GSH. The hydroxyl group of the tyrosine residue in 
position 7 acts as a hydrogen bond donor to the thiol group of the glutathione 
molecule. This encourages the formation and stabilisation of the extremely reactive 
thiolate anion which is the target for nucleophilic attack by electrophilic substrates 
(Oakley et al., 1997; Aliya et al., 2003; Frova, 2006). Consequently, residue Tyr7 is 
involved in catalysis and is not necessarily involved in binding of glutathione or the 
electrophilic substrate. Similarly, residue Asp98 from subunit B, contributes to the 
catalytic mechanism without playing a role in the binding of GSH (Widersten et al., 
1992). On the other hand, amino acid residues Arg13, Lys44, Gln51 and Gln64 play 
a significant role in the binding of GSH to the G-site. Residue Arg13 is also very 
important for the structure of the enzyme, as removal of the side chain of this 
arginine resulted in a less stable hGSTP1-A (Widersten et al., 1992). 
 The glutathione molecule occupies the same position in the G-site of the 
enzyme independently of being conjugated with a substrate or not. The exception is 
the thiol group of the tripeptide molecule which rotates and points towards the 
hydroxyl group of the Tyr7 residue when the substrate is not present, as figure 4.10 
illustrates. As mentioned before, the hydrogen bond between the hydroxyl group of 
the Tyr7 residue and GSH stabilises the thiolate anion form of the tripeptide (Oakley 
et al., 1997; Parker et al., 2008). In figure 4.11 glutathione is conjugated with the 
substrate chlorambucil where the thiol group is rotated towards the substrate 
displacing one of its chlorine groups (Parker et al., 2008).   
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Figure 4.9 - Ribbon representation of the hGSTP1-D dimer. a) Vertical view. b) 
Horizontal view. Each subunit is shown in a different colour. The program PyMOL 
(Delano Scientific) was used to produce this figure.  
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 In contrast to the G-site, the H-site is specific for each GST subunit providing 
a hydrophobic environment for the binding of structurally diverse electrophilic 
substrates (Aliya et al., 2003; Frova, 2006). Figures 4.11 and 4.12 show the active 
site of hGSTP1-A where glutathione is conjugated with the anticancer drug 
chlorambucil. 
 The anticancer drug chlorambucil was used as an example to explain the 
interactions that take place in the H-site. Figures 4.11 and 4.12 were adapted from 
the structure of hGSTP1-A in complex with the chlorambucil-glutathione conjugate 
(PDB ID: 3CSH) (Parker et al., 2008).   
 The substrate chlorambucil interacts with several amino acid residues in the 
H-site. The aromatic ring of this substrate is sandwiched between the aromatic 
rings of Tyr108 and Phe8. It forms van der Waals interactions with residues Val35, 
Val10, Pro9 and Gly205 and a pi-pi stacking interaction with residue Phe8. The 
carboxylate group of the drug is involved in water-mediated interactions with 
hydroxyl group of residue Asn204 and the amino group of residue Gly207. 
 The second chloroethyl group of chlorambucil does not form any interactions 
with the protein and appears to be fairly flexible, in both subunits (Parker et al., 
2008). 
 Different substrates may occupy the active site in a slightly different manner 
by interacting differently with its amino acid residues of the active site. For 
instances, when comparing the active site of hGSTP1-A complexed with ethacrynic 
acid (EA) and γ-glutamyl-(S-benzyl)cysteinyl-D-phenyl-glycine (TER-117), Oakley 
et al. (1997) found out that the aromatic ring of EA stacks against the side-chain of 
residue Tyr108 in a similar way to the benzyl ring of TER-117. However, EA forms 
alternative interactions in the H-site which are not present in the complex with TER-
117, and vice versa. The chlorine atoms of EA interact with residue Ile104 and its 
butyryl group interacts with residue Val10. On the other hand, the phenyl ring of 
TER-117 stacks perpendicularly to the ring of residue Phe8 and forms van der 
Waals interactions with amino acid Trp38. EA does not have the equivalent of the 
phenyl ring of TER-117 and so it does not form these interactions (Oakley et al., 
1997).  
 
 
154 
 
Figure 4.10 - Diagram of the active site of hGSTP1-A in complex with glutathione 
(PDB ID: 5GSS) (in dark blue) superimposed with hGSTP1-D (in green and light 
blue). Amino acid residues important for glutathione binding to the G-site are also 
shown as stick models. The program PyMOL (Delano Scientific) was used to 
produce this figure.  
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Figure 4.11 - Diagram of the active site. Cartoon representation of the hGSTP1-A 
in complex with the chlorambucil-glutathione conjugate (PDB ID: 3CSH). Isoleucine 
in position 104 and amino acid residues important for glutathione binding to the G-
site are also illustrated as stick models. The program PyMOL (Delano Scientific) 
was used to produce this figure.  
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Figure 4.12 - Cartoon representation of the hGSTP1-A dimer in complex with the 
chlorambucil-glutathione conjugate in both active sites (PDB ID: 3CSH). a) Vertical 
view. b) Horizontal view. Each subunit is shown in a different colour. The program 
PyMOL (Delano Scientific) was used to produce this figure.  
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6.3.2 Amino acid residues 104 and 113  
  
 The four hGSTP1 polymorphisms vary in one or two amino acid residues. 
The hGSTP1-A enzyme, considered to be the wild type, has in position 104 an 
isoleucine and in position 113 an alanine. The hGSTP1-B isoform has in position 
104 a valine and in position 113 an alanine. The hGSTP1-C variant has in both 
positions a valine, and finally the hGSTP1-D enzyme has in position 104 an 
isoleucine and in position 113 a valine. Figure 4.13 illustrates the structural location 
and orientation of the four different amino acid combinations. Amino acid 104 is 
located in helix 4 in the H-site nearby residue Tyr108. This is an important and 
flexible region involved in the catalytic process, whereas residue 113 is located 
completely outside of the active site at the N-terminal end of helix 5 (Zimniak et al., 
1994; Parker et al., 2008). 
 As mentioned before this was the first time that hGSTP1-D was crystallised 
and X-ray diffracted to obtain its structure. As illustrated by figure 4.13 the side 
chains of both amino acid residues Ile104 and Val113 occupy their positions in the 
same orientation as the side chains of residues Val104 and Ala113 of hGSTP1-B 
(PDB ID: 2PGT). The same is true for the quaternary structures of both enzymes.  
The hGSTP1-B structure was chosen for superimposition to allow visualisation and 
demonstrate all four amino acid combinations.       
 In spite of having the same orientation it has been suggested that the 
presence of the amino acid residue isoleucine versus valine in position 104 can 
change substrate binding resulting in change of enzyme activity. The bulkier 
isoleucine amino acid is likely to result in a smaller and more restrictive H-site 
(Zimniak et al., 1994). In section 3.3.1 of chapter 3 it was demonstrated that 
hGSTP1-A and -D enzymes, which possess in position 104 the isoleucine residue, 
have a higher specific activity towards CDNB (substrate used in the activity assay) 
than hGSTP1-B and -C, which contain in position 104 the valine residue. This 
difference may be due to a better fit of the relatively small substrate into the H-site 
of hGSTP1-A and -D isoforms and to the different hydrophobicity of the side chain 
of residue 104. The same result was observed by Parker et al. (2008) when the four 
hGSTP1 isozymes reacted with chlorambucil in the presence of glutathione. 
However, when hGSTP1-A and -B enzymes reacted with bromosulfophthalein, a 
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bulky and rigid substrate, the order of the specific activities was reversed (Zimniak 
et al., 1994).           
       
  
Figure 4.13 - Diagram displaying mutations of the amino acid residues in positions 
104 and 113. The hGSTP1-B is complexed with glutathione (PDB ID: 2PGT) (in 
blue) where amino acid residues 104 and 113 are valine and alanine, respectively; 
superimposed with hGSTP1-D (in green) where amino acid residues 104 and 113 
are isoleucine and valine, respectively. The program PyMOL (Delano Scientific) 
was used to produce this figure.  
  
 According to Zimniak et al. (1994) and Parker et al. (2008) other effects 
could also contribute to the differences observed on the Ile104Val substitution. The 
amino acid residue Tyr108 modulates enzyme activity through a combination of 
steric and chemical effects. This amino acid is also positioned close enough to 
residue 104 to have contact with it. The side chains of isoleucine and valine in 
position 104 present different bulkiness and hydrophobicity. These differences alter 
the geometry of the H-site and create different hydrophobic environments which 
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may influence the function of residue Tyr108 together with the nature of the 
substrate. 
 The effect of amino acid substitution in position 113 from alanine to valine on 
enzymatic activity is harder to explain due to the fact that this residue is positioned 
outside the active site. More precisely its location is at the opening of a solvent 
channel in the dimer interface and at the top of the helix-turn-helix motif between 
helices 4 and 5 (Parker et al., 2008). As mentioned at the end of section 4.3.1 of 
chapter 4, Hu et al. (1997) suggested that amino acid residue 113 of subunit A 
forms a "hydrophobic clamp" with residue 113 of subunit B, which could possibly 
control access of substrates to the active site. The theory is that residue 113 could 
then be important in determining substrate specificity of the enzymes through the 
size of its side chain and hydrophobicity. However, Parker et al., (2008) did not find 
evidence to support this theory in either hGSTP1-A (PDB ID: 3CSH) and -C (PDB 
ID: 3CSI) complexed with GSH-chlorambucil as their active sites extend through a 
wide and open solvent-exposed gap.          
          
6.3.3 Buffer binding sites 
 
 In addition to the H-site another binding site has been identified for 
hydrophilic anionic ligands such as sulphonate buffers. This binding site is not in the 
vicinity of the active site of these enzymes (Kolobe et al., 2004). The MES 
molecules that occupy both buffer binding sites of hGSTP1-D, one in each subunit, 
interact with the same amino acid residues as hGSTP1-A  (5GSS and 3CSH) 
(figure 4.14a). The orientation of the ring of the MES molecule is perpendicular to 
the aromatic ring of the Trp28 residue. MES forms van der Waals interactions with 
Ala22, Trp28, Glu30 and Phe192 residues, and the nitrogen atom interacts with the 
carboxyl group of the Glu197 residue through a salt bridge. However, the sulfonic 
acid group does not form interactions. Instead, its orientation is towards the solvent. 
It is not unusual for buffer molecules to bind to crystallised protein but not to the 
same protein in solution. The fact that Trp28 residue is located close to the MES 
molecule made it possible for Prade et al., (1997) to detect binding of this buffer 
molecule in solution by fluorescence measurements. The results showed that when 
MES binds to the buffer binding site it induces a shift to UV in the fluorescence 
spectra. Buffers binding to this site have no influence on the activity of hGSTP1. 
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 A further binding site for MES buffer has been identified by Oakley et al., 
(1997) in the structure of hGSTP1-A complexed with glutathione (5GSS). This third 
binding site is located at the bottom of the dimer interface (figure 4.14b) where the 
MES molecule binds between residues Tyr79 of both subunits through hydrophobic 
interactions. Other interactions are with amino acid residues Asp82, Gln83, Arg74, 
Ala86 of subunit A and Arg74 of subunit B. As discussed in section 3.3.6.2 of 
chapter 3, a MES molecule that binds to this site is likely to destabilise intersubunit 
interactions between the above amino acid residues.             
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Figure 4.14 - A diagram to show the MES binding sites. a) MES molecules bound 
to each buffer binding site on hGSTP1-D dimer solved in this thesis. Each subunit is 
shown in a different colour. b) MES molecules bound to each buffer binding site on 
the hGSTP1-D dimer (green and blue subunits), superimposed with hGSTP1-A in 
complex with glutathione and complexed with a third MES molecule bound in 
between subunits (grey dimer) (PDB ID: 5GSS). The program PyMOL (Delano 
Scientific) was used to produce this figure.   
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4.4 Summary 
 
 In order to crystallise the hGSTP1-D enzyme several microbatch protein 
crystallisation kits were tested with no success. However, two hGSTP1-D plate 
shaped crystals grew in conditions based on publications that reported the 
successful crystallisation of variant A. These crystallisation experiments constituted 
the first step to understand the structural and functional role that amino acid Val113 
plays in the substrate binding site of hGSTP1-D enzyme when compared to the 
other variants.   
 The structure of the crystallised hGSTP1-D enzyme was obtained through X-
ray diffraction studies. This has never been achieved before as only the structures 
of the other three isoforms have previously been solved, especially hGSTP1-A 
enzyme complexed with a variety of different substrates. Unfortunately, co-
crystallisation experiments with glutathione, a substrate or an inhibitor were 
unsuccessful. The side chains of both amino acid residues Ile104 and Val113 
appear to occupy their positions in the same orientation as the side chains of 
residues of other hGSTP1 enzymes that have previously been crystallised. The 
structure of hGSTP1-D also contained a MES molecule in each of its buffer binding 
sites but not in between subunits.  
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Chapter 5 - Conclusions and Future Work 
 
 This work aimed to clone, over-express and purify the four hGSTP1 
isozymes in order to investigate their activity and interaction with five nitrosourea 
compounds used in chemotherapy. There are four polymorphisms of this enzyme 
which differ in one to two amino acid residues in positions 104 and 113. They either 
possess an isoleucine or valine in position 104 and an alanine or valine in position 
113. 
 The polymerase chain reaction was used to amplify the hGSTP1-B cDNA 
coding sequence which was subsequently inserted into the pGEM-T cloning vector 
with restriction sites incorporated for further sub-cloning into the pET-28a 
expression vector. Site directed mutagenesis was then used to create the other 
three variants (hGSTP1-A, -C and -D). BL21-CodonPlus (DE3)-RIPL competent 
cells were used in the over-expression of the four hGSTP1 enzymes which were 
subsequently purified to homogeneity by nickel affinity chromatography using the 
incorporation of a His-tag on the N-terminus of the proteins and gel filtration 
chromatography.    
 Activity assays were performed with CDNB, the standard substrate used for 
this purpose, in order to determine the different activity of the hGSTP1 isozymes. 
This is a novel method that has the potencial to become a widely used screen to 
identify substrates or inhibitors of hGSTP1 enzymes which in turn may in the furure 
be used as a medical treatment for cancer and other diseases.  Its use can also be 
extended to the majority of the other GST classes as they also utilise CDNB as a 
substrate. The hGSTP1-A and -D were found to have a higher specific activity in 
comparison to variants B and C. It is suggested that by sharing amino acid Ile104, 
enzymes hGSTP1-A and -D have more affinity to this substrate than the other 
isozymes. After the activity assays, several enzymatic assays with the five 
nitrosourea anticancer drugs (carmustine, lomustine, semustine, streptozocin and 
ethylnitrosourea) were carried out. The possible reaction products resulting from the 
incubation of the hGSTP1 enzymes with the above drugs could not be analysed by 
HPLC using UV detection methods. This was due to the fact that during the 
wavelength scans both the incubation solution and the drugs absorbed at the same 
wavelength of 225 nm. Consequently, the incubation solution was analysed by 
mass spectrometry to confirm the presence or absence of the glutathione 
conjugates. The data obtained from the mass spectrometry assays showed that 
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none of the drugs are substrates of hGSTP1 enzymes as there were no glutathione 
conjugates identified in the reaction solutions after incubation of the enzymes with 
the drugs. This was also confirmed by the denitrosation assays as there was no 
nitrite formation. Taking into account the two assays described above, the results of 
the inhibition assays may suggest that the drugs carmustine, lomustine, semustine, 
and ethylnitrosourea could be weak inhibitors of the four isozymes. However, the 
thermofluor shift assays performed to investigate this theory did not show any 
increased protein stability due to drug binding. In spite of this result, thermofluor 
shift assay is a robust method that however has not been used very often to 
investigate and access GST stability towards inhibitors.This research could benefit 
from additional studies to co-crystallise drugs with the hGSTP1 protein and to carry 
out docking studies to determine if these four drugs do bind as inhibitors of the 
hGSTP1 enzymes. The drug streptozocin did not appear to be either a substrate or 
an inhibitor to any of the hGSTP1 enzymes.           
 X-ray diffraction studies were carried out after successful growth of hGSTP1-
D crystals. The side chains of both residues Ile104 and Val113 appeared to occupy 
their positions in the same orientation as the side chains of residues of other 
hGSTP1 enzymes. However, as mentioned above isozymes A and D were more 
active towards the substrate CDNB. This was most probably due to the fact that 
they possess, in position 104, the amino acid residue isoleucine instead of valine. 
The geometry of the substrate binding site is affected not only by the nature of the 
substrate but also by the different size and hydrophobicity of the side chains of 
these two amino acids as they can interact with the catalytically important Tyr108 
residue. The hGSTP1-D structure was also found to have a MES molecule in the 
buffer binding site of each subunit but not in between subunits as seen for other 
hGSTP1 protein structures.  
 Although only a small percentage of the human population express the 
hGSTP1-D enzyme, they should not be considered any less than the rest of the 
population that express the other variants. Consequently, it is important that like 
other studies with hGSTP1 variants, future co-crystallisation studies of hGSTP1-D 
with different known substrates, such as the anticancer drug chlorambucil and the 
inhibitor EA are carried out. This information would allow a better understanding of 
how Ile104 and Val113 polymorphisms contribute to the catalytic mechanism of this 
hGSTP1 isozyme and their potential impact on cancer treatment. In the future, 
cancer patients expressing hGSTP1-D could benefit from this knowledge.   
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 The four hGSTP1 cDNA coding sequences could in the future be cloned into 
an appropriate vector in order to be used in transfection experiments with the 
objective of over-expressing the respective enzymes in human cancer cell lines 
such as Hep-3B and Hep-G2. To investigate enzymatic activity and expression 
levels, a fluorometric assay with monochlorobimane (MCB) could be performed to 
detect over-expression levels of hGSTP1 activity in transformed cells in comparison 
to control cells which would have not been transformed. It is then proposed that 
anticancer drugs already known to be substrates of this class of hGSTs 
(doxorubicin, cisplatin, cyclophosphamide, melphalan, busulfan, chlorambucil, 
thiotepa, vincristine, and etoposide), many of which are used in the treatment of the 
same types of cancer, are applied to Hep-3B or Hep-G2 cells over-expressing the 
four active isozymes. After this, there are a number of experiments such as flow 
cytometry, fluorometric lactate dehydrogenase (LDH) release assay, measurement 
of caspases and agarose gel electrophoresis to identify the DNA laddering effect, 
which would allow measurement and identification of the type of cell death 
(necrosis or apoptosis). These results should also confirm the results produced by 
the enzymatic assays between the four hGSTP1 isozymes and the anticancer 
drugs mentioned above. This evidence could result in useful information regarding 
the differential activity of these enzymes towards several different substrates which 
could potentially lead to medical trials and subsequently personalised cancer 
treatments according to the genetic makeup of cancer patients. Regarding the 
possible medical trials, as the drugs mentioned above are already used in 
chemotherapy they would involve few if any ethical problems. The treatment would 
involve administering the drugs that have the least activity towards the four variants 
which would result in a slower metabolism of the drugs. The above suggestion 
could also be extended by carrying out enzymatic assays with the four hGSTP1 
enzymes towards other groups of anticancer drugs, such as antibiotics, plant 
alkaloids and hormonal agents.   
 Experiments with inhibitors of hGSTP1 enzymes could also be performed to 
find out differences between the response of the four hGSTP1 enzymes. 
Compounds known to be inhibitors include ethacrynic acid, GSH analogs, 
clofibrate, gossypol, indomethacin, misonidazole, piriprost and sulfasalazine. The 
treatment would involve administering a suitable inhibitor at the same time as the 
chemotherapy treatment. This would aid the efficacy of the anticancer drug against 
resistant tumours through inhibition of drug metabolism by the hGSTP1 enzymes. 
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In fact, the understanding of the catalytic mechanism of the hGSTP1 enzymes 
towards anticancer drugs should result in the design of new inhibitors of this class 
of enzymes. These new inhibitors should present fewer side effects for the patients 
than the inhibitors that are already known. For example, the inhibitor ethacrynic acid 
has been known to improve the cytotoxic effect of the anticancer drug chlorambucil 
in patients with colon carcinoma. However, the use of ethacrynic acid as an inhibitor 
was limited due to its side effects (Tew et al., 1988). 
 As mentioned in chapter 3, hGSTP1 enzymes play an important role in the 
signalling pathway responsible for cell apoptosis and survival. This class of GSTs 
inhibit the activation of the c-Jun N-terminal kinase which regulates apoptosis and 
cell proliferation. So, it is especially important for those patients that show increased 
expression of hGSTP1 enzymes in their tumours to find or design suitable inhibitors 
even when the chemotherapeutic drug used is not metabolised by this class of 
GSTs. For this reason it is important and beneficial to investigate the involvement of 
these isozymes in multidrug-resistance by understanding the mechanism by which 
they bind and inhibit JNK (figure 5.1). Protein-protein interaction studies using 
methods developed in this research should be carried out. Thermal shift assays to 
investigate differential enzyme stability and activity assays should be carried out to 
investigate the effects that JNK has on the catalytic mechanism of the isozymes.  X-
ray diffraction studies should also be carried out in order to find out the JNK binding 
site and the mechanism of binding of these two proteins.     
 
 
Figure 5.1 - The role of hGSTP1 in cell signalling (taken from Laborde, 2010). 
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 Another suggestion for further work is to study other hGST classes towards 
the nitrosourea anticancer drugs. As carmustine is known to be a substrate for 
class Mu and Theta, there is no reason why the other four drugs should not be 
tested not just against classes Mu and Theta but also against classes Alpha and 
Zeta.   
 The polymorphism Val104 has been associated with reduced enzymatic 
activity in comparison to Ile104 and cancers where hGSTP1-B and -C are 
expressed are easier to treat or the survival time is longer. However, people that 
express these variants are at a higher risk or more susceptible of developing cancer 
due to the slower metabolism of the carcinogens. Currently, despite this fact 
hGSTP1 enzymes are not considered as cancer markers when determining cancer 
risk. This is due to expensive genetic tests which are reserved for well established 
high-risk genes and oncogenes and to accession of family history which is a cheap 
and reliable method of predicting cancer (Yoon et al., 2002). To overcome this 
limitation it would be very beneficial for cancer patients who over-express hGSTP1 
enzymes that cheap metabolomic tests are developed to identify and quantify a 
specific sub-product originated from the catalysis of a specially designed substrate 
with specific activity for this class of hGSTs. The method should be able to identify 
hGSTP1 over-expression due to high levels of the specific sub-product in urine or 
blood samples. It should also give an indication of which isozyme is expressed due 
to the differential specific activity of the four isozymes towards the same substrate 
at a specific time after its administration. The results of this test together with the 
development of the further work suggested in this conclusion would then allow for a 
more informed and efficient personalised medicine.  
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Appendix 1 
 
 
DNA hyperladder 1 (Bioline) 
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Appendix 2 
 
 
Map of the pGEM-T vector 
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Appendix 3 
 
 
Map of the pET-28a vector 
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Appendix 4 
 
 
BioRad precision protein ladder 
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Appendix 5 
 
 
Mass Spectrometry 
 
Q-TOF source conditions 
 
 The desolvation gas temperature was 300°C and gas flow rate was 4 L/min. 
The capillary voltage was 1850 V with all analysis being carried out in positive ion 
mode. The fragmentor voltage was 175 V and skimmer 70 V. Scanning was 
performed using the auto MS/MS function at 4 scans sec-1 with a sloped collision 
energy of 3.7 V/100 Da with an offset of 5 V. 
 
QQQ source conditions 
 
 Gas temperature was 350°C, drying gas flow rate was 9 L/min, nebuliser 
pressure 35 psig, capillary voltage ±4 kV. Data was collected in selected ion 
monitoring (SIM) mode using masses generated empirically and where possible, 
confirmed by the accurate mass measurements using the QTOF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
